"id_redcap","id_covidence","covid","rsv","flu","infant","child","adult","elder","preg","immunocomp","doi","pmid","pmcid","link","article","published_year","journal","title","virus","population"
1,"#9075",0,1,0,1,0,0,0,1,0,"10.1016/j.vaccine.2024.06.009",38853036,,"https://pubmed.ncbi.nlm.nih.gov/38853036","Otsuki 2024",2024,"Vaccine","Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial","RSV","Pediatric"
1,"#9075",0,1,0,1,0,0,0,1,0,"10.1016/j.vaccine.2024.06.009",38853036,,"https://pubmed.ncbi.nlm.nih.gov/38853036","Otsuki 2024",2024,"Vaccine","Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial","RSV","Pregnant"
2,"#3443",0,1,0,0,0,0,0,1,0,"10.1097/aog.0000000000005816",39746212,,"https://pubmed.ncbi.nlm.nih.gov/39746212","Simes 2025",2025,"Obstet Gynecol","Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial","RSV","Pregnant"
4,"#6167",0,0,1,1,0,0,0,0,0,"10.1093/infdis/jiad539",39052720,"PMC11272077","https://pmc.ncbi.nlm.nih.gov/articles/PMC11272077","Fell 2024",2024,"J Infect Dis","Effectiveness of Influenza Vaccination During Pregnancy Against Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada","Influenza","Pediatric"
5,"#21721",0,1,0,1,0,0,0,0,0,"10.1097/inf.0000000000004878",40440704,,"https://pubmed.ncbi.nlm.nih.gov/40440704","Gentile 2025",2025,"Pediatr Infect Dis J","Maternal Immunization With RSVpreF Vaccine: Effectiveness in Preventing Respiratory Syncytial Virus-associated Hospitalizations in Infants Under 6 Months in Argentina: Multicenter Case-control Study","RSV","Pediatric"
6,"#1471",1,0,0,0,0,0,0,1,0,"10.1016/j.vaccine.2025.126894",39970594,,"https://pubmed.ncbi.nlm.nih.gov/39970594","Hall 2025",2025,"Vaccine","COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021","COVID","Pregnant"
7,"#6794",1,0,0,1,0,0,0,0,0,"10.15585/mmwr.mm7338a1",39325677,"PMC11563568","https://pmc.ncbi.nlm.nih.gov/articles/PMC11563568","Havers 2024",2024,"MMWR Morb Mortal Wkly Rep","COVID-19-Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months - COVID-NET, 12 States, October 2022-April 2024","COVID","Pediatric"
8,"#6950",0,0,1,0,0,0,0,1,0,"10.1016/j.xagr.2024.100395",39512761,"PMC11541679","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541679","Hsiao 2024",2024,"AJOG Global Reports","Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants","Influenza","Pregnant"
10,"_#2063",0,0,1,0,0,0,0,1,0,"10.1002/cpt.3565",39854110,,"https://pubmed.ncbi.nlm.nih.gov/39854110","Lee 2025",2025,"Clin Pharmacol Ther","Association of Influenza Vaccination During Pregnancy with Health Outcomes in Mothers and Children: A Population-Based Cohort Study","Influenza","Pregnant"
11,"#9276",0,0,1,0,1,0,0,0,0,"10.2807/1560-7917.Es.2024.29.40.2400618",39364601,,"https://pubmed.ncbi.nlm.nih.gov/39364601","Prez-Gimeno 2024",2024,"Euro Surveill","Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24","Influenza","Pediatric"
12,"#23773",0,1,0,1,0,0,0,0,0,"10.1016/s1473-3099(25)00156-2",40339585,,"https://pubmed.ncbi.nlm.nih.gov/40339585","PrezMarc 2025",2025,"Lancet Infect Dis","Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study","RSV","Pediatric"
13,"#10470",1,0,0,1,0,0,0,0,0,"10.1111/apa.17329",38923614,,"https://pubmed.ncbi.nlm.nih.gov/38923614","Tamir-Hostovsky 2024",2024,"Acta Paediatr","Association of BNT162b2 SARS-CoV-2 vaccination during pregnancy with postnatal outcomes in premature infants","COVID","Pediatric"
14,"#3965",0,1,0,1,0,0,0,0,0,"10.1016/S2352-4642(25)00155-5",40690922,,"https://pubmed.ncbi.nlm.nih.gov/40690922","Williams 2025",2025,"Lancet Child Adolesc Health","Bivalent Prefusion F Vaccination in Pregnancy and Respiratory Syncytial Virus Hospitalisation in Infants: Results of a Prospective, Multi-Centre, Test-Negative Study","RSV","Pediatric"
15,"#4454",1,0,0,0,0,1,0,0,0,"10.1002/hsr2.2142",38784253,"PMC11112633","https://pmc.ncbi.nlm.nih.gov/articles/PMC11112633","Al-Haddad 2024",2024,"Health Science Reports","The impact of SARS-CoV-2 mRNA vaccine on intracytoplasmic sperm injection outcomes at a fertility center in Iraq: A prospective cohort study","COVID","Adult"
16,"_#116",0,1,0,0,0,0,0,1,0,"10.1136/bmjopen-2024-087850",40187782,"PMC11973799","https://pmc.ncbi.nlm.nih.gov/articles/PMC11973799","Alami 2025",2025,"BMJ Open","Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System","RSV","Pregnant"
18,"#5488",1,0,0,0,1,1,1,0,0,"10.1093/eurheartj/ehae335",38993069,,"https://pubmed.ncbi.nlm.nih.gov/38993069","Choi 2024",2024,"Eur Heart J","Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study","COVID","Pediatric"
18,"#5488",1,0,0,0,1,1,1,0,0,"10.1093/eurheartj/ehae335",38993069,,"https://pubmed.ncbi.nlm.nih.gov/38993069","Choi 2024",2024,"Eur Heart J","Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study","COVID","Adult"
19,"#782",0,0,1,0,0,0,0,1,0,"10.1016/j.vaccine.2024.126506",39591703,,"https://pubmed.ncbi.nlm.nih.gov/39591703","Choi 2025",2025,"Vaccine","The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination","Influenza","Pregnant"
20,"#5806",1,0,0,0,0,0,0,1,0,"10.1097/aog.0000000000005632",38843526,,"https://pubmed.ncbi.nlm.nih.gov/38843526","Denoble 2024",2024,"Obstet Gynecol","Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink","COVID","Pregnant"
21,"#6443",0,0,1,0,0,0,0,1,0,"10.1001/jamanetworkopen.2024.34857",39298167,"PMC11413712","https://pmc.ncbi.nlm.nih.gov/articles/PMC11413712","Getahun 2024",2024,"JAMA Netw Open","Safety of the Seasonal Influenza Vaccine in 2 Successive Pregnancies","Influenza","Pregnant"
22,"#15755",1,0,0,0,0,0,0,1,0,"10.1136/bmjmed-2023-000743",39574424,"PMC11579536","https://pmc.ncbi.nlm.nih.gov/articles/PMC11579536","Jorgensen 2024",2024,"BMJ Med","Association between maternal mRNA covid-19 vaccination in early pregnancy and major congenital anomalies in offspring: population based cohort study with sibling matched analysis","COVID","Pregnant"
24,"#2008",1,0,0,0,0,0,0,1,0,"10.1016/j.therap.2024.06.003",38997859,,"https://pubmed.ncbi.nlm.nih.gov/38997859","Lacroix 2025",2025,"Therapie","COVACPREG, a French prospective cohort study of women vaccinated against COVID-19 during pregnancy","COVID","Pregnant"
25,"#16358",1,0,1,1,1,1,1,1,0,"10.1002/jmv.29693",38859751,,"https://pubmed.ncbi.nlm.nih.gov/38859751","Lee 2024",2024,"J Med Virol","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database","COVID","Pediatric"
25,"#16358",1,0,1,1,1,1,1,1,0,"10.1002/jmv.29693",38859751,,"https://pubmed.ncbi.nlm.nih.gov/38859751","Lee 2024",2024,"J Med Virol","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database","Influenza","Pediatric"
25,"#16358",1,0,1,1,1,1,1,1,0,"10.1002/jmv.29693",38859751,,"https://pubmed.ncbi.nlm.nih.gov/38859751","Lee 2024",2024,"J Med Virol","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database","COVID","Adult"
25,"#16358",1,0,1,1,1,1,1,1,0,"10.1002/jmv.29693",38859751,,"https://pubmed.ncbi.nlm.nih.gov/38859751","Lee 2024",2024,"J Med Virol","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database","Influenza","Adult"
25,"#16358",1,0,1,1,1,1,1,1,0,"10.1002/jmv.29693",38859751,,"https://pubmed.ncbi.nlm.nih.gov/38859751","Lee 2024",2024,"J Med Virol","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database","COVID","Pregnant"
25,"#16358",1,0,1,1,1,1,1,1,0,"10.1002/jmv.29693",38859751,,"https://pubmed.ncbi.nlm.nih.gov/38859751","Lee 2024",2024,"J Med Virol","Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database","Influenza","Pregnant"
26,"#8321",1,0,0,0,0,0,0,1,0,"10.1016/j.ajog.2024.04.028",38697336,,"https://pubmed.ncbi.nlm.nih.gov/38697336","Magnus 2024",2024,"Am J Obstet Gynecol","COVID-19 vaccination during pregnancy is not associated with an increased risk of severe postpartum hemorrhage","COVID","Pregnant"
27,"#2339",0,0,1,0,0,0,0,1,0,"10.1016/j.vaccine.2025.127297",40418866,,"https://pubmed.ncbi.nlm.nih.gov/40418866","Malange 2025",2025,"Vaccine","Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019","Influenza","Pregnant"
28,"#8569",1,0,0,0,0,0,0,1,0,"10.1111/1471-0528.17949",39279662,,"https://pubmed.ncbi.nlm.nih.gov/39279662","Mensah 2024",2024,"Bjog","COVID-19 Vaccine Safety in Pregnancy, A Nested Case-Control Study in Births From April 2021 to March 2022, England","COVID","Pregnant"
29,"#8588",1,0,0,0,0,0,0,1,0,"10.1097/aog.0000000000005670",38991216,,"https://pubmed.ncbi.nlm.nih.gov/38991216","Metz 2024",2024,"Obstet Gynecol","Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy","COVID","Pregnant"
30,"#9547",0,0,1,0,0,0,0,1,0,"10.1097/aog.0000000000005279",37535959,,"https://pubmed.ncbi.nlm.nih.gov/37535959","Regan 2023",2023,"Obstet Gynecol","Risk of Miscarriage in Relation to Seasonal Influenza Vaccination Before or During Pregnancy","Influenza","Pregnant"
31,"#9546",0,0,1,0,0,0,0,1,0,"10.1016/j.vaccine.2024.126256",39260053,"PMC11911014","https://pmc.ncbi.nlm.nih.gov/articles/PMC11911014","Regan 2024",2024,"Vaccine","Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study","Influenza","Pregnant"
34,"#3394",1,0,0,0,0,0,0,1,0,"10.1097/aog.0000000000005904",40311142,,"https://pubmed.ncbi.nlm.nih.gov/40311142","Sheth 2025",2025,"Obstet Gynecol","Coronavirus Disease 2019 (COVID-19) Vaccination and Spontaneous Abortion","COVID","Pregnant"
35,"#10424",1,0,0,0,0,0,0,1,0,"10.1016/j.lanepe.2024.101025",39974773,"PMC11838104","https://pmc.ncbi.nlm.nih.gov/articles/PMC11838104","Suseeladevi 2024",2024,"The Lancet Regional Health - Europe","COVID-19 vaccination and birth outcomes of 186,990 women vaccinated before pregnancy: an England-wide cohort study","COVID","Pregnant"
37,"#3980",1,0,0,0,0,0,0,1,0,"10.1002/bdr2.2490",40476384,"PMC12142568","https://pmc.ncbi.nlm.nih.gov/articles/PMC12142568","Woestenberg 2025",2025,"Birth Defects Res","Comparison of Perceived Adverse Events After COVID-19 Vaccination Between Pregnant and NonPregnant Women Using Two Cohort Studies in the Netherlands","COVID","Pregnant"
38,"#4651",0,1,0,1,1,0,0,0,0,"10.1093/cid/ciae596",39656748,,"https://pubmed.ncbi.nlm.nih.gov/39656748","Arbetter 2024",2024,"Clin Infect Dis","Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)","RSV","Pediatric"
39,"#5870",1,0,0,0,1,0,0,0,0,"10.1016/s1473-3099(24)00101-4",38518789,,"https://pubmed.ncbi.nlm.nih.gov/38518789","Dixit 2024",2024,"Lancet Infect Dis","Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial","COVID","Pediatric"
40,"#21593",0,0,1,0,1,1,0,0,0,"10.1016/s1473-3099(25)00153-7",40412421,,"https://pubmed.ncbi.nlm.nih.gov/40412421","Folegatti 2025",2025,"Lancet Infect Dis","Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study","Influenza","Pediatric"
40,"#21593",0,0,1,0,1,1,0,0,0,"10.1016/s1473-3099(25)00153-7",40412421,,"https://pubmed.ncbi.nlm.nih.gov/40412421","Folegatti 2025",2025,"Lancet Infect Dis","Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study","Influenza","Adult"
41,"#1605",0,0,1,1,1,0,0,0,0,"10.3390/vaccines13050467",40432079,"PMC12116156","https://pmc.ncbi.nlm.nih.gov/articles/PMC12116156","Huang 2025",2025,"Vaccines","The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 635 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial","Influenza","Pediatric"
42,"#7666",0,0,1,0,1,0,0,0,0,"10.1080/21645515.2024.2416329",39445787,"PMC11508945","https://pmc.ncbi.nlm.nih.gov/articles/PMC11508945","Kothari 2024",2024,"Hum Vaccin Immunother","A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months","Influenza","Pediatric"
43,"#2376",0,1,0,0,0,1,0,0,0,"10.1111/cts.70095",39736101,"PMC11684469","https://pmc.ncbi.nlm.nih.gov/articles/PMC11684469","Mao 2025",2025,"Clin Transl Sci","A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults","RSV","Adult"
44,"#2631",0,1,0,1,1,0,0,0,0,"10.1016/s2352-4642(25)00102-6",40379431,,"https://pubmed.ncbi.nlm.nih.gov/40379431","Munro 2025",2025,"Lancet Child Adolesc Health","180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial","RSV","Pediatric"
45,"#2667",0,0,1,0,1,0,0,0,0,"10.1016/j.jiac.2024.06.023",38959995,,"https://pubmed.ncbi.nlm.nih.gov/38959995","Nakayama 2025",2025,"J Infect Chemother","The efficacy and safety of a quadrivalent live attenuated influenza nasal vaccine in Japanese children: A phase 3, randomized, placebo-controlled study","Influenza","Pediatric"
46,"#10945",0,0,1,0,1,0,0,0,0,"10.1080/21645515.2024.2425149",39540202,"PMC11572236","https://pmc.ncbi.nlm.nih.gov/articles/PMC11572236","Wang 2024",2024,"Hum Vaccin Immunother","Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6-35 months of age in China: A randomized, double-blind, clinical trial","Influenza","Pediatric"
47,"#428",1,0,0,0,1,0,0,0,0,"10.1016/j.jinf.2025.106428",39874991,,"https://pubmed.ncbi.nlm.nih.gov/39874991","Bennett 2025",2025,"J Infect","Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial","COVID","Pediatric"
49,"#4486",0,1,0,1,1,0,0,0,0,"10.1007/s00431-024-05634-z",38910199,,"https://pubmed.ncbi.nlm.nih.gov/38910199","Alejandre 2024",2024,"Eur J Pediatr","Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care","RSV","Pediatric"
50,"#20369",1,1,1,1,1,0,0,0,0,"10.1097/inf.0000000000004866",40440707,,"https://pubmed.ncbi.nlm.nih.gov/40440707","Andersen 2025",2025,"Pediatr Infect Dis J","Clinical Outcomes in Children <5 Years of Age Hospitalized for Respiratory Syncytial Virus, COVID-19 or Influenza in the United States","COVID","Pediatric"
50,"#20369",1,1,1,1,1,0,0,0,0,"10.1097/inf.0000000000004866",40440707,,"https://pubmed.ncbi.nlm.nih.gov/40440707","Andersen 2025",2025,"Pediatr Infect Dis J","Clinical Outcomes in Children <5 Years of Age Hospitalized for Respiratory Syncytial Virus, COVID-19 or Influenza in the United States","RSV","Pediatric"
50,"#20369",1,1,1,1,1,0,0,0,0,"10.1097/inf.0000000000004866",40440707,,"https://pubmed.ncbi.nlm.nih.gov/40440707","Andersen 2025",2025,"Pediatr Infect Dis J","Clinical Outcomes in Children <5 Years of Age Hospitalized for Respiratory Syncytial Virus, COVID-19 or Influenza in the United States","Influenza","Pediatric"
51,"#13170",0,1,0,1,1,0,0,0,0,"10.1016/s1473-3099(24)00215-9",38701823,,"https://pubmed.ncbi.nlm.nih.gov/38701823","Ares-Gmez 2024",2024,"Lancet Infect Dis","Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","RSV","Pediatric"
52,"#4837",0,1,0,1,0,0,0,0,0,"10.3389/fpubh.2024.1441786",39220460,"PMC11361977","https://pmc.ncbi.nlm.nih.gov/articles/PMC11361977","BarbasDelBuey 2024",2024,"Front Public Health","The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study","RSV","Pediatric"
53,"#4960",1,0,0,0,1,0,0,0,0,"10.1093/cid/ciae420",39158584,"PMC11650855","https://pmc.ncbi.nlm.nih.gov/articles/PMC11650855","Berthaud 2024",2024,"Clin Infect Dis","Safety and Immunogenicity of an mRNA-1273 Booster in Children","COVID","Pediatric"
57,"#5255",0,1,0,1,1,0,0,0,0,"10.1016/s2352-4642(24)00171-8",39208832,,"https://pubmed.ncbi.nlm.nih.gov/39208832","Carbajal 2024",2024,"Lancet Child Adolesc Health","Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France","RSV","Pediatric"
58,"#633",0,1,0,1,1,0,0,0,0,"10.1097/inf.0000000000004715",39773919,,"https://pubmed.ncbi.nlm.nih.gov/39773919","Carcione 2025",2025,"Pediatr Infect Dis J","ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL-JULY 2024","RSV","Pediatric"
59,"#5520",1,0,0,0,1,0,0,0,0,"10.1111/petr.14786",38766983,,"https://pubmed.ncbi.nlm.nih.gov/38766983","Churilla 2024",2024,"Pediatr Transplant","Safety and infectious outcomes in pediatric kidney transplant recipients after COVID-19 vaccination: A pediatric nephrology research consortium study","COVID","Pediatric"
60,"#5560",0,1,0,1,0,0,0,0,0,"10.1136/archdischild-2024-327153",38857952,"PMC11347209","https://pmc.ncbi.nlm.nih.gov/articles/PMC11347209","Coma 2024",2024,"Arch Dis Child","Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)","RSV","Pediatric"
61,"#28053",1,0,0,0,1,0,0,0,0,"10.1038/s41467-024-47745-z",38802362,"PMC11130197","https://pmc.ncbi.nlm.nih.gov/articles/PMC11130197","Copland 2024",2024,"Nat Commun","Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England","COVID","Pediatric"
62,"#21167",0,0,1,1,1,0,0,0,0,"10.3390/vaccines13010042",39852821,"PMC11769184","https://pmc.ncbi.nlm.nih.gov/articles/PMC11769184","Dammann 2025",2025,"Vaccines (Basel)","Influenza Immunization in Very-Low-Birth-Weight Infants: Epidemiology and Long-Term Outcomes","Influenza","Pediatric"
63,"#5883",0,1,0,1,1,0,0,0,1,"10.1542/peds.2024-066508",39257380,,"https://pubmed.ncbi.nlm.nih.gov/39257380","Domachowske 2024",2024,"Pediatrics","Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children","RSV","Immunocomp"
64,"#6030",1,0,0,0,1,1,1,0,0,"10.1016/j.cegh.2024.101689",,,"https://doi.org/10.1016/j.cegh.2024.101689","ElHilali 2024",2024,"Clinical Epidemiology and Global Health","Adverse effects of COVID-19 vaccines in the Moroccan adults and children during the pandemic","COVID","Pediatric"
64,"#6030",1,0,0,0,1,1,1,0,0,"10.1016/j.cegh.2024.101689",,,"https://doi.org/10.1016/j.cegh.2024.101689","ElHilali 2024",2024,"Clinical Epidemiology and Global Health","Adverse effects of COVID-19 vaccines in the Moroccan adults and children during the pandemic","COVID","Adult"
65,"#1130",0,1,0,1,1,0,0,0,0,"10.3390/vaccines13060623",40573954,"PMC12197746","https://pmc.ncbi.nlm.nih.gov/articles/PMC12197746","Estrella-Porter 2025",2025,"Vaccines (Basel)","Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain's 2023-2024 RSV Immunisation Campaign","RSV","Pediatric"
66,"#1181",0,0,1,1,1,0,0,0,0,"10.15585/mmwr.mm7406a3",40014654,"PMC11867584","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867584","Fazal 2025",2025,"MMWR Morb Mortal Wkly Rep","Reports of Encephalopathy Among Children with Influenza-Associated Mortality - United States, 2010-11 Through 2024-25 Influenza Seasons","Influenza","Pediatric"
67,"#1407",1,0,0,1,1,0,0,0,0,"10.3238/arztebl.m2025.0032",40101263,,"https://pubmed.ncbi.nlm.nih.gov/40101263","Grieshaber 2025",2025,"Dtsch Arztebl Int","The Long-Term Tolerability of BNT162b2 in Children and Adolescents (the CoVacU18 Study)","COVID","Pediatric"
68,"#1574",1,0,0,0,1,0,0,0,0,"10.1007/s15010-024-02427-2",39527343,"PMC11971181","https://pmc.ncbi.nlm.nih.gov/articles/PMC11971181","Holzwarth 2025",2025,"Infection","PaedVacCOVID - safety of the BNT162b2 vaccine against the SARS-CoV-2 in children with and without comorbidities aged 5 to 11 years","COVID","Pediatric"
69,"#1900",1,0,0,0,1,0,0,0,0,"10.3346/jkms.2025.40.e10",39834222,"PMC11745927","https://pmc.ncbi.nlm.nih.gov/articles/PMC11745927","Kim 2025",2025,"J Korean Med Sci","Risk of Kawasaki Disease/Multisystem Inflammatory Syndrome Following COVID-19 Vaccination in Korean Children: A Self-Controlled Case Series Study","COVID","Pediatric"
70,"#7737",1,0,0,0,1,1,0,0,1,"10.24953/turkjpediatr.2024.4512",39387432,,"https://pubmed.ncbi.nlm.nih.gov/39387432","Kurucu 2024",2024,"Turk J Pediatr","Safety and efficacy of COVID-19 vaccines in children and adolescents with cancer","COVID","Immunocomp"
72,"#7891",0,0,1,0,1,0,0,0,0,"10.1016/j.jvacx.2024.100570",39886534,"PMC11780392","https://pmc.ncbi.nlm.nih.gov/articles/PMC11780392","Lee 2024",2024,"VACCINE: X","Influenza vaccine effectiveness against influenza-associated hospitalizations in children, Hong Kong, November 2023 to June 2024","Influenza","Pediatric"
73,"#2068",1,0,0,0,1,0,0,0,0,"10.1093/pch/pxae101",40756534,"PMC12316524","https://pmc.ncbi.nlm.nih.gov/articles/PMC12316524","Lee 2025",2025,"PAEDIATRICS & CHILD HEALTH","Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: A population-based study","COVID","Pediatric"
74,"#7907",0,1,0,1,1,0,0,0,0,"10.15585/mmwr.mm7345a1",39541241,"PMC11576050","https://pmc.ncbi.nlm.nih.gov/articles/PMC11576050","Lefferts 2024",2024,"MMWR Morb Mortal Wkly Rep","Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024","RSV","Pediatric"
75,"#8011",0,0,1,0,1,0,0,0,0,"10.3390/vaccines12030321",38543956,"PMC10975893","https://pmc.ncbi.nlm.nih.gov/articles/PMC10975893","Li 2024",2024,"Vaccines","Exploratory Study of the Phase IV Immunization Schedule of Quadrivalent Influenza Split-Virion Vaccine in Children Aged 38 Years","Influenza","Pediatric"
76,"#22825",1,0,0,0,1,0,0,0,0,"10.1016/j.jacig.2024.100387",39844915,"PMC11750530","https://pmc.ncbi.nlm.nih.gov/articles/PMC11750530","Lim 2025",2025,"J Allergy Clin Immunol Glob","Outcomes of pediatric patients with suspected allergies to COVID-19 vaccines","COVID","Pediatric"
77,"#2222",1,0,0,0,1,0,0,0,0,"10.1080/14740338.2024.2348568",38666296,,"https://pubmed.ncbi.nlm.nih.gov/38666296","Liu 2025",2025,"Expert Opin Drug Saf","Analysis of new-onset seizures following use of COVID-19 vaccinations in children based on VAERS","COVID","Pediatric"
78,"#16794",1,0,0,0,1,0,0,0,0,"10.1001/jamanetworkopen.2024.47492",39585698,"PMC11589793","https://pmc.ncbi.nlm.nih.gov/articles/PMC11589793","Madni 2024",2024,"JAMA Netw Open","COVID-19 Vaccine Reactogenicity Among Young Children","COVID","Pediatric"
79,"#11770",0,1,0,1,0,0,0,0,0,"10.1007/s00431-025-06050-7",40044918,,"https://pubmed.ncbi.nlm.nih.gov/40044918","Marouk 2025",2025,"Eur J Pediatr","Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3months: a retrospective study","RSV","Pediatric"
81,"#2559",0,1,0,1,1,0,0,0,0,"10.1001/jamapediatrics.2024.5572",39652359,"PMC11667569","https://pmc.ncbi.nlm.nih.gov/articles/PMC11667569","Moline 2025",2025,"JAMA Pediatr","Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024","RSV","Pediatric"
82,"#8693",1,0,0,0,1,0,0,0,0,"10.1186/s13293-024-00651-x",39327617,"PMC11426002","https://pmc.ncbi.nlm.nih.gov/articles/PMC11426002","Moor 2024",2024,"Biol Sex Differ","Sex differences in symptoms following the administration of BNT162b2 mRNA COVID-19 vaccine in children below 5 years of age in Germany (CoVacU5): a retrospective cohort study","COVID","Pediatric"
83,"#2751",0,1,0,1,1,0,0,0,0,"10.2807/1560-7917.Es.2025.30.5.2400596",39916606,,"https://pubmed.ncbi.nlm.nih.gov/39916606","Nez 2025",2025,"Euro Surveill","Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season","RSV","Pediatric"
85,"#2768",0,1,0,1,0,0,0,0,0,"10.1016/j.eclinm.2024.102986",39726670,"PMC11669793","https://pmc.ncbi.nlm.nih.gov/articles/PMC11669793","OcanadeSentuary 2025",2025,"eClinicalMedicine","Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France","RSV","Pediatric"
87,"#2916",0,1,0,1,1,0,0,0,0,"10.15585/mmwr.mm7416a1",40338822,"PMC12061057","https://pmc.ncbi.nlm.nih.gov/articles/PMC12061057","Patton 2025",2025,"MMWR Morb Mortal Wkly Rep","Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025","RSV","Pediatric"
88,"#2957",0,1,0,1,0,0,0,0,0,"10.1097/inf.0000000000004672",39823640,,"https://pubmed.ncbi.nlm.nih.gov/39823640","Perramon-Malavez 2025",2025,"Pediatr Infect Dis J","Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-related Outcomes in Hospital Care Settings: A Seasonal Cohort Study of Infants in Catalonia, Spain","RSV","Pediatric"
89,"#2956",0,1,0,1,1,0,0,0,0,"10.1016/j.lanepe.2025.101334",40950943,"PMC12426819","https://pmc.ncbi.nlm.nih.gov/articles/PMC12426819","Perramon-Malavez 2025",2025,"The Lancet Regional Health - Europe","Real-world impact of nirsevimab immunisation against respiratory disease on emergency department attendances and admissions among infants: a multinational retrospective analysis","RSV","Pediatric"
90,"#9295",1,0,0,0,1,0,0,0,0,"10.1016/j.vaccine.2024.06.057",39003104,,"https://pubmed.ncbi.nlm.nih.gov/39003104","Pham-Huy 2024",2024,"Vaccine","Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center","COVID","Pediatric"
92,"#23868",1,0,0,0,1,0,0,0,0,"10.3390/children12060678",40564636,"PMC12190996","https://pmc.ncbi.nlm.nih.gov/articles/PMC12190996","Prasertsakul 2025",2025,"Children (Basel)","Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study","COVID","Pediatric"
93,"#9612",0,0,1,0,1,0,0,0,0,"10.1016/j.vaccine.2025.126946",40023131,,"https://pubmed.ncbi.nlm.nih.gov/40023131","Rigamonti 2024",2024,"Vaccine","Real-World Effectiveness of Live Attenuated vs. Inactivated Influenza Vaccines in Children","Influenza","Pediatric"
94,"#3135",0,0,1,0,1,0,0,0,0,"10.1016/j.vaccine.2025.126946",40023131,,"https://pubmed.ncbi.nlm.nih.gov/40023131","Rigamonti 2025",2025,"Vaccine","Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children","Influenza","Pediatric"
95,"#3137",0,1,0,1,1,0,0,0,0,"10.1111/apa.70066",40135713,,"https://pubmed.ncbi.nlm.nih.gov/40135713","Rius-Peris 2025",2025,"Acta Paediatr","Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus-Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns","RSV","Pediatric"
97,"#10102",0,0,1,0,1,0,0,0,0,"10.3390/vaccines11101586",37896989,"PMC10611167","https://pmc.ncbi.nlm.nih.gov/articles/PMC10611167","Shi 2023",2023,"Vaccines","Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 38 Years","Influenza","Pediatric"
98,"#10114",0,0,1,0,1,0,0,0,0,"10.1016/j.vaccine.2024.126241",39178768,,"https://pubmed.ncbi.nlm.nih.gov/39178768","Shinjoh 2024",2024,"Vaccine","Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures","Influenza","Pediatric"
99,"#24371",0,0,1,0,1,0,0,0,0,"10.1016/j.vaccine.2025.127429",40578174,,"https://pubmed.ncbi.nlm.nih.gov/40578174","Shinjoh 2025",2025,"Vaccine","Influenza vaccination in Japanese children, 2024/25: Effectiveness of inactivated vaccine and limited use of newly introduced live-attenuated vaccine","Influenza","Pediatric"
100,"#18764",1,0,0,0,1,0,0,0,0,"10.1016/j.lana.2024.100949",39659558,"PMC11629564","https://pmc.ncbi.nlm.nih.gov/articles/PMC11629564","Soe 2024",2024,"Lancet Reg Health Am","mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study","COVID","Pediatric"
101,"#19017",1,0,0,0,1,0,0,0,0,"10.1001/jamanetworkopen.2024.49944",39666343,"PMC11638790","https://pmc.ncbi.nlm.nih.gov/articles/PMC11638790","Tartof 2024",2024,"JAMA Netw Open","BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age","COVID","Pediatric"
102,"#19044",0,0,1,0,1,1,1,0,0,"10.1093/cid/ciae597",39656838,"PMC12287760","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287760","Tenforde 2024",2024,"Clin Infect Dis","Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States","Influenza","Pediatric"
102,"#19044",0,0,1,0,1,1,1,0,0,"10.1093/cid/ciae597",39656838,"PMC12287760","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287760","Tenforde 2024",2024,"Clin Infect Dis","Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States","Influenza","Adult"
103,"#24752",1,0,0,1,1,0,0,0,0,"10.1016/j.jpeds.2025.114642",40373954,,"https://pubmed.ncbi.nlm.nih.gov/40373954","Top 2025",2025,"J Pediatr","Active Surveillance for Myocarditis and Pericarditis in Canadian Children from 2021 to 2022: A Canadian Immunization Monitoring Program ACTive Study","COVID","Pediatric"
104,"#3727",0,1,0,1,1,0,0,0,0,"10.1016/s1473-3099(25)00233-6",40513593,,"https://pubmed.ncbi.nlm.nih.gov/40513593","Torres 2025",2025,"Lancet Infect Dis","Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study","RSV","Pediatric"
105,"#3948",0,0,1,0,1,0,0,0,0,"10.1080/21645515.2025.2468074",39993940,"PMC11853548","https://pmc.ncbi.nlm.nih.gov/articles/PMC11853548","Wen 2025",2025,"Hum Vaccin Immunother","Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3-8 years with or without previous influenza vaccination histories","Influenza","Pediatric"
106,"#25149",1,0,0,0,1,1,0,0,0,"10.1016/j.eclinm.2024.102962",39720603,"PMC11667630","https://pmc.ncbi.nlm.nih.gov/articles/PMC11667630","Wu 2025",2025,"EClinicalMedicine","Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents","COVID","Pediatric"
106,"#25149",1,0,0,0,1,1,0,0,0,"10.1016/j.eclinm.2024.102962",39720603,"PMC11667630","https://pmc.ncbi.nlm.nih.gov/articles/PMC11667630","Wu 2025",2025,"EClinicalMedicine","Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents","COVID","Adult"
107,"#4131",1,0,0,0,1,0,0,0,0,"10.1001/jamanetworkopen.2024.59672",39992656,"PMC11851240","https://pmc.ncbi.nlm.nih.gov/articles/PMC11851240","Yousaf 2025",2025,"JAMA Netw Open","COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years","COVID","Pediatric"
109,"#4409",1,0,0,0,1,0,0,0,0,"10.3346/jkms.2024.39.e317",39716863,"PMC11666327","https://pmc.ncbi.nlm.nih.gov/articles/PMC11666327","Ahn 2024",2024,"J Korean Med Sci","Epidemiological Characteristics and Outcome of Myocarditis and Pericarditis Temporally Associated With BNT162b2 COVID-19 Vaccine in Adolescents: Korean National Surveillance","COVID","Pediatric"
111,"#13386",1,0,0,0,1,1,1,0,0,"10.1210/clinem/dgae858",39657695,,"https://pubmed.ncbi.nlm.nih.gov/39657695","Bea 2024",2024,"J Clin Endocrinol Metab","The Impact of COVID-19 Vaccination on Thyroid Disease in 7 Million Adult and 0.2 Million Adolescent Vaccine Recipients","COVID","Pediatric"
111,"#13386",1,0,0,0,1,1,1,0,0,"10.1210/clinem/dgae858",39657695,,"https://pubmed.ncbi.nlm.nih.gov/39657695","Bea 2024",2024,"J Clin Endocrinol Metab","The Impact of COVID-19 Vaccination on Thyroid Disease in 7 Million Adult and 0.2 Million Adolescent Vaccine Recipients","COVID","Adult"
112,"#6208",1,0,0,0,1,0,0,0,0,"10.1016/j.eclinm.2024.102720",39091673,"PMC11293523","https://pmc.ncbi.nlm.nih.gov/articles/PMC11293523","Figueroa 2024",2024,"eClinicalMedicine","Safety and durability of mRNA-1273induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial","COVID","Pediatric"
113,"#1212",1,0,0,0,1,0,0,0,0,"10.1016/s1473-3099(24)00501-2",39332418,,"https://pubmed.ncbi.nlm.nih.gov/39332418","Figueroa 2025",2025,"Lancet Infect Dis","Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial","COVID","Pediatric"
114,"#1210",1,0,0,0,1,0,0,0,0,"10.1080/21645515.2024.2436714",39836458,,"https://pubmed.ncbi.nlm.nih.gov/39836458","Figueroa 2025",2025,"Hum Vaccin Immunother","Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents","COVID","Pediatric"
115,"#6236",1,0,0,0,1,0,0,0,0,"10.1016/j.vaccine.2024.06.045",38910092,,"https://pubmed.ncbi.nlm.nih.gov/38910092","Fitzpatrick 2024",2024,"Vaccine","Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study","COVID","Pediatric"
116,"#7598",1,0,0,0,1,0,0,0,0,"10.24171/j.phrp.2024.0081",38988090,"PMC11391368","https://pmc.ncbi.nlm.nih.gov/articles/PMC11391368","Ko 2024",2024,"Osong Public Health and Research Perspectives","Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea","COVID","Pediatric"
119,"#3691",1,0,0,0,1,0,0,0,0,"10.1177/09612033251331244",40156281,,"https://pubmed.ncbi.nlm.nih.gov/40156281","Thepveera 2025",2025,"Lupus","Disease exacerbation and COVID-19 following mRNA COVID-19 vaccination in adolescents with Systemic Lupus Erythematosus","COVID","Pediatric"
120,"#25300",1,0,0,0,1,1,0,0,0,"10.1093/eurjcn/zvaf033",40085436,,"https://pubmed.ncbi.nlm.nih.gov/40085436","Yoon 2025",2025,"Eur J Cardiovasc Nurs","Health-related quality of life in adolescents with myocarditis and pericarditis after BNT162b2 COVID-19 vaccination: Korean national surveillance","COVID","Pediatric"
120,"#25300",1,0,0,0,1,1,0,0,0,"10.1093/eurjcn/zvaf033",40085436,,"https://pubmed.ncbi.nlm.nih.gov/40085436","Yoon 2025",2025,"Eur J Cardiovasc Nurs","Health-related quality of life in adolescents with myocarditis and pericarditis after BNT162b2 COVID-19 vaccination: Korean national surveillance","COVID","Adult"
121,"#38922",0,1,0,1,0,0,0,0,0,"10.3390/vaccines12101160",39460326,"PMC11510999","https://pmc.ncbi.nlm.nih.gov/articles/PMC11510999","JimenoRuiz 2024",2024,"Vaccines","Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain.","RSV","Pediatric"
122,"#4622",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2024.05.009",38762360,"PMC11252665","https://pmc.ncbi.nlm.nih.gov/articles/PMC11252665","AnnCostaClemens 2024",2024,"Vaccine","Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice","COVID","Adult"
123,"#4716",0,1,1,0,0,0,1,0,0,"10.1093/cid/ciad707",37992000,"PMC11093669","https://pmc.ncbi.nlm.nih.gov/articles/PMC11093669","Athan 2024",2024,"Clin Infect Dis","Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults","RSV","Adult"
123,"#4716",0,1,1,0,0,0,1,0,0,"10.1093/cid/ciad707",37992000,"PMC11093669","https://pmc.ncbi.nlm.nih.gov/articles/PMC11093669","Athan 2024",2024,"Clin Infect Dis","Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults","Influenza","Adult"
124,"#4880",1,0,1,0,0,1,1,0,0,"10.1016/j.vaccine.2024.03.061",38580516,,"https://pubmed.ncbi.nlm.nih.gov/38580516","Baum 2024",2024,"Vaccine","Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial","COVID","Adult"
124,"#4880",1,0,1,0,0,1,1,0,0,"10.1016/j.vaccine.2024.03.061",38580516,,"https://pubmed.ncbi.nlm.nih.gov/38580516","Baum 2024",2024,"Vaccine","Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial","Influenza","Adult"
125,"#416",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2025.127392",40561570,,"https://pubmed.ncbi.nlm.nih.gov/40561570","Beller 2025",2025,"Vaccine","Impact of the medical briefing and vaccine type on adverse events following COVID-19 vaccination: A randomized clinical trial","COVID","Adult"
126,"#4933",1,0,0,0,0,1,0,0,0,"10.1093/infdis/jiad508",39052718,"PMC11272042","https://pmc.ncbi.nlm.nih.gov/articles/PMC11272042","Bennett 2024",2024,"J Infect Dis","Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial","COVID","Adult"
127,"#4932",1,0,0,0,0,1,0,0,1,"10.1016/j.jinf.2024.106285",39343247,,"https://pubmed.ncbi.nlm.nih.gov/39343247","Bennett 2024",2024,"J Infect","Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial","COVID","Immunocomp"
128,"#5191",0,1,0,0,0,0,1,0,0,"10.1007/s40121-024-00985-4",38981954,"PMC11266338","https://pmc.ncbi.nlm.nih.gov/articles/PMC11266338","Buynak 2024",2024,"Infectious Diseases and Therapy","Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged  65","RSV","Adult"
129,"#5332",1,0,0,0,0,1,0,0,0,"10.1093/infdis/jiae067",38349280,"PMC11326827","https://pmc.ncbi.nlm.nih.gov/articles/PMC11326827","Chalkias 2024",2024,"J Infect Dis","Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines","COVID","Adult"
130,"#13821",0,1,0,0,0,0,1,0,0,"10.1093/cid/ciad786",38189778,,"https://pubmed.ncbi.nlm.nih.gov/38189778","Chandler 2024",2024,"Clin Infect Dis","Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial","RSV","Adult"
131,"#763",0,1,1,0,0,1,0,0,0,"10.1093/infdis/jiae342",38970327,"PMC11793055","https://pmc.ncbi.nlm.nih.gov/articles/PMC11793055","Chime 2025",2025,"J Infect Dis","Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine","RSV","Adult"
131,"#763",0,1,1,0,0,1,0,0,0,"10.1093/infdis/jiae342",38970327,"PMC11793055","https://pmc.ncbi.nlm.nih.gov/articles/PMC11793055","Chime 2025",2025,"J Infect Dis","Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine","Influenza","Adult"
132,"#5532",0,1,1,0,0,0,1,0,0,"10.1093/cid/ciae365",39099085,"PMC11478588","https://pmc.ncbi.nlm.nih.gov/articles/PMC11478588","Clark 2024",2024,"Clin Infect Dis","Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial","RSV","Adult"
132,"#5532",0,1,1,0,0,0,1,0,0,"10.1093/cid/ciae365",39099085,"PMC11478588","https://pmc.ncbi.nlm.nih.gov/articles/PMC11478588","Clark 2024",2024,"Clin Infect Dis","Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial","Influenza","Adult"
134,"#907",0,1,0,0,0,1,0,0,0,"10.1093/cid/ciae550",39523547,"PMC12043053","https://pmc.ncbi.nlm.nih.gov/articles/PMC12043053","Davis 2025",2025,"Clin Infect Dis","Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions","RSV","Adult"
135,"#5965",1,0,1,0,0,1,1,0,0,"10.1016/j.lanepe.2023.100628",37261212,"PMC10091277","https://pmc.ncbi.nlm.nih.gov/articles/PMC10091277","Dulfer 2023",2023,"The Lancet Regional Health - Europe","Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial","COVID","Adult"
135,"#5965",1,0,1,0,0,1,1,0,0,"10.1016/j.lanepe.2023.100628",37261212,"PMC10091277","https://pmc.ncbi.nlm.nih.gov/articles/PMC10091277","Dulfer 2023",2023,"The Lancet Regional Health - Europe","Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial","Influenza","Adult"
136,"#6180",0,1,0,0,0,1,1,0,0,"10.1093/cid/ciae364",39099093,"PMC11478578","https://pmc.ncbi.nlm.nih.gov/articles/PMC11478578","Ferguson 2024",2024,"Clin Infect Dis","Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to 60 Years of Age","RSV","Adult"
137,"#6376",0,0,1,0,1,1,0,0,0,"10.1016/j.vaccine.2024.126182",39116486,,"https://pubmed.ncbi.nlm.nih.gov/39116486","Gao 2024",2024,"Vaccine","Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial","Influenza","Pediatric"
137,"#6376",0,0,1,0,1,1,0,0,0,"10.1016/j.vaccine.2024.126182",39116486,,"https://pubmed.ncbi.nlm.nih.gov/39116486","Gao 2024",2024,"Vaccine","Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial","Influenza","Adult"
138,"#6524",1,0,0,0,0,1,1,0,1,"10.1016/s2665-9913(24)00065-1",38734019,,"https://pubmed.ncbi.nlm.nih.gov/38734019","Goodyear 2024",2024,"Lancet Rheumatol","Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial","COVID","Immunocomp"
139,"#1388",1,1,1,0,0,1,1,0,0,"10.1016/s1473-3099(24)00589-9",39608389,,"https://pubmed.ncbi.nlm.nih.gov/39608389","Goswami 2025",2025,"Lancet Infect Dis","Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial","COVID","Adult"
139,"#1388",1,1,1,0,0,1,1,0,0,"10.1016/s1473-3099(24)00589-9",39608389,,"https://pubmed.ncbi.nlm.nih.gov/39608389","Goswami 2025",2025,"Lancet Infect Dis","Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial","RSV","Adult"
139,"#1388",1,1,1,0,0,1,1,0,0,"10.1016/s1473-3099(24)00589-9",39608389,,"https://pubmed.ncbi.nlm.nih.gov/39608389","Goswami 2025",2025,"Lancet Infect Dis","Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial","Influenza","Adult"
140,"#1665",0,1,0,0,0,1,1,0,0,"10.1016/s2213-2600(25)00048-7",40245915,,"https://pubmed.ncbi.nlm.nih.gov/40245915","Ison 2025",2025,"Lancet Respir Med","Efficacy, safety, and immunogenicity of the AS01(E)-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial","RSV","Adult"
141,"#1705",0,1,0,0,0,1,1,0,0,"10.1016/j.vaccine.2024.126514",39536455,,"https://pubmed.ncbi.nlm.nih.gov/39536455","Jastorff 2025",2025,"Vaccine","Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial","RSV","Adult"
142,"#1761",1,0,0,0,0,1,1,0,0,"10.1016/j.jinf.2024.106405",39756693,,"https://pubmed.ncbi.nlm.nih.gov/39756693","Jorda 2025",2025,"J Infect","Immunogenicity, safety, and reactogenicity of concomitant administration of the novavax vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent pneumococcal conjugate vaccine in adults aged 60 years: A randomised, double-blind, placebo-controlled, non-inferiority trial","COVID","Adult"
143,"#1798",0,0,1,0,0,1,1,0,0,"10.1080/21645515.2025.2484088",40174609,"PMC11970786","https://pmc.ncbi.nlm.nih.gov/articles/PMC11970786","Kandinov 2025",2025,"Hum Vaccin Immunother","An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers","Influenza","Adult"
144,"#7465",1,0,0,0,0,1,1,0,0,"10.1016/j.jaci.2024.03.001",38460680,"PMC11162316","https://pmc.ncbi.nlm.nih.gov/articles/PMC11162316","Khalid 2024",2024,"J Allergy Clin Immunol","A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination","COVID","Adult"
145,"#2378",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2024.126569",39643572,,"https://pubmed.ncbi.nlm.nih.gov/39643572","Marchese 2025",2025,"Vaccine","Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)","COVID","Adult"
147,"#8551",0,0,1,0,0,1,1,0,1,"10.15789/2220-7619-SAE-17550",,,"https://doi.org/10.15789/2220-7619-SAE-17550","Meidani 2024",2024,"Russian Journal of Infection and Immunity","SAFETY AND EFFECTIVENESS OF SINGLE- VERSUS DOUBLE-DOSE OF SEASONAL INFLUENZA VACCINE IN KIDNEY TRANSPLANT RECIPIENTS: A RANDOMIZED CLINICAL TRIAL","Influenza","Immunocomp"
148,"#2581",1,0,0,0,0,1,0,0,0,"10.1016/j.lana.2025.101031",40083966,"PMC11904515","https://pmc.ncbi.nlm.nih.gov/articles/PMC11904515","MoreiraPuga 2025",2025,"The Lancet Regional Health - Americas","Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil","COVID","Adult"
149,"#8828",1,0,1,0,0,1,1,0,0,"10.1080/21645515.2024.2327736",38513689,"PMC10962584","https://pmc.ncbi.nlm.nih.gov/articles/PMC10962584","Naficy 2024",2024,"Hum Vaccin Immunother","No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial","COVID","Adult"
149,"#8828",1,0,1,0,0,1,1,0,0,"10.1080/21645515.2024.2327736",38513689,"PMC10962584","https://pmc.ncbi.nlm.nih.gov/articles/PMC10962584","Naficy 2024",2024,"Hum Vaccin Immunother","No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial","Influenza","Adult"
150,"#2779",1,0,0,0,0,1,1,0,0,"10.1016/s1473-3099(24)00565-6",39461355,,"https://pubmed.ncbi.nlm.nih.gov/39461355","Okada 2025",2025,"Lancet Infect Dis","Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial","COVID","Adult"
151,"#9379",0,0,1,0,0,1,0,0,0,"10.1016/j.vaccine.2023.11.050",38042698,"PMC10733862","https://pmc.ncbi.nlm.nih.gov/articles/PMC10733862","Prasert 2024",2024,"Vaccine","Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial","Influenza","Adult"
152,"#9507",1,0,1,0,0,1,1,0,0,"10.1016/j.vaccine.2023.10.050",37903680,,"https://pubmed.ncbi.nlm.nih.gov/37903680","Ramsay 2023",2023,"Vaccine","A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)","COVID","Adult"
152,"#9507",1,0,1,0,0,1,1,0,0,"10.1016/j.vaccine.2023.10.050",37903680,,"https://pubmed.ncbi.nlm.nih.gov/37903680","Ramsay 2023",2023,"Vaccine","A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)","Influenza","Adult"
153,"#3188",1,0,1,0,0,1,1,0,0,"10.1001/jama.2025.5646",40332892,"PMC12060023","https://pmc.ncbi.nlm.nih.gov/articles/PMC12060023","RudmanSpergel 2025",2025,"Jama","Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults 50 Years: A Randomized Clinical Trial","COVID","Adult"
153,"#3188",1,0,1,0,0,1,1,0,0,"10.1001/jama.2025.5646",40332892,"PMC12060023","https://pmc.ncbi.nlm.nih.gov/articles/PMC12060023","RudmanSpergel 2025",2025,"Jama","Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults 50 Years: A Randomized Clinical Trial","Influenza","Adult"
154,"#9910",0,0,1,0,0,0,1,0,0,"10.1001/jamanetworkopen.2024.40817",39446325,"PMC11581605","https://pmc.ncbi.nlm.nih.gov/articles/PMC11581605","Schmader 2024",2024,"JAMA Netw Open","Safety of Simultaneous Vaccination With Adjuvanted Zoster Vaccine and Adjuvanted Influenza Vaccine: A Randomized Clinical Trial","Influenza","Adult"
156,"#3484",0,0,1,0,0,1,1,0,0,"10.1016/j.vaccine.2025.126847",39919447,,"https://pubmed.ncbi.nlm.nih.gov/39919447","Soens 2025",2025,"Vaccine","A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults","Influenza","Adult"
157,"#3665",1,0,1,0,0,1,1,0,0,"10.1016/j.eclinm.2024.103016",39866854,"PMC11764035","https://pmc.ncbi.nlm.nih.gov/articles/PMC11764035","Tapia-Calle 2025",2025,"eClinicalMedicine","Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial","COVID","Adult"
157,"#3665",1,0,1,0,0,1,1,0,0,"10.1016/j.eclinm.2024.103016",39866854,"PMC11764035","https://pmc.ncbi.nlm.nih.gov/articles/PMC11764035","Tapia-Calle 2025",2025,"eClinicalMedicine","Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial","Influenza","Adult"
159,"#10879",1,0,1,0,1,1,1,0,0,"10.1001/jamanetworkopen.2024.43166",39504023,"PMC11541642","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541642","Walter 2024",2024,"JAMA Netw Open","Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial","COVID","Pediatric"
159,"#10879",1,0,1,0,1,1,1,0,0,"10.1001/jamanetworkopen.2024.43166",39504023,"PMC11541642","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541642","Walter 2024",2024,"JAMA Netw Open","Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial","Influenza","Pediatric"
159,"#10879",1,0,1,0,1,1,1,0,0,"10.1001/jamanetworkopen.2024.43166",39504023,"PMC11541642","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541642","Walter 2024",2024,"JAMA Netw Open","Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial","COVID","Adult"
159,"#10879",1,0,1,0,1,1,1,0,0,"10.1001/jamanetworkopen.2024.43166",39504023,"PMC11541642","https://pmc.ncbi.nlm.nih.gov/articles/PMC11541642","Walter 2024",2024,"JAMA Netw Open","Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial","Influenza","Adult"
161,"#8982",1,0,0,0,0,1,1,0,0,"10.29399/npa.28418",39258123,"PMC11382557","https://pmc.ncbi.nlm.nih.gov/articles/PMC11382557","cek 2024",2024,"Noropsikiyatri Arsivi","Evaluation of Clinical Effects of COVID-19 Infection and Vaccines on Myasthenia Gravis","COVID","Adult"
162,"#9094",1,0,0,0,1,1,0,0,0,"10.5114/pja.2024.138498",,,"https://doi.org/10.5114/pja.2024.138498","zdemir 2024",2024,"Alergologia Polska - Polish Journal of Allergology","The effect of COVID-19 and COVID-19 vaccines on chronic spontaneous urticaria: single center experience","COVID","Pediatric"
162,"#9094",1,0,0,0,1,1,0,0,0,"10.5114/pja.2024.138498",,,"https://doi.org/10.5114/pja.2024.138498","zdemir 2024",2024,"Alergologia Polska - Polish Journal of Allergology","The effect of COVID-19 and COVID-19 vaccines on chronic spontaneous urticaria: single center experience","COVID","Adult"
163,"#4695",1,0,0,0,0,1,0,0,0,"10.1007/s13760-024-02536-7",38619748,,"https://pubmed.ncbi.nlm.nih.gov/38619748","A_knTuran 2024",2024,"Acta Neurol Belg","A retrospective cohort study: is COVID-19 BNT162b2 mRNA vaccination a trigger factor for cluster headache?","COVID","Adult"
164,"#19",1,0,0,0,0,1,1,0,0,"10.1186/s12889-025-21765-w",40055620,"PMC11889865","https://pmc.ncbi.nlm.nih.gov/articles/PMC11889865","AbdulRahim 2025",2025,"BMC Public Health","Association of COVID-19 infection and COVID-19 vaccination with idiopathic sudden sensorineural hearing loss in Malaysia: a case-control study","COVID","Adult"
165,"#4320",1,0,0,0,0,1,1,0,0,,,,"https://scielo.sld.cu/pdf/vac/v33/1025-0298-vac-33-e073324.pdf","Abdurakhmanov 2024",2024,"VacciMonitor","Effect of inactivated and mRNA COVID-19 vaccines on thrombocytopenia in immune thrombocytopenia patients","COVID","Adult"
166,"#24",0,0,1,0,1,1,1,0,0,"10.1080/22221751.2025.2466699",40071892,"PMC11980197","https://pmc.ncbi.nlm.nih.gov/articles/PMC11980197","AbouChakra 2025",2025,"Emerg Microbes Infect","Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024","Influenza","Pediatric"
166,"#24",0,0,1,0,1,1,1,0,0,"10.1080/22221751.2025.2466699",40071892,"PMC11980197","https://pmc.ncbi.nlm.nih.gov/articles/PMC11980197","AbouChakra 2025",2025,"Emerg Microbes Infect","Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024","Influenza","Adult"
167,"#4303",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2024.126465",39447251,,"https://pubmed.ncbi.nlm.nih.gov/39447251","AbRahman 2024",2024,"Vaccine","Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study","COVID","Adult"
168,"#4340",1,0,0,0,1,1,1,0,0,"10.2147/IJGM.S466838",39100722,"PMC11297544","https://pmc.ncbi.nlm.nih.gov/articles/PMC11297544","Abukhalil 2024",2024,"International Journal of General Medicine","COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine","COVID","Pediatric"
168,"#4340",1,0,0,0,1,1,1,0,0,"10.2147/IJGM.S466838",39100722,"PMC11297544","https://pmc.ncbi.nlm.nih.gov/articles/PMC11297544","Abukhalil 2024",2024,"International Journal of General Medicine","COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine","COVID","Adult"
169,"#36",1,0,0,0,0,0,1,0,0,"10.1093/gerona/glaf108",40371440,"PMC12202091","https://pmc.ncbi.nlm.nih.gov/articles/PMC12202091","Abul 2025",2025,"J Gerontol A Biol Sci Med Sci","Incidence of Long COVID Diagnoses in 3.6 Million U.S. Medicare Beneficiaries With COVID-19","COVID","Adult"
170,"#40",0,0,1,0,0,1,1,0,0,"10.3390/vaccines13030309",40266236,"PMC11946095","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946095","AcutiMartellucci 2025",2025,"Vaccines","The Effectiveness of Four Quadrivalent, Inactivated Influenza Vaccines Administered Alone or in Combination with Pneumococcal and/or SARS-CoV-2 Vaccines: A Population-Wide Cohort Study","Influenza","Adult"
171,"#46",1,0,0,0,0,1,0,0,0,"10.1016/j.jaci.2025.03.015",40154575,,"https://pubmed.ncbi.nlm.nih.gov/40154575","Adelglass 2025",2025,"J Allergy Clin Immunol","Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses","COVID","Adult"
172,"#4362",1,0,0,0,0,1,1,0,0,"10.1097/mnm.0000000000001833",38465449,,"https://pubmed.ncbi.nlm.nih.gov/38465449","Adin 2024",2024,"Nucl Med Commun","Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines","COVID","Adult"
173,"#4368",1,0,0,0,1,1,1,0,0,"10.1016/j.ophtha.2024.01.020",38242364,,"https://pubmed.ncbi.nlm.nih.gov/38242364","Aftab 2024",2024,"Ophthalmology","Ophthalmologic Complications in Coronavirus Disease 2019 Immunization: A National Vaccine Adverse Event Reporting System Analysis","COVID","Pediatric"
173,"#4368",1,0,0,0,1,1,1,0,0,"10.1016/j.ophtha.2024.01.020",38242364,,"https://pubmed.ncbi.nlm.nih.gov/38242364","Aftab 2024",2024,"Ophthalmology","Ophthalmologic Complications in Coronavirus Disease 2019 Immunization: A National Vaccine Adverse Event Reporting System Analysis","COVID","Adult"
174,"#77",1,0,0,0,0,1,1,0,0,"10.1016/j.cegh.2025.101975",,,"https://doi.org/10.1016/j.cegh.2025.101975","AhmedAlQahtani 2025",2025,"Clinical Epidemiology and Global Health","Short and long-term side effects of eligible COVID-19 vaccines in Saudi Arabia, Southern Region, 2023","COVID","Adult"
176,"#4459",1,0,0,0,1,1,1,0,0,"10.1016/j.imu.2024.101564",,,"https://doi.org/10.1016/j.imu.2024.101564","Al-Rousan 2024",2024,"Informatics in Medicine Unlocked","Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis","COVID","Pediatric"
176,"#4459",1,0,0,0,1,1,1,0,0,"10.1016/j.imu.2024.101564",,,"https://doi.org/10.1016/j.imu.2024.101564","Al-Rousan 2024",2024,"Informatics in Medicine Unlocked","Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis","COVID","Adult"
177,"#4476",1,0,0,0,0,1,0,0,0,"10.2147/IJWH.S472953",39421715,"PMC11484768","https://pmc.ncbi.nlm.nih.gov/articles/PMC11484768","Alawfi 2024",2024,"International Journal of Women's Health","Health of Saudi Women in the Post-Pandemic Era: Candidiasis Incidence and Post COVID-19 and COVID-19-Vaccination","COVID","Adult"
178,"#119",1,0,0,0,0,1,1,0,0,"10.1016/j.rcsop.2025.100614",40502459,"PMC12152863","https://pmc.ncbi.nlm.nih.gov/articles/PMC12152863","Albahari 2025",2025,"Exploratory Research in Clinical and Social Pharmacy","Impact of mRNA COVID-19 vaccination on hematological parameters in patients maintained on clozapine: A retrospective study from Qatar","COVID","Adult"
180,"#13033",1,0,0,0,1,1,0,0,0,"10.4103/heartviews.heartviews_62_24",40488147,"PMC12139649","https://pmc.ncbi.nlm.nih.gov/articles/PMC12139649","Ali 2024",2024,"Heart Views","A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination","COVID","Pediatric"
180,"#13033",1,0,0,0,1,1,0,0,0,"10.4103/heartviews.heartviews_62_24",40488147,"PMC12139649","https://pmc.ncbi.nlm.nih.gov/articles/PMC12139649","Ali 2024",2024,"Heart Views","A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination","COVID","Adult"
182,"#156",0,1,0,0,0,1,1,0,1,"10.3390/vaccines13030328",40266222,"PMC11946143","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946143","Almeida 2025",2025,"Vaccines","Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults","RSV","Immunocomp"
183,"#4532",1,0,0,0,0,1,1,0,0,"10.1016/j.vacun.2024.04.004",,,"https://doi.org/10.1016/j.vacun.2024.04.004","Almodvar-Fernndez 2024",2024,"Vacunas","SARS-CoV-2 vaccination effect over coagulation in 60s patients treated with acenocumarol","COVID","Adult"
184,"#177",1,0,0,0,0,1,1,0,0,"10.1016/s1473-3099(24)00670-4",39824198,,"https://pubmed.ncbi.nlm.nih.gov/39824198","Alves 2025",2025,"Lancet Infect Dis","Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study","COVID","Adult"
185,"#178",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2025.127046",40184816,,"https://pubmed.ncbi.nlm.nih.gov/40184816","Alves 2025",2025,"Vaccine","Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study","COVID","Adult"
186,"#183",0,0,1,0,1,1,1,0,0,"10.1080/21645515.2025.2475616",40098448,,"https://pubmed.ncbi.nlm.nih.gov/40098448","AmaraldeAvilaMachado 2025",2025,"Hum Vaccin Immunother","Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season","Influenza","Pediatric"
186,"#183",0,0,1,0,1,1,1,0,0,"10.1080/21645515.2025.2475616",40098448,,"https://pubmed.ncbi.nlm.nih.gov/40098448","AmaraldeAvilaMachado 2025",2025,"Hum Vaccin Immunother","Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season","Influenza","Adult"
187,"#4579",0,0,1,0,0,0,1,0,0,"10.1080/21645515.2023.2190279",36919537,"PMC10072113","https://pmc.ncbi.nlm.nih.gov/articles/PMC10072113","Amicizia 2023",2023,"Hum Vaccin Immunother","Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season","Influenza","Adult"
188,"#4590",1,0,0,0,1,1,1,0,1,"10.1093/infdis/jiae291",38848312,"PMC11481330","https://pmc.ncbi.nlm.nih.gov/articles/PMC11481330","Amstutz 2024",2024,"J Infect Dis","Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study","COVID","Immunocomp"
189,"#202",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2025.126881",39987879,,"https://pubmed.ncbi.nlm.nih.gov/39987879","Andersen 2025",2025,"Vaccine","Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states","COVID","Adult"
190,"#13126",1,0,0,0,0,0,1,0,0,"10.1136/bmjmed-2024-001074",39902239,"PMC11789462","https://pmc.ncbi.nlm.nih.gov/articles/PMC11789462","Andersson 2024",2024,"BMJ Med","Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data","COVID","Adult"
192,"#4633",1,0,0,0,0,1,1,0,0,"10.1111/irv.13360",39145535,"PMC11325250","https://pmc.ncbi.nlm.nih.gov/articles/PMC11325250","Antunes 2024",2024,"Influenza Other Respir Viruses","Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024","COVID","Adult"
194,"#233",1,0,0,0,0,1,1,0,0,"10.1038/s41467-025-59344-7",40301395,"PMC12041242","https://pmc.ncbi.nlm.nih.gov/articles/PMC12041242","Appaneal 2025",2025,"Nat Commun","Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System","COVID","Adult"
195,"#20412",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2025.127337",40479930,,"https://pubmed.ncbi.nlm.nih.gov/40479930","Arcolaci 2025",2025,"Vaccine","A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines","COVID","Adult"
196,"#244",1,0,0,0,0,1,1,0,0,"10.1097/iae.0000000000004413",39841907,,"https://pubmed.ncbi.nlm.nih.gov/39841907","Arepalli 2025",2025,"Retina","THE HETEROGENEOUS PRESENTATIONS OF DE NOVO AND RECURRENT OCULAR INFLAMMATION AFTER COVID-19 VACCINATION : A Multicenter Report and a Review of the Literature","COVID","Adult"
197,"#20449",1,0,0,0,0,1,1,0,0,"10.2147/ijgm.S520084",40547349,,"https://pubmed.ncbi.nlm.nih.gov/40547349","Asiri 2025",2025,"Int J Gen Med","Adverse Cutaneous Reactions Following COVID-19 Vaccination Among Patients with Pre-Existing Urticaria: A Cross-Sectional Study at a Tertiary Care Center in Saudi Arabia","COVID","Adult"
198,"#290",1,0,0,0,1,1,1,0,0,"10.1371/journal.pone.0311459",40173404,"PMC11964452","https://pmc.ncbi.nlm.nih.gov/articles/PMC11964452","Awasthi 2025",2025,"PLoS One","Emergence to dominance: Estimating time to dominance of SARS-CoV-2 variants using nonlinear statistical models","COVID","Pediatric"
198,"#290",1,0,0,0,1,1,1,0,0,"10.1371/journal.pone.0311459",40173404,"PMC11964452","https://pmc.ncbi.nlm.nih.gov/articles/PMC11964452","Awasthi 2025",2025,"PLoS One","Emergence to dominance: Estimating time to dominance of SARS-CoV-2 variants using nonlinear statistical models","COVID","Adult"
199,"#4742",1,0,1,0,0,1,1,0,0,"10.1080/22221751.2023.2292068",38054302,"PMC10798284","https://pmc.ncbi.nlm.nih.gov/articles/PMC10798284","Aydillo 2024",2024,"Emerg Microbes Infect","Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines","COVID","Adult"
199,"#4742",1,0,1,0,0,1,1,0,0,"10.1080/22221751.2023.2292068",38054302,"PMC10798284","https://pmc.ncbi.nlm.nih.gov/articles/PMC10798284","Aydillo 2024",2024,"Emerg Microbes Infect","Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines","Influenza","Adult"
200,"#4744",1,0,0,0,0,1,0,0,0,"10.52142/omujecm.41.2.13",,,"https://doi.org/10.52142/omujecm.41.2.13","Aydin 2024",2024,"Journal of Experimental and Clinical Medicine (Turkey)","Effect of COVID-19 mRNA vaccine on serum AMH, TSH, FSH and LH concentrations","COVID","Adult"
201,"#4765",1,0,0,0,1,1,1,0,0,"10.1111/1346-8138.17188",38605482,,"https://pubmed.ncbi.nlm.nih.gov/38605482","Baba 2024",2024,"J Dermatol","Cutaneous adverse events following COVID-19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies","COVID","Pediatric"
201,"#4765",1,0,0,0,1,1,1,0,0,"10.1111/1346-8138.17188",38605482,,"https://pubmed.ncbi.nlm.nih.gov/38605482","Baba 2024",2024,"J Dermatol","Cutaneous adverse events following COVID-19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies","COVID","Adult"
202,"#314",1,0,0,0,0,1,1,0,0,"10.1016/j.lana.2024.100984",39866362,"PMC11764319","https://pmc.ncbi.nlm.nih.gov/articles/PMC11764319","Babalola 2025",2025,"The Lancet Regional Health - Americas","SARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: a retrospective cohort study","COVID","Adult"
203,"#4774",1,0,0,0,0,1,1,0,0,"10.1038/s41467-024-50376-z",39209823,"PMC11362294","https://pmc.ncbi.nlm.nih.gov/articles/PMC11362294","Baden 2024",2024,"Nat Commun","Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases","COVID","Adult"
204,"#328",0,0,1,0,1,0,0,0,1,"10.1093/infdis/jiae454",39279435,"PMC11793066","https://pmc.ncbi.nlm.nih.gov/articles/PMC11793066","Bahakel 2025",2025,"J Infect Dis","Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season","Influenza","Immunocomp"
205,"#338",0,1,0,0,0,0,1,0,1,"10.1016/S1473-3099(24)00796-5",39848264,,"https://pubmed.ncbi.nlm.nih.gov/39848264","Bajema 2025",2025,"LANCET INFECTIOUS DISEASES","Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study","RSV","Immunocomp"
206,"#337",1,1,1,0,0,1,1,0,0,"10.1001/jamainternmed.2024.7452",39869355,"PMC11773409","https://pmc.ncbi.nlm.nih.gov/articles/PMC11773409","Bajema 2025",2025,"JAMA Intern Med","Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus","COVID","Adult"
206,"#337",1,1,1,0,0,1,1,0,0,"10.1001/jamainternmed.2024.7452",39869355,"PMC11773409","https://pmc.ncbi.nlm.nih.gov/articles/PMC11773409","Bajema 2025",2025,"JAMA Intern Med","Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus","RSV","Adult"
206,"#337",1,1,1,0,0,1,1,0,0,"10.1001/jamainternmed.2024.7452",39869355,"PMC11773409","https://pmc.ncbi.nlm.nih.gov/articles/PMC11773409","Bajema 2025",2025,"JAMA Intern Med","Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus","Influenza","Adult"
207,"#367",1,0,0,0,0,1,1,0,0,"10.1016/j.neurol.2025.04.007",40307085,,"https://pubmed.ncbi.nlm.nih.gov/40307085","Barnay 2025",2025,"Rev Neurol (Paris)","The safety of COVID-19 vaccines in a large French series of patients with neuromuscular conditions and the impacts of vaccination on their daily lives","COVID","Adult"
208,"#4849",1,0,1,0,0,1,1,0,0,"10.1093/ofid/ofae144",38567194,"PMC10986856","https://pmc.ncbi.nlm.nih.gov/articles/PMC10986856","Barouch 2024",2024,"Open Forum Infectious Diseases","Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses","COVID","Adult"
208,"#4849",1,0,1,0,0,1,1,0,0,"10.1093/ofid/ofae144",38567194,"PMC10986856","https://pmc.ncbi.nlm.nih.gov/articles/PMC10986856","Barouch 2024",2024,"Open Forum Infectious Diseases","Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses","Influenza","Adult"
209,"#4877",1,0,0,0,0,1,1,0,0,"10.1089/derm.2023.0379",38535725,,"https://pubmed.ncbi.nlm.nih.gov/38535725","Battis 2024",2024,"Dermatitis","Patient-Reported Association Between COVID-19 Infection or Vaccination and Onset of Allergic Contact Dermatitis","COVID","Adult"
210,"#4916",1,0,0,0,0,0,0,0,1,"10.1007/s40264-024-01449-x",38907947,"PMC11399172","https://pmc.ncbi.nlm.nih.gov/articles/PMC11399172","Bellitto 2024",2024,"Drug Saf","What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European ""Covid Vaccine Monitor"" Active Surveillance Study","COVID","Immunocomp"
211,"#13419",1,0,0,0,0,1,1,0,1,"10.1177/10781552241285034",39285730,,"https://pubmed.ncbi.nlm.nih.gov/39285730","BenKridis 2024",2024,"J Oncol Pharm Pract","Local and systemic side effects of COVID-19 vaccine in Tunisian cancer patients: A prospective single center study","COVID","Immunocomp"
212,"#448",1,0,0,0,1,1,1,0,0,"10.1016/j.therap.2024.08.002",39294069,,"https://pubmed.ncbi.nlm.nih.gov/39294069","Beurrier 2025",2025,"Therapie","Retinal vascular occlusion after COVID-19 vaccination: Analysis of the French pharmacovigilance database","COVID","Pediatric"
212,"#448",1,0,0,0,1,1,1,0,0,"10.1016/j.therap.2024.08.002",39294069,,"https://pubmed.ncbi.nlm.nih.gov/39294069","Beurrier 2025",2025,"Therapie","Retinal vascular occlusion after COVID-19 vaccination: Analysis of the French pharmacovigilance database","COVID","Adult"
213,"#4993",0,1,1,0,0,1,1,0,0,"10.1016/j.vaccine.2024.03.060",38531725,,"https://pubmed.ncbi.nlm.nih.gov/38531725","Biegus 2024",2024,"Vaccine","The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure","RSV","Adult"
213,"#4993",0,1,1,0,0,1,1,0,0,"10.1016/j.vaccine.2024.03.060",38531725,,"https://pubmed.ncbi.nlm.nih.gov/38531725","Biegus 2024",2024,"Vaccine","The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure","Influenza","Adult"
215,"#470",1,0,0,0,1,1,1,0,0,"10.2459/jcm.0000000000001693",39976066,,"https://pubmed.ncbi.nlm.nih.gov/39976066","Birtolo 2025",2025,"J Cardiovasc Med (Hagerstown)","Myocarditis and pericarditis during COVID-19 pandemic: a study of the Italian Society of Cardiology","COVID","Pediatric"
215,"#470",1,0,0,0,1,1,1,0,0,"10.2459/jcm.0000000000001693",39976066,,"https://pubmed.ncbi.nlm.nih.gov/39976066","Birtolo 2025",2025,"J Cardiovasc Med (Hagerstown)","Myocarditis and pericarditis during COVID-19 pandemic: a study of the Italian Society of Cardiology","COVID","Adult"
216,"#484",0,0,1,0,0,0,1,0,0,"10.2807/1560-7917.Es.2025.30.7.2500074",39980426,,"https://pubmed.ncbi.nlm.nih.gov/39980426","Blanquart 2025",2025,"Euro Surveill","Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025","Influenza","Adult"
218,"#506",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2025.126907",40073670,"PMC11975468","https://pmc.ncbi.nlm.nih.gov/articles/PMC11975468","Bolu 2025",2025,"Vaccine","Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021","COVID","Adult"
220,"#5079",0,1,0,0,0,1,0,0,0,"10.1093/ofid/ofae597",39474445,"PMC11521338","https://pmc.ncbi.nlm.nih.gov/articles/PMC11521338","Bosch 2024",2024,"Open Forum Infectious Diseases","Incidence of Respiratory Syncytial Virus in Community-Dwelling Adults Aged 18-64 Years Over 2 Seasons, 2022-2024, in a North American Community","RSV","Adult"
222,"#525",1,0,0,0,0,1,1,0,0,"10.1007/s40264-024-01495-5",39638989,"PMC11829932","https://pmc.ncbi.nlm.nih.gov/articles/PMC11829932","Boulefaa 2025",2025,"Drug Saf","Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database","COVID","Adult"
225,"#548",1,0,0,0,0,1,1,0,0,"10.1016/j.msard.2024.106253",39756168,,"https://pubmed.ncbi.nlm.nih.gov/39756168","Briggs 2025",2025,"Mult Scler Relat Disord","Self-reported longitudinal COVID-19 vaccination reactogenicity profiles in persons with multiple sclerosis","COVID","Adult"
226,"#5193",1,0,0,0,0,1,1,0,0,"10.1038/s41598-024-73940-5",39420039,"PMC11487014","https://pmc.ncbi.nlm.nih.gov/articles/PMC11487014","Byoun 2024",2024,"Sci Rep","Nationwide Cohort observational study on the safety and efficacy of COVID-19 vaccination in patients with Moyamoya disease","COVID","Adult"
227,"#5200",1,0,0,0,0,1,1,0,1,"10.1038/s41467-024-53842-w",39488521,"PMC11531596","https://pmc.ncbi.nlm.nih.gov/articles/PMC11531596","Caffrey 2024",2024,"Nat Commun","Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System","COVID","Immunocomp"
228,"#630",1,0,0,0,0,0,1,0,0,"10.1371/journal.pone.0325269",40460407,"PMC12133164","https://pmc.ncbi.nlm.nih.gov/articles/PMC12133164","Carazo 2025",2025,"PLoS One","Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up","COVID","Adult"
235,"#5392",1,0,0,1,1,1,1,0,0,"10.1016/j.ijid.2024.107095",38777080,,"https://pubmed.ncbi.nlm.nih.gov/38777080","Chemaitelly 2024",2024,"Int J Infect Dis","Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar","COVID","Pediatric"
235,"#5392",1,0,0,1,1,1,1,0,0,"10.1016/j.ijid.2024.107095",38777080,,"https://pubmed.ncbi.nlm.nih.gov/38777080","Chemaitelly 2024",2024,"Int J Infect Dis","Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar","COVID","Adult"
236,"#5393",1,0,0,0,1,1,1,0,0,"10.1111/irv.13357",39343986,"PMC11439586","https://pmc.ncbi.nlm.nih.gov/articles/PMC11439586","Chemaitelly 2024",2024,"Influenza Other Respir Viruses","BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar","COVID","Pediatric"
236,"#5393",1,0,0,0,1,1,1,0,0,"10.1111/irv.13357",39343986,"PMC11439586","https://pmc.ncbi.nlm.nih.gov/articles/PMC11439586","Chemaitelly 2024",2024,"Influenza Other Respir Viruses","BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar","COVID","Adult"
238,"#5400",1,0,0,0,0,1,1,0,0,"10.3390/jcm13154494",39124761,"PMC11313347","https://pmc.ncbi.nlm.nih.gov/articles/PMC11313347","Chen 2024",2024,"Journal of Clinical Medicine","De Novo Biopsy-Proven Glomerular Disease Following COVID-19 Vaccination","COVID","Adult"
239,"#5402",1,0,0,0,1,1,1,0,1,"10.1186/s12916-024-03457-1",38858672,"PMC11165729","https://pmc.ncbi.nlm.nih.gov/articles/PMC11165729","Chen 2024",2024,"BMC Med","Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England","COVID","Immunocomp"
240,"#706",0,0,1,0,0,1,1,0,0,"10.1016/j.eclinm.2025.103171",40276143,"PMC12018050","https://pmc.ncbi.nlm.nih.gov/articles/PMC12018050","Chen 2025",2025,"eClinicalMedicine","Interaction between influenza vaccine and statins affecting the risk of rhabdomyolysis in Taiwan: a nationwide case-centred analysis","Influenza","Adult"
241,"#5454",0,0,1,0,0,1,1,0,1,"10.1016/j.vaccine.2024.06.042",38897892,,"https://pubmed.ncbi.nlm.nih.gov/38897892","Cheng 2024",2024,"Vaccine","Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine","Influenza","Immunocomp"
243,"#20993",1,0,0,0,1,1,1,0,0,"10.1210/clinem/dgaf064",39883558,,"https://pubmed.ncbi.nlm.nih.gov/39883558","Cheng 2025",2025,"J Clin Endocrinol Metab","Long-term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2,333,496 Patients from the TriNetX Network","COVID","Pediatric"
243,"#20993",1,0,0,0,1,1,1,0,0,"10.1210/clinem/dgaf064",39883558,,"https://pubmed.ncbi.nlm.nih.gov/39883558","Cheng 2025",2025,"J Clin Endocrinol Metab","Long-term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2,333,496 Patients from the TriNetX Network","COVID","Adult"
244,"#5464",1,0,0,0,0,0,0,0,1,"10.1371/journal.pone.0310781",39509358,"PMC11542819","https://pmc.ncbi.nlm.nih.gov/articles/PMC11542819","Chewaskulyong 2024",2024,"PLoS One","Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients","COVID","Immunocomp"
245,"#5478",0,0,1,0,0,0,1,0,0,"10.1002/pds.70006",39238434,,"https://pubmed.ncbi.nlm.nih.gov/39238434","Cho 2024",2024,"Pharmacoepidemiol Drug Saf","Association Between Influenza Vaccination and Acute Kidney Injury Among the Elderly: A Self-Controlled Case Series","Influenza","Adult"
246,"#768",0,0,1,1,1,1,1,0,0,"10.3346/jkms.2025.40.e101",40132537,"PMC11932827","https://pmc.ncbi.nlm.nih.gov/articles/PMC11932827","Cho 2025",2025,"J Korean Med Sci","Global Burden of Vaccine-Associated Cerebrovascular Venous Sinus Thrombosis, 1968-2024: A Critical Analysis From the WHO Global Pharmacovigilance Database","Influenza","Pediatric"
246,"#768",0,0,1,1,1,1,1,0,0,"10.3346/jkms.2025.40.e101",40132537,"PMC11932827","https://pmc.ncbi.nlm.nih.gov/articles/PMC11932827","Cho 2025",2025,"J Korean Med Sci","Global Burden of Vaccine-Associated Cerebrovascular Venous Sinus Thrombosis, 1968-2024: A Critical Analysis From the WHO Global Pharmacovigilance Database","Influenza","Adult"
247,"#5483",1,0,1,0,0,1,1,0,0,"10.1016/j.cmi.2024.01.010",38253313,,"https://pubmed.ncbi.nlm.nih.gov/38253313","Choi 2024",2024,"Clin Microbiol Infect","Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference","COVID","Adult"
247,"#5483",1,0,1,0,0,1,1,0,0,"10.1016/j.cmi.2024.01.010",38253313,,"https://pubmed.ncbi.nlm.nih.gov/38253313","Choi 2024",2024,"Clin Microbiol Infect","Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference","Influenza","Adult"
248,"#5489",0,0,1,0,0,1,1,0,0,"10.3346/jkms.2024.39.e146",38651226,"PMC11035711","https://pmc.ncbi.nlm.nih.gov/articles/PMC11035711","Choi 2024",2024,"J Korean Med Sci","Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea","Influenza","Adult"
249,"#5486",1,0,0,0,0,1,1,0,0,"10.24171/j.phrp.2024.0194",39557576,"PMC11700711","https://pmc.ncbi.nlm.nih.gov/articles/PMC11700711","Choi 2024",2024,"Osong Public Health and Research Perspectives","Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea","COVID","Adult"
250,"#784",0,0,1,0,0,1,1,0,0,"10.3390/vaccines13020197",40006743,"PMC11861641","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861641","Choi 2025",2025,"Vaccines","Early and Late Influenza Vaccine Effectiveness in South Korea During the 20232024 Season","Influenza","Adult"
251,"#776",1,0,0,0,0,1,1,0,0,"10.1093/ofid/ofaf115",40110421,"PMC11919815","https://pmc.ncbi.nlm.nih.gov/articles/PMC11919815","Choi 2025",2025,"Open Forum Infectious Diseases","Rates of Hospitalization and Death due to COVID-19 in US Veterans with SARS-CoV-2 Infection in the XBB-, JN.1-, and KP-Predominant Eras","COVID","Adult"
252,"#5494",1,0,0,0,0,1,1,0,0,"10.1093/cid/ciae339",38922669,,"https://pubmed.ncbi.nlm.nih.gov/38922669","Chong 2024",2024,"Clin Infect Dis","Risks of SARS-CoV-2 JN.1 Infection and COVID-19-Associated Emergency Department Visits/Hospitalizations Following Updated Boosters and Prior Infection: A Population-Based Cohort Study","COVID","Adult"
253,"#21056",0,0,1,0,1,1,1,0,0,"10.1093/cid/ciae658",39761230,"PMC12287938","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287938","Chung 2025",2025,"Clin Infect Dis","Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season","Influenza","Pediatric"
253,"#21056",0,0,1,0,1,1,1,0,0,"10.1093/cid/ciae658",39761230,"PMC12287938","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287938","Chung 2025",2025,"Clin Infect Dis","Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season","Influenza","Adult"
254,"#5539",1,0,0,0,1,1,1,0,0,"10.2807/1560-7917.Es.2024.29.50.2400164",39668765,,"https://pubmed.ncbi.nlm.nih.gov/39668765","Clothier 2024",2024,"Euro Surveill","Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023","COVID","Pediatric"
254,"#5539",1,0,0,0,1,1,1,0,0,"10.2807/1560-7917.Es.2024.29.50.2400164",39668765,,"https://pubmed.ncbi.nlm.nih.gov/39668765","Clothier 2024",2024,"Euro Surveill","Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023","COVID","Adult"
255,"#5595",0,0,1,0,1,1,1,0,0,"10.3390/vaccines12030305",38543939,"PMC10976042","https://pmc.ncbi.nlm.nih.gov/articles/PMC10976042","Costantino 2024",2024,"Vaccines","Mid-Term Estimates of Influenza Vaccine Effectiveness against the A(H1N1)pdm09 Prevalent Circulating Subtype in the 2023/24 Season: Data from the Sicilian RespiVirNet Surveillance System","Influenza","Pediatric"
255,"#5595",0,0,1,0,1,1,1,0,0,"10.3390/vaccines12030305",38543939,"PMC10976042","https://pmc.ncbi.nlm.nih.gov/articles/PMC10976042","Costantino 2024",2024,"Vaccines","Mid-Term Estimates of Influenza Vaccine Effectiveness against the A(H1N1)pdm09 Prevalent Circulating Subtype in the 2023/24 Season: Data from the Sicilian RespiVirNet Surveillance System","Influenza","Adult"
256,"#5609",1,0,0,0,0,1,0,0,0,"10.1016/j.tjnut.2024.09.032",39396761,"PMC11662230","https://pmc.ncbi.nlm.nih.gov/articles/PMC11662230","Couvillion 2024",2024,"J Nutr","Associations between SARS-CoV-2 Infection or COVID-19 Vaccination and Human Milk Composition: A Multi-Omics Approach","COVID","Adult"
259,"#5696",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2024.126460",39447252,,"https://pubmed.ncbi.nlm.nih.gov/39447252","Darko 2024",2024,"Vaccine","Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study","COVID","Pediatric"
259,"#5696",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2024.126460",39447252,,"https://pubmed.ncbi.nlm.nih.gov/39447252","Darko 2024",2024,"Vaccine","Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study","COVID","Adult"
260,"#871",1,0,0,0,0,1,1,0,1,"10.1016/j.gastrohep.2024.502202",38723765,,"https://pubmed.ncbi.nlm.nih.gov/38723765","daSilva 2025",2025,"Gastroenterol Hepatol","Vaccine adherence and adverse events of the SARS-COV vaccine in patients with inflammatory bowel disease","COVID","Immunocomp"
261,"#5779",1,0,0,0,0,1,0,0,0,"10.3389/fmed.2024.1338317",38983365,"PMC11231098","https://pmc.ncbi.nlm.nih.gov/articles/PMC11231098","de-la-Plaza-San-Frutos 2024",2024,"Frontiers in Medicine","Effects of vaccination against COVID-19 on overactive bladder symptoms on young population","COVID","Adult"
262,"#5758",0,0,1,0,1,1,1,0,0,"10.1007/s40264-024-01456-y",38949714,"PMC11485106","https://pmc.ncbi.nlm.nih.gov/articles/PMC11485106","delaCueva 2024",2024,"Drug Saf","Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season","Influenza","Pediatric"
262,"#5758",0,0,1,0,1,1,1,0,0,"10.1007/s40264-024-01456-y",38949714,"PMC11485106","https://pmc.ncbi.nlm.nih.gov/articles/PMC11485106","delaCueva 2024",2024,"Drug Saf","Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season","Influenza","Adult"
263,"#5811",1,0,0,0,0,0,1,0,0,"10.1111/jce.16372",39039649,,"https://pubmed.ncbi.nlm.nih.gov/39039649","Deshmukh 2024",2024,"J Cardiovasc Electrophysiol","Association between COVID-19 vaccination and atrial arrhythmias in individuals with cardiac implantable electronic devices","COVID","Adult"
264,"#1001",1,0,0,0,0,1,0,0,0,"10.1016/j.vaccine.2025.126869",39999538,,"https://pubmed.ncbi.nlm.nih.gov/39999538","Diya 2025",2025,"Vaccine","A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults 18 years old","COVID","Adult"
265,"#5888",0,0,1,0,0,1,1,0,0,"10.1016/j.ijid.2024.107202",39122207,,"https://pubmed.ncbi.nlm.nih.gov/39122207","Domnich 2024",2024,"Int J Infect Dis","Influenza epidemiology and vaccine effectiveness during the 2023/2024 season in Italy: A test-negative case-control study","Influenza","Adult"
266,"#1013",0,1,0,0,0,1,1,0,0,"10.1016/j.jvacx.2025.100647",,,"https://doi.org/10.1016/j.jvacx.2025.100647","Domnich 2025",2025,"VACCINE: X","Enhanced safety surveillance of the adjuvanted respiratory syncytial virus vaccine among Italian older adults","RSV","Adult"
269,"#5917",0,0,1,0,1,1,1,0,0,"10.1007/s40264-024-01395-8",38483767,"PMC10955014","https://pmc.ncbi.nlm.nih.gov/articles/PMC10955014","DosSantos 2024",2024,"Drug Saf","An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older","Influenza","Pediatric"
269,"#5917",0,0,1,0,1,1,1,0,0,"10.1007/s40264-024-01395-8",38483767,"PMC10955014","https://pmc.ncbi.nlm.nih.gov/articles/PMC10955014","DosSantos 2024",2024,"Drug Saf","An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older","Influenza","Adult"
271,"#1051",1,0,0,0,1,1,1,0,0,"10.1177/14034948251333901",40439194,,"https://pubmed.ncbi.nlm.nih.gov/40439194","Dudukina 2025",2025,"Scand J Public Health","Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark","COVID","Pediatric"
271,"#1051",1,0,0,0,1,1,1,0,0,"10.1177/14034948251333901",40439194,,"https://pubmed.ncbi.nlm.nih.gov/40439194","Dudukina 2025",2025,"Scand J Public Health","Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark","COVID","Adult"
272,"#5982",1,0,0,0,0,1,1,0,0,"10.1016/j.eprac.2024.05.001",38729568,,"https://pubmed.ncbi.nlm.nih.gov/38729568","Duskin-Bitan 2024",2024,"Endocr Pract","Subacute Thyroiditis Following COVID-19 and COVID-19 Vaccination","COVID","Adult"
274,"#6041",1,0,0,0,0,1,1,0,0,"10.1093/ofid/ofae287",38868305,"PMC11167675","https://pmc.ncbi.nlm.nih.gov/articles/PMC11167675","Elbaz 2024",2024,"Open Forum Infectious Diseases","Varicella-Zoster Virus-Induced Neurologic Disease After COVID-19 Vaccination: A Multicenter Observational Cohort Study","COVID","Adult"
275,"#6043",1,0,0,0,1,1,1,0,0,"10.53555/6vk1cf91",,,"https://doi.org/10.53555/6vk1cf91","Elemuwa 2024",2024,"Journal of Population Therapeutics and Clinical Pharmacology","TRENDS OF COVID-19 VACCINE ADVERSE EVENT FOLLOWING IMMUNIZATION (AEFI): A ONE-YEAR RETROSPECTIVE REVIEW USING THE PASSIVE SURVEILLANCE DATA IN THE NIGERIAN NATIONAL DATABASE (VIGIFLOW)","COVID","Pediatric"
275,"#6043",1,0,0,0,1,1,1,0,0,"10.53555/6vk1cf91",,,"https://doi.org/10.53555/6vk1cf91","Elemuwa 2024",2024,"Journal of Population Therapeutics and Clinical Pharmacology","TRENDS OF COVID-19 VACCINE ADVERSE EVENT FOLLOWING IMMUNIZATION (AEFI): A ONE-YEAR RETROSPECTIVE REVIEW USING THE PASSIVE SURVEILLANCE DATA IN THE NIGERIAN NATIONAL DATABASE (VIGIFLOW)","COVID","Adult"
276,"#1107",0,0,1,0,0,0,1,0,0,"10.2807/1560-7917.Es.2025.30.12.2500174",40156348,,"https://pubmed.ncbi.nlm.nih.gov/40156348","Emborg 2025",2025,"Euro Surveill","Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025","Influenza","Adult"
278,"#1117",0,0,1,0,1,1,1,0,0,"10.1111/irv.70115",40328669,"PMC12055342","https://pmc.ncbi.nlm.nih.gov/articles/PMC12055342","Erdwiens 2025",2025,"Influenza Other Respir Viruses","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance","Influenza","Pediatric"
278,"#1117",0,0,1,0,1,1,1,0,0,"10.1111/irv.70115",40328669,"PMC12055342","https://pmc.ncbi.nlm.nih.gov/articles/PMC12055342","Erdwiens 2025",2025,"Influenza Other Respir Viruses","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance","Influenza","Adult"
279,"#6099",1,0,0,0,1,1,0,0,0,"10.3390/ijerph21081090",39200699,"PMC11354165","https://pmc.ncbi.nlm.nih.gov/articles/PMC11354165","Esteban-Cledera 2024",2024,"Int J Environ Res Public Health","Association between COVID-19 Vaccines and Menstrual Disorders: Retrospective Cohort Study of Women Aged 12-55 Years Old in Catalonia, Spain","COVID","Pediatric"
279,"#6099",1,0,0,0,1,1,0,0,0,"10.3390/ijerph21081090",39200699,"PMC11354165","https://pmc.ncbi.nlm.nih.gov/articles/PMC11354165","Esteban-Cledera 2024",2024,"Int J Environ Res Public Health","Association between COVID-19 Vaccines and Menstrual Disorders: Retrospective Cohort Study of Women Aged 12-55 Years Old in Catalonia, Spain","COVID","Adult"
280,"#21482",1,0,0,0,0,1,1,0,0,"10.3390/cancers17121948",40563598,"PMC12191419","https://pmc.ncbi.nlm.nih.gov/articles/PMC12191419","Fabbri 2025",2025,"Cancers (Basel)","Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study","COVID","Adult"
281,"#6143",1,0,0,0,0,1,1,0,0,"10.1136/ard-2024-225869",38816065,"PMC11503143","https://pmc.ncbi.nlm.nih.gov/articles/PMC11503143","Farisogullari 2024",2024,"Ann Rheum Dis","Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry","COVID","Adult"
282,"#1175",1,0,0,0,0,1,0,0,0,"10.53555/thn9g804",,,"https://doi.org/10.53555/thn9g804","Fatima 2025",2025,"Journal of Population Therapeutics and Clinical Pharmacology","MENSTRUAL IRREGULARITIES IN WOMEN AFTER COVID-19 INFECTION AND VACCINATION: A COMMUNITY BASED STUDY AMONG DUBAI HOSPITAL FEMALE STAFF AND WOMEN ATTENDING GYNECOLOGY CLINIC AND EMERGENCY","COVID","Adult"
283,"#1199",1,0,0,0,0,1,1,0,0,"10.3390/vaccines13040396",40333295,"PMC12031101","https://pmc.ncbi.nlm.nih.gov/articles/PMC12031101","Ferraioli 2025",2025,"Vaccines","Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive Therapies","COVID","Adult"
284,"#6193",1,0,0,0,1,1,1,0,0,"10.1007/s11739-024-03641-4",39042210,,"https://pubmed.ncbi.nlm.nih.gov/39042210","Ferrari 2024",2024,"Intern Emerg Med","Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting","COVID","Pediatric"
284,"#6193",1,0,0,0,1,1,1,0,0,"10.1007/s11739-024-03641-4",39042210,,"https://pubmed.ncbi.nlm.nih.gov/39042210","Ferrari 2024",2024,"Intern Emerg Med","Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting","COVID","Adult"
285,"#1202",1,0,0,1,1,1,1,0,0,"10.3389/fmed.2025.1501921",40046918,"PMC11879978","https://pmc.ncbi.nlm.nih.gov/articles/PMC11879978","Ferreira-da-Silva 2025",2025,"Front Med (Lausanne)","Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance","COVID","Pediatric"
285,"#1202",1,0,0,1,1,1,1,0,0,"10.3389/fmed.2025.1501921",40046918,"PMC11879978","https://pmc.ncbi.nlm.nih.gov/articles/PMC11879978","Ferreira-da-Silva 2025",2025,"Front Med (Lausanne)","Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance","COVID","Adult"
286,"#1208",1,1,0,0,0,1,1,0,0,"10.3389/fimmu.2025.1501275",40276503,"PMC12018429","https://pmc.ncbi.nlm.nih.gov/articles/PMC12018429","Fierro 2025",2025,"Front Immunol","Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study","COVID","Adult"
286,"#1208",1,1,0,0,0,1,1,0,0,"10.3389/fimmu.2025.1501275",40276503,"PMC12018429","https://pmc.ncbi.nlm.nih.gov/articles/PMC12018429","Fierro 2025",2025,"Front Immunol","Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study","RSV","Adult"
287,"#6209",1,0,0,0,0,1,1,0,0,"10.1093/infdis/jiae140",38513368,"PMC11420796","https://pmc.ncbi.nlm.nih.gov/articles/PMC11420796","Figueroa 2024",2024,"J Infect Dis","Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients","COVID","Adult"
288,"#1221",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127254",40398329,,"https://pubmed.ncbi.nlm.nih.gov/40398329","Fitzpatrick 2025",2025,"Vaccine","Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network","COVID","Pediatric"
288,"#1221",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127254",40398329,,"https://pubmed.ncbi.nlm.nih.gov/40398329","Fitzpatrick 2025",2025,"Vaccine","Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network","COVID","Adult"
290,"#6252",0,0,1,0,0,1,1,0,0,"10.1016/j.vaccine.2023.12.074",38154990,,"https://pubmed.ncbi.nlm.nih.gov/38154990","Fonseca 2024",2024,"Vaccine","In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial","Influenza","Adult"
291,"#6253",1,0,0,0,0,1,1,0,0,"10.14309/ajg.0000000000002702",38314748,"PMC11296936","https://pmc.ncbi.nlm.nih.gov/articles/PMC11296936","Fontana 2024",2024,"Am J Gastroenterol","ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study","COVID","Adult"
292,"#6266",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2024.126375",39298999,,"https://pubmed.ncbi.nlm.nih.gov/39298999","Fotakis 2024",2024,"Vaccine","Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023-March 2024)","COVID","Adult"
293,"#1246",1,0,0,1,1,1,1,0,1,"10.1038/s41598-025-98313-4",40289148,"PMC12034749","https://pmc.ncbi.nlm.nih.gov/articles/PMC12034749","Fraenza 2025",2025,"Sci Rep","Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination","COVID","Immunocomp"
294,"#21621",1,0,0,0,0,1,1,0,0,"10.1371/journal.pone.0326231",40644466,"PMC12250466","https://pmc.ncbi.nlm.nih.gov/articles/PMC12250466","Frankenthal 2025",2025,"PLoS One","Evaluation of adverse events and comorbidity exacerbation following the COVID-19 booster dose: A national survey among randomly-selected booster recipients","COVID","Adult"
295,"#6300",0,0,1,0,1,0,1,0,0,"10.15585/mmwr.mm7308a3",38421935,"PMC10907036","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Frutos 2024",2024,"MMWR Morb Mortal Wkly Rep","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States","Influenza","Pediatric"
295,"#6300",0,0,1,0,1,0,1,0,0,"10.15585/mmwr.mm7308a3",38421935,"PMC10907036","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Frutos 2024",2024,"MMWR Morb Mortal Wkly Rep","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States","Influenza","Adult"
296,"#1265",0,0,1,0,1,1,1,0,0,"10.15585/mmwr.mm7406a2",40014791,"PMC11867582","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Frutos 2025",2025,"MMWR Morb Mortal Wkly Rep","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025","Influenza","Pediatric"
296,"#1265",0,0,1,0,1,1,1,0,0,"10.15585/mmwr.mm7406a2",40014791,"PMC11867582","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Frutos 2025",2025,"MMWR Morb Mortal Wkly Rep","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025","Influenza","Adult"
297,"#1266",0,1,0,0,0,1,1,0,1,"10.1001/jamanetworkopen.2025.8322",40343698,"PMC12065041","https://pmc.ncbi.nlm.nih.gov/articles/PMC12065041","Fry 2025",2025,"JAMA Netw Open","Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older","RSV","Immunocomp"
298,"#6318",1,0,0,0,0,1,1,0,0,"10.1016/j.jiph.2024.102562",39418956,,"https://pubmed.ncbi.nlm.nih.gov/39418956","Fuller 2024",2024,"J Infect Public Health","Sex, vaccination status, and comorbidities influence long COVID persistence","COVID","Adult"
299,"#6372",0,0,1,0,1,1,1,0,0,"10.1093/ofid/ofae456",39220659,"PMC11365065","https://pmc.ncbi.nlm.nih.gov/articles/PMC11365065","Go 2024",2024,"Open Forum Infectious Diseases","Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season","Influenza","Pediatric"
299,"#6372",0,0,1,0,1,1,1,0,0,"10.1093/ofid/ofae456",39220659,"PMC11365065","https://pmc.ncbi.nlm.nih.gov/articles/PMC11365065","Go 2024",2024,"Open Forum Infectious Diseases","Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season","Influenza","Adult"
300,"#1359",1,0,0,0,1,1,1,0,0,"10.3390/vaccines13020113",40006661,"PMC11861871","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861871","Gbel 2025",2025,"Vaccines (Basel)","Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used","COVID","Pediatric"
300,"#1359",1,0,0,0,1,1,1,0,0,"10.3390/vaccines13020113",40006661,"PMC11861871","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861871","Gbel 2025",2025,"Vaccines (Basel)","Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used","COVID","Adult"
301,"#6336",1,0,1,0,0,1,1,0,0,"10.1055/a-2183-5269",38053618,"PMC10695705","https://pmc.ncbi.nlm.nih.gov/articles/PMC10695705","Gaddh 2023",2023,"TH Open","Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations","COVID","Adult"
301,"#6336",1,0,1,0,0,1,1,0,0,"10.1055/a-2183-5269",38053618,"PMC10695705","https://pmc.ncbi.nlm.nih.gov/articles/PMC10695705","Gaddh 2023",2023,"TH Open","Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations","Influenza","Adult"
302,"#6348",0,0,1,0,1,1,1,0,0,"10.1002/ohn.833",38822762,,"https://pubmed.ncbi.nlm.nih.gov/38822762","Gallagher 2024",2024,"Otolaryngol Head Neck Surg","Association of COVID-19 Vaccination With Changes in Smell and Taste","Influenza","Pediatric"
302,"#6348",0,0,1,0,1,1,1,0,0,"10.1002/ohn.833",38822762,,"https://pubmed.ncbi.nlm.nih.gov/38822762","Gallagher 2024",2024,"Otolaryngol Head Neck Surg","Association of COVID-19 Vaccination With Changes in Smell and Taste","Influenza","Adult"
303,"#6361",1,0,0,0,1,1,1,0,0,"10.1002/brb3.3587",38940313,"PMC11212002","https://pmc.ncbi.nlm.nih.gov/articles/PMC11212002","Ganelin-Cohen 2024",2024,"Brain Behav","The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI","COVID","Pediatric"
303,"#6361",1,0,0,0,1,1,1,0,0,"10.1002/brb3.3587",38940313,"PMC11212002","https://pmc.ncbi.nlm.nih.gov/articles/PMC11212002","Ganelin-Cohen 2024",2024,"Brain Behav","The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI","COVID","Adult"
305,"#21702",1,0,0,0,0,1,1,0,1,"10.1016/j.eclinm.2024.103054",39902315,"PMC11788791","https://pmc.ncbi.nlm.nih.gov/articles/PMC11788791","Garrett 2025",2025,"EClinicalMedicine","Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study","COVID","Immunocomp"
306,"#6425",1,0,0,0,0,1,1,0,0,"10.1186/s12879-024-10226-1",39558292,"PMC11572516","https://pmc.ncbi.nlm.nih.gov/articles/PMC11572516","Gennaro 2024",2024,"BMC Infect Dis","Protective role of vaccination on the development of long COVID: data from a large, multicenter, prospective cohort study","COVID","Adult"
307,"#1336",0,0,1,0,1,1,1,0,1,"10.1016/s2214-109x(24)00473-x",39890222,,"https://pubmed.ncbi.nlm.nih.gov/39890222","Gharpure 2025",2025,"Lancet Glob Health","Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design","Influenza","Immunocomp"
308,"#14940",0,0,1,0,0,1,1,0,0,"10.14745/ccdr.v50i12a02",38655243,"PMC11037881","https://pmc.ncbi.nlm.nih.gov/articles/PMC11037881","Giang 2024",2024,"Can Commun Dis Rep","Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022","Influenza","Adult"
309,"#21752",0,0,1,1,1,1,1,0,0,"10.3390/microorganisms13030469",40142362,"PMC11945264","https://pmc.ncbi.nlm.nih.gov/articles/PMC11945264","Giovanetti 2025",2025,"Microorganisms","Epidemiological Transitions in Influenza Dynamics in the United States: Insights from Recent Pandemic Challenges","Influenza","Pediatric"
309,"#21752",0,0,1,1,1,1,1,0,0,"10.3390/microorganisms13030469",40142362,"PMC11945264","https://pmc.ncbi.nlm.nih.gov/articles/PMC11945264","Giovanetti 2025",2025,"Microorganisms","Epidemiological Transitions in Influenza Dynamics in the United States: Insights from Recent Pandemic Challenges","Influenza","Adult"
310,"#21760",1,0,1,0,1,0,0,0,0,"10.1016/j.therap.2025.02.007",40090811,,"https://pubmed.ncbi.nlm.nih.gov/40090811","Gligorov 2025",2025,"Therapie","Vaccines and the risk of Guillain-Barr syndrome: A French pharmacovigilance analysis","COVID","Pediatric"
310,"#21760",1,0,1,0,1,0,0,0,0,"10.1016/j.therap.2025.02.007",40090811,,"https://pubmed.ncbi.nlm.nih.gov/40090811","Gligorov 2025",2025,"Therapie","Vaccines and the risk of Guillain-Barr syndrome: A French pharmacovigilance analysis","Influenza","Pediatric"
312,"#6513",1,0,1,0,0,1,1,0,0,"10.1001/jamanetworkopen.2023.32813",37682571,"PMC10492184","https://pmc.ncbi.nlm.nih.gov/articles/PMC10492184","Gonen 2023",2023,"JAMA Netw Open","Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines","COVID","Adult"
312,"#6513",1,0,1,0,0,1,1,0,0,"10.1001/jamanetworkopen.2023.32813",37682571,"PMC10492184","https://pmc.ncbi.nlm.nih.gov/articles/PMC10492184","Gonen 2023",2023,"JAMA Netw Open","Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines","Influenza","Adult"
313,"#15013",1,0,0,0,1,1,1,0,0,"10.1002/ski2.367",38846690,"PMC11150739","https://pmc.ncbi.nlm.nih.gov/articles/PMC11150739","Gordon 2024",2024,"Skin Health Dis","Exploring cutaneous lymphoproliferative disorders in the wake of COVID-19 vaccination","COVID","Pediatric"
313,"#15013",1,0,0,0,1,1,1,0,0,"10.1002/ski2.367",38846690,"PMC11150739","https://pmc.ncbi.nlm.nih.gov/articles/PMC11150739","Gordon 2024",2024,"Skin Health Dis","Exploring cutaneous lymphoproliferative disorders in the wake of COVID-19 vaccination","COVID","Adult"
315,"#6561",1,0,0,0,0,1,1,0,0,"10.3389/fphar.2024.1376474",39175548,"PMC11338880","https://pmc.ncbi.nlm.nih.gov/articles/PMC11338880","GranjaLpez 2024",2024,"Frontiers in Pharmacology","Neurological manifestations of immune origin after COVID-19 vaccination: retrospective case study","COVID","Adult"
316,"#6597",0,0,1,0,0,1,1,0,1,"10.1016/j.vaccine.2024.01.023",38341288,,"https://pubmed.ncbi.nlm.nih.gov/38341288","Grima 2024",2024,"Vaccine","The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data","Influenza","Immunocomp"
317,"#12280",0,0,1,0,1,1,1,0,1,"10.1001/jamaneurol.2023.2968",37669073,"PMC10481324","https://pmc.ncbi.nlm.nih.gov/articles/PMC10481324","Grimaldi 2023",2023,"JAMA Neurol","Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups","Influenza","Immunocomp"
318,"#1415",1,0,0,0,1,1,1,0,0,"10.1111/ene.16510",40115993,"PMC11926444","https://pmc.ncbi.nlm.nih.gov/articles/PMC11926444","Grisanti 2025",2025,"Eur J Neurol","Neurological long COVID in the outpatient clinic: Is it so long?","COVID","Pediatric"
318,"#1415",1,0,0,0,1,1,1,0,0,"10.1111/ene.16510",40115993,"PMC11926444","https://pmc.ncbi.nlm.nih.gov/articles/PMC11926444","Grisanti 2025",2025,"Eur J Neurol","Neurological long COVID in the outpatient clinic: Is it so long?","COVID","Adult"
321,"#6708",1,0,0,0,0,1,1,0,0,"10.5001/omj.2024.107",40196803,"PMC11973885","https://pmc.ncbi.nlm.nih.gov/articles/PMC11973885","Hammam 2024",2024,"Oman Medical Journal","Safety of COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: A Cross-sectional Study in Egypt","COVID","Adult"
322,"#6771",0,0,1,0,0,0,1,0,0,"10.1080/09286586.2023.2289990",38085757,,"https://pubmed.ncbi.nlm.nih.gov/38085757","Hashimoto 2024",2024,"Ophthalmic Epidemiol","Ocular Adverse Events After Influenza Vaccination in Older Adults: Self-Controlled Case Series Using a Large Database in Japan","Influenza","Adult"
323,"#1527",0,1,0,0,0,0,0,0,1,"10.1016/j.ajt.2025.03.025",40169094,,"https://pubmed.ncbi.nlm.nih.gov/40169094","Havlin 2025",2025,"Am J Transplant","Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees","RSV","Immunocomp"
325,"#15356",1,0,0,0,0,1,1,0,0,"10.7759/cureus.63410",39070394,"PMC11283873","https://pmc.ncbi.nlm.nih.gov/articles/PMC11283873","Hikichi 2024",2024,"Cureus","Comparison of Transient and Persistent Adverse Events After COVID-19 Vaccination: A Retrospective Analysis","COVID","Adult"
327,"#6931",1,0,0,0,0,1,0,0,0,"10.3390/medicina60060956",38929574,"PMC11206152","https://pmc.ncbi.nlm.nih.gov/articles/PMC11206152","HospitalEspaoldePachucaResearch 2024",2024,"Medicina (Kaunas)","Anti-COVID-19 Vaccination Alters the Menstrual Cycle and Dose Accumulation Enhances the Effect","COVID","Adult"
329,"#1606",1,0,0,0,0,1,1,0,0,"10.1155/ijbc/8126974",39991115,"PMC11846679","https://pmc.ncbi.nlm.nih.gov/articles/PMC11846679","Huang 2025",2025,"International Journal of Breast Cancer","Reactive Axillary Lymphadenopathy Among Different COVID-19 Vaccines: A Retrospective Study in Breast Sonography","COVID","Adult"
330,"#1629",1,0,0,0,1,1,1,0,0,"10.1016/j.ajo.2024.08.015",39179130,,"https://pubmed.ncbi.nlm.nih.gov/39179130","Hwang 2025",2025,"Am J Ophthalmol","COVID-19 Vaccination and Ocular Adverse Events: A Self-Controlled Case Series Study From the Entire South Korean Population","COVID","Pediatric"
330,"#1629",1,0,0,0,1,1,1,0,0,"10.1016/j.ajo.2024.08.015",39179130,,"https://pubmed.ncbi.nlm.nih.gov/39179130","Hwang 2025",2025,"Am J Ophthalmol","COVID-19 Vaccination and Ocular Adverse Events: A Self-Controlled Case Series Study From the Entire South Korean Population","COVID","Adult"
331,"#1627",0,0,1,0,1,1,1,0,0,"10.1038/s41598-025-88713-x",39939373,"PMC11821952","https://pmc.ncbi.nlm.nih.gov/articles/PMC11821952","Hwang 2025",2025,"Sci Rep","Global burden of vaccine-associated kidney injury using an international pharmacovigilance database","Influenza","Pediatric"
331,"#1627",0,0,1,0,1,1,1,0,0,"10.1038/s41598-025-88713-x",39939373,"PMC11821952","https://pmc.ncbi.nlm.nih.gov/articles/PMC11821952","Hwang 2025",2025,"Sci Rep","Global burden of vaccine-associated kidney injury using an international pharmacovigilance database","Influenza","Adult"
332,"#1635",1,0,0,0,0,1,1,0,0,"10.1016/j.cmi.2024.12.002",39662823,,"https://pubmed.ncbi.nlm.nih.gov/39662823","Iba 2025",2025,"Clin Microbiol Infect","Booster vaccination and post-COVID-19 condition during the Omicron variant-dominant wave: a large population-based study","COVID","Adult"
334,"#1647",1,0,0,0,0,1,1,0,0,"10.7326/annals-24-01015",39903865,,"https://pubmed.ncbi.nlm.nih.gov/39903865","Ioannou 2025",2025,"Ann Intern Med","Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation","COVID","Adult"
335,"#7078",1,0,0,0,0,1,1,0,0,"10.1038/s41467-024-49634-x",39085208,"PMC11291640","https://pmc.ncbi.nlm.nih.gov/articles/PMC11291640","Ip 2024",2024,"Nat Commun","Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England","COVID","Adult"
336,"#1648",1,0,0,0,0,1,1,0,0,"10.1016/j.ijid.2024.107324",39637971,,"https://pubmed.ncbi.nlm.nih.gov/39637971","Ip 2025",2025,"Int J Infect Dis","COVID-19 vaccination and cerebral small vessel disease progression-A prospective cohort study","COVID","Adult"
337,"#7105",1,0,0,0,0,1,1,0,0,"10.1038/s41598-024-73004-8",39375365,"PMC11458568","https://pmc.ncbi.nlm.nih.gov/articles/PMC11458568","Itamochi 2024",2024,"Sci Rep","COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 nave nursing home residents","COVID","Adult"
338,"#1670",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2025.126754",39879847,,"https://pubmed.ncbi.nlm.nih.gov/39879847","Ito 2025",2025,"Vaccine","Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan","COVID","Adult"
339,"#12347",1,0,0,0,1,1,1,0,0,"10.1097/wno.0000000000001900",37314860,,"https://pubmed.ncbi.nlm.nih.gov/37314860","Jaffry 2023",2023,"J Neuroophthalmol","Optic Neuritis After COVID-19 Vaccination: An Analysis of the Vaccine Adverse Event Reporting System","COVID","Pediatric"
339,"#12347",1,0,0,0,1,1,1,0,0,"10.1097/wno.0000000000001900",37314860,,"https://pubmed.ncbi.nlm.nih.gov/37314860","Jaffry 2023",2023,"J Neuroophthalmol","Optic Neuritis After COVID-19 Vaccination: An Analysis of the Vaccine Adverse Event Reporting System","COVID","Adult"
340,"#7139",1,0,0,0,1,1,0,0,0,"10.1016/j.eclinm.2024.102809",39290640,"PMC11406334","https://pmc.ncbi.nlm.nih.gov/articles/PMC11406334","Jain 2024",2024,"eClinicalMedicine","Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study","COVID","Pediatric"
340,"#7139",1,0,0,0,1,1,0,0,0,"10.1016/j.eclinm.2024.102809",39290640,"PMC11406334","https://pmc.ncbi.nlm.nih.gov/articles/PMC11406334","Jain 2024",2024,"eClinicalMedicine","Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study","COVID","Adult"
341,"#7142",1,0,0,0,1,1,0,0,0,"10.1016/j.vaccine.2024.07.031",39004527,,"https://pubmed.ncbi.nlm.nih.gov/39004527","Jajou 2024",2024,"Vaccine","GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands","COVID","Pediatric"
341,"#7142",1,0,0,0,1,1,0,0,0,"10.1016/j.vaccine.2024.07.031",39004527,,"https://pubmed.ncbi.nlm.nih.gov/39004527","Jajou 2024",2024,"Vaccine","GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands","COVID","Adult"
342,"#22192",1,0,0,0,0,1,1,0,0,"10.1002/bcp.70045",40099868,"PMC12304821","https://pmc.ncbi.nlm.nih.gov/articles/PMC12304821","Jajou 2025",2025,"Br J Clin Pharmacol","General practitioner consultation for postmenopausal bleeding after COVID-19 vaccination-a self-controlled cohort study","COVID","Adult"
343,"#7164",1,0,0,0,0,1,1,0,0,"10.1080/21645515.2024.2334084",38563792,"PMC10989707","https://pmc.ncbi.nlm.nih.gov/articles/PMC10989707","Jarrot 2024",2024,"Hum Vaccin Immunother","Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey","COVID","Adult"
345,"#15668",0,0,1,0,1,1,1,0,0,"10.1002/jmv.29682",38783823,,"https://pubmed.ncbi.nlm.nih.gov/38783823","Jeong 2024",2024,"J Med Virol","Global and regional burden of vaccine-associated facial paralysis, 1967-2023: Findings from the WHO international pharmacovigilance database","Influenza","Pediatric"
345,"#15668",0,0,1,0,1,1,1,0,0,"10.1002/jmv.29682",38783823,,"https://pubmed.ncbi.nlm.nih.gov/38783823","Jeong 2024",2024,"J Med Virol","Global and regional burden of vaccine-associated facial paralysis, 1967-2023: Findings from the WHO international pharmacovigilance database","Influenza","Adult"
346,"#7190",0,0,1,0,1,1,1,0,0,"10.1038/s41598-024-74729-2",39427003,"PMC11490553","https://pmc.ncbi.nlm.nih.gov/articles/PMC11490553","Jeong 2024",2024,"Sci Rep","Global burden of vaccine-associated Guillain-Barr syndrome over 170 countries from 1967 to 2023","Influenza","Pediatric"
346,"#7190",0,0,1,0,1,1,1,0,0,"10.1038/s41598-024-74729-2",39427003,"PMC11490553","https://pmc.ncbi.nlm.nih.gov/articles/PMC11490553","Jeong 2024",2024,"Sci Rep","Global burden of vaccine-associated Guillain-Barr syndrome over 170 countries from 1967 to 2023","Influenza","Adult"
347,"#1712",0,0,1,1,1,1,1,0,0,"10.1038/s41598-025-98106-9",40247100,"PMC12006434","https://pmc.ncbi.nlm.nih.gov/articles/PMC12006434","Jeong 2025",2025,"Sci Rep","Global and regional estimates of vaccine-associated herpes zoster and their related vaccines from 1969 to 2023","Influenza","Pediatric"
347,"#1712",0,0,1,1,1,1,1,0,0,"10.1038/s41598-025-98106-9",40247100,"PMC12006434","https://pmc.ncbi.nlm.nih.gov/articles/PMC12006434","Jeong 2025",2025,"Sci Rep","Global and regional estimates of vaccine-associated herpes zoster and their related vaccines from 1969 to 2023","Influenza","Adult"
348,"#22221",0,0,1,0,1,1,1,0,0,"10.1007/s00228-025-03854-2",40478262,,"https://pubmed.ncbi.nlm.nih.gov/40478262","Jeong 2025",2025,"Eur J Clin Pharmacol","Global burden of vaccine-associated Raynaud's phenomenon, 1968-2024: A comprehensive analysis of the pharmacovigilance database","Influenza","Pediatric"
348,"#22221",0,0,1,0,1,1,1,0,0,"10.1007/s00228-025-03854-2",40478262,,"https://pubmed.ncbi.nlm.nih.gov/40478262","Jeong 2025",2025,"Eur J Clin Pharmacol","Global burden of vaccine-associated Raynaud's phenomenon, 1968-2024: A comprehensive analysis of the pharmacovigilance database","Influenza","Adult"
349,"#7191",1,0,0,0,0,1,1,0,0,"10.3390/jcm13206173",39458123,"PMC11508506","https://pmc.ncbi.nlm.nih.gov/articles/PMC11508506","J__kowiak-Kossakowska 2024",2024,"Journal of Clinical Medicine","Impact of Comorbidities and Skin Diseases on Post-Vaccination Reactions: A Study on COVID-19 Vaccinations in Poland","COVID","Adult"
350,"#1735",0,0,1,0,1,0,0,0,0,"10.1080/22221751.2025.2490531",40192342,"PMC12164376","https://pmc.ncbi.nlm.nih.gov/articles/PMC12164376","Jiang 2025",2025,"Emerg Microbes Infect","Influenza vaccine effectiveness among primary and secondary school students in Shenzhen during the 2023/24 influenza season","Influenza","Pediatric"
351,"#1737",1,0,0,0,0,1,1,0,0,"10.3390/vaccines13020147",40006694,"PMC11861186","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861186","Jimnez-Corona 2025",2025,"Vaccines","COVID-19 Vaccination Uptake and Effectiveness for Hospitalized Cases Among Healthcare Workers in Tertiary Hospital","COVID","Adult"
352,"#1739",0,1,0,0,0,0,0,1,0,"10.1016/j.ajog.2025.04.067",40324666,"PMC12353535","https://pmc.ncbi.nlm.nih.gov/articles/PMC12353535","JinHsieh 2025",2025,"Am J Obstet Gynecol","Investigation of Maternal Outcomes Following Respiratory Syncytial Virus Vaccination in the Third Trimester: Insights from a Real-World U.S. Electronic Health Records Database","RSV","Pregnant"
353,"#7241",1,0,0,0,0,1,1,0,0,"10.7774/cevr.2024.13.4.309",39525675,"PMC11543796","https://pmc.ncbi.nlm.nih.gov/articles/PMC11543796","Jirawattanadon 2024",2024,"Clinical and Experimental Vaccine Research","Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination","COVID","Adult"
354,"#11951",0,1,0,0,1,1,1,0,0,"10.15585/mmwr.mm7411a1",40179043,"PMC11970723","https://pmc.ncbi.nlm.nih.gov/articles/PMC11970723","Jobe 2025",2025,"MMWR Morb Mortal Wkly Rep","Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus - United States, 2014-2024","RSV","Pediatric"
354,"#11951",0,1,0,0,1,1,1,0,0,"10.15585/mmwr.mm7411a1",40179043,"PMC11970723","https://pmc.ncbi.nlm.nih.gov/articles/PMC11970723","Jobe 2025",2025,"MMWR Morb Mortal Wkly Rep","Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus - United States, 2014-2024","RSV","Adult"
356,"#7297",1,0,0,0,1,1,1,0,0,"10.1038/s41467-024-50656-8",39039113,"PMC11263712","https://pmc.ncbi.nlm.nih.gov/articles/PMC11263712","Jung 2024",2024,"Nat Commun","Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study","COVID","Pediatric"
356,"#7297",1,0,0,0,1,1,1,0,0,"10.1038/s41467-024-50656-8",39039113,"PMC11263712","https://pmc.ncbi.nlm.nih.gov/articles/PMC11263712","Jung 2024",2024,"Nat Commun","Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study","COVID","Adult"
357,"#7327",1,0,0,0,0,1,1,0,0,"10.1016/j.jaut.2024.103325",39413503,,"https://pubmed.ncbi.nlm.nih.gov/39413503","Klin 2024",2024,"J Autoimmun","SARS-CoV-2 mRNA vaccines do not worsen autoimmunity in patients with autoimmune liver diseases","COVID","Adult"
358,"#7705",1,0,0,0,0,1,0,0,0,"10.1097/md.0000000000038771",38941384,,"https://pubmed.ncbi.nlm.nih.gov/38941384","Kkerdem 2024",2024,"Medicine (Baltimore)","Evaluation of menstrual irregularities following COVID-19 infection or vaccination: The impact of COVID anxiety and associated risk factors","COVID","Adult"
360,"#15830",1,0,1,0,0,1,1,0,0,"10.4168/aair.2024.16.6.613",39622686,"PMC11621480","https://pmc.ncbi.nlm.nih.gov/articles/PMC11621480","Kang 2024",2024,"Allergy Asthma Immunol Res","Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database","COVID","Adult"
360,"#15830",1,0,1,0,0,1,1,0,0,"10.4168/aair.2024.16.6.613",39622686,"PMC11621480","https://pmc.ncbi.nlm.nih.gov/articles/PMC11621480","Kang 2024",2024,"Allergy Asthma Immunol Res","Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database","Influenza","Adult"
361,"#7370",1,0,0,0,0,1,1,0,0,"10.1186/s12889-024-20297-z",39434043,"PMC11495130","https://pmc.ncbi.nlm.nih.gov/articles/PMC11495130","Karam 2024",2024,"BMC Public Health","Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database","COVID","Adult"
362,"#7400",1,0,0,0,0,1,1,0,0,"10.7774/cevr.2024.13.3.218",39144130,"PMC11319113","https://pmc.ncbi.nlm.nih.gov/articles/PMC11319113","Katatbeh 2024",2024,"Clinical and Experimental Vaccine Research","Incidence of narcolepsy symptoms after taking COVID-19 vaccines: a Jordanian cross-sectional study","COVID","Adult"
363,"#22376",1,0,1,0,0,1,1,0,0,"10.1016/j.jiac.2025.102728",40456446,,"https://pubmed.ncbi.nlm.nih.gov/40456446","Kawai 2025",2025,"J Infect Chemother","Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season","COVID","Adult"
363,"#22376",1,0,1,0,0,1,1,0,0,"10.1016/j.jiac.2025.102728",40456446,,"https://pubmed.ncbi.nlm.nih.gov/40456446","Kawai 2025",2025,"J Infect Chemother","Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season","Influenza","Adult"
365,"#1849",1,0,0,0,0,1,1,0,1,"10.3390/vaccines13020103",40006650,"PMC11860179","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860179","Kern 2025",2025,"Vaccines","Leukocyte Count in Solid Organ Transplant Recipients After SARS-CoV-2 mRNA Vaccination and Infection","COVID","Immunocomp"
366,"#7501",1,0,0,0,0,1,1,0,0,"10.1080/25785826.2023.2300163",38189429,,"https://pubmed.ncbi.nlm.nih.gov/38189429","Kikuchi 2024",2024,"Immunol Med","Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus","COVID","Adult"
367,"#7509",1,0,0,0,0,1,1,0,0,"10.1212/CPJ.0000000000200166",37251368,"PMC10212233","https://pmc.ncbi.nlm.nih.gov/articles/PMC10212233","Kim 2023",2023,"Neurology: Clinical Practice","Observational Study of Patients Hospitalized With Neurologic Events After SARS-CoV-2 Vaccination, December 2020-June 2021","COVID","Adult"
370,"#7521",1,0,0,0,1,1,1,0,0,"10.1001/jamaophthalmol.2024.0973",38662361,"PMC11046406","https://pmc.ncbi.nlm.nih.gov/articles/PMC11046406","Kim 2024",2024,"JAMA Ophthalmol","COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis","COVID","Pediatric"
370,"#7521",1,0,0,0,1,1,1,0,0,"10.1001/jamaophthalmol.2024.0973",38662361,"PMC11046406","https://pmc.ncbi.nlm.nih.gov/articles/PMC11046406","Kim 2024",2024,"JAMA Ophthalmol","COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis","COVID","Adult"
373,"#1896",1,0,0,1,0,0,0,1,0,"10.3346/jkms.2025.40.e63",40329789,"PMC12056060","https://pmc.ncbi.nlm.nih.gov/articles/PMC12056060","Kim 2025",2025,"J Korean Med Sci","Maternal Exposures to COVID-19 Vaccine and Adverse Birth Outcomes: National Population Study in Korea","COVID","Pediatric"
373,"#1896",1,0,0,1,0,0,0,1,0,"10.3346/jkms.2025.40.e63",40329789,"PMC12056060","https://pmc.ncbi.nlm.nih.gov/articles/PMC12056060","Kim 2025",2025,"J Korean Med Sci","Maternal Exposures to COVID-19 Vaccine and Adverse Birth Outcomes: National Population Study in Korea","COVID","Pregnant"
374,"#1913",1,0,0,0,0,1,1,0,0,"10.1080/09286586.2024.2399345",39288331,,"https://pubmed.ncbi.nlm.nih.gov/39288331","Kim 2025",2025,"Ophthalmic Epidemiol","Retinal Vascular Occlusions After COVID-19 Vaccination in South Korea: A Nation-Wide Population-Based Study","COVID","Adult"
375,"#7563",1,0,0,0,0,1,1,0,0,"10.1016/j.jinf.2024.106177",38719110,,"https://pubmed.ncbi.nlm.nih.gov/38719110","Kirsebom 2024",2024,"J Infect","Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study","COVID","Adult"
376,"#7564",1,0,0,0,0,1,0,0,0,"10.1016/j.jinf.2024.106293",39343245,,"https://pubmed.ncbi.nlm.nih.gov/39343245","Kirwan 2024",2024,"J Infect","Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024","COVID","Adult"
377,"#1921",0,0,1,0,1,1,1,0,0,"10.2807/1560-7917.Es.2025.30.23.2500011",40511473,,"https://pubmed.ncbi.nlm.nih.gov/40511473","Kissling 2025",2025,"Euro Surveill","Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24","Influenza","Pediatric"
377,"#1921",0,0,1,0,1,1,1,0,0,"10.2807/1560-7917.Es.2025.30.23.2500011",40511473,,"https://pubmed.ncbi.nlm.nih.gov/40511473","Kissling 2025",2025,"Euro Surveill","Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24","Influenza","Adult"
378,"#1934",1,0,0,0,0,1,1,0,0,"10.4178/epih.e2025024",40340265,,"https://pubmed.ncbi.nlm.nih.gov/40340265","Ko 2025",2025,"Epidemiol Health","Risk of new-onset seizures following immunization against COVID-19: a self-controlled case-series study","COVID","Adult"
379,"#1948",1,0,0,0,0,1,1,0,0,"10.1080/21645515.2025.2518646",40555671,,"https://pubmed.ncbi.nlm.nih.gov/40555671","Konishi 2025",2025,"Hum Vaccin Immunother","Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions","COVID","Adult"
380,"#16179",1,0,0,0,1,1,1,0,0,"10.1016/j.xops.2024.100474",38827031,"PMC11141252","https://pmc.ncbi.nlm.nih.gov/articles/PMC11141252","Kumar 2024",2024,"Ophthalmol Sci","Risk of Recurrent Noninfectious Uveitis After Coronavirus Disease 2019 Vaccination in the United States","COVID","Pediatric"
380,"#16179",1,0,0,0,1,1,1,0,0,"10.1016/j.xops.2024.100474",38827031,"PMC11141252","https://pmc.ncbi.nlm.nih.gov/articles/PMC11141252","Kumar 2024",2024,"Ophthalmol Sci","Risk of Recurrent Noninfectious Uveitis After Coronavirus Disease 2019 Vaccination in the United States","COVID","Adult"
382,"#22585",0,0,1,0,1,1,0,0,0,,40455969,"PMC12186818","https://pmc.ncbi.nlm.nih.gov/articles/PMC12186818","Kwaah 2025",2025,"MSMR","Mid-season vaccine effectiveness estimates for influenza: the Department of Defense Global Respiratory Pathogen Surveillance Program, 2024-2025 season","Influenza","Pediatric"
382,"#22585",0,0,1,0,1,1,0,0,0,,40455969,"PMC12186818","https://pmc.ncbi.nlm.nih.gov/articles/PMC12186818","Kwaah 2025",2025,"MSMR","Mid-season vaccine effectiveness estimates for influenza: the Department of Defense Global Respiratory Pathogen Surveillance Program, 2024-2025 season","Influenza","Adult"
383,"#22595",1,0,1,1,1,1,1,0,0,"10.1159/000541797",39369714,"PMC11805550","https://pmc.ncbi.nlm.nih.gov/articles/PMC11805550","Kyung 2025",2025,"Med Princ Pract","Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database","COVID","Pediatric"
383,"#22595",1,0,1,1,1,1,1,0,0,"10.1159/000541797",39369714,"PMC11805550","https://pmc.ncbi.nlm.nih.gov/articles/PMC11805550","Kyung 2025",2025,"Med Princ Pract","Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database","Influenza","Pediatric"
383,"#22595",1,0,1,1,1,1,1,0,0,"10.1159/000541797",39369714,"PMC11805550","https://pmc.ncbi.nlm.nih.gov/articles/PMC11805550","Kyung 2025",2025,"Med Princ Pract","Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database","COVID","Adult"
383,"#22595",1,0,1,1,1,1,1,0,0,"10.1159/000541797",39369714,"PMC11805550","https://pmc.ncbi.nlm.nih.gov/articles/PMC11805550","Kyung 2025",2025,"Med Princ Pract","Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database","Influenza","Adult"
384,"#8197",1,0,0,0,0,1,0,0,0,"10.24875/CIRUE.M23000425",,,"https://doi.org/10.24875/CIRUE.M23000425","Lpez-Contreras 2023",2023,"Cirugia y Cirujanos","Incidence and factors associated with early and late adverse reactions after the first dose of Pfizer-BioNTech vaccine among healthcare workers","COVID","Adult"
385,"#2252",1,0,0,0,1,1,1,0,0,"10.3390/ph18050636",40430457,"PMC12114770","https://pmc.ncbi.nlm.nih.gov/articles/PMC12114770","LpezdeLasHuertas 2025",2025,"Pharmaceuticals (Basel)","Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance","COVID","Pediatric"
385,"#2252",1,0,0,0,1,1,1,0,0,"10.3390/ph18050636",40430457,"PMC12114770","https://pmc.ncbi.nlm.nih.gov/articles/PMC12114770","LpezdeLasHuertas 2025",2025,"Pharmaceuticals (Basel)","Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance","COVID","Adult"
386,"#7774",1,0,0,0,0,0,1,0,0,"10.1080/21645515.2024.2368681",38953297,"PMC11221462","https://pmc.ncbi.nlm.nih.gov/articles/PMC11221462","Lafleur 2024",2024,"Hum Vaccin Immunother","Omission of alcohol skin cleansing and risk of adverse events in long-term care residents undergoing COVID-19 vaccination: A cohort study","COVID","Adult"
387,"#2023",1,0,0,0,1,1,1,0,0,"10.1080/23744235.2024.2399108",39226235,,"https://pubmed.ncbi.nlm.nih.gov/39226235","Lambo 2025",2025,"Infect Dis (Lond)","The descriptive epidemiology of adverse events following two doses of mRNA COVID-19 vaccination in Curaao, the Caribbean","COVID","Pediatric"
387,"#2023",1,0,0,0,1,1,1,0,0,"10.1080/23744235.2024.2399108",39226235,,"https://pubmed.ncbi.nlm.nih.gov/39226235","Lambo 2025",2025,"Infect Dis (Lond)","The descriptive epidemiology of adverse events following two doses of mRNA COVID-19 vaccination in Curaao, the Caribbean","COVID","Adult"
388,"#7803",1,0,0,0,1,1,1,0,0,"10.2196/47070",38833299,"PMC11185909","https://pmc.ncbi.nlm.nih.gov/articles/PMC11185909","Lang 2024",2024,"J Med Internet Res","COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application-Based Prospective Observational Cohort Study","COVID","Pediatric"
388,"#7803",1,0,0,0,1,1,1,0,0,"10.2196/47070",38833299,"PMC11185909","https://pmc.ncbi.nlm.nih.gov/articles/PMC11185909","Lang 2024",2024,"J Med Internet Res","COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application-Based Prospective Observational Cohort Study","COVID","Adult"
389,"#2033",1,0,0,0,1,1,1,1,1,"10.1111/irv.70120",40395132,"PMC12093050","https://pmc.ncbi.nlm.nih.gov/articles/PMC12093050","LanieceDelaunay 2025",2025,"Influenza Other Respir Viruses","COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network","COVID","Immunocomp"
390,"#22655",0,1,0,0,0,1,1,0,0,"10.1001/jama.2025.1225",40063039,"PMC12277020","https://pmc.ncbi.nlm.nih.gov/articles/PMC12277020","Lauring 2025",2025,"Jama","Genomic Characterization of RSV in the US by Vaccination Status","RSV","Adult"
391,"#2043",0,1,0,1,1,1,1,0,0,"10.1093/ofid/ofaf334",40567998,,"https://pubmed.ncbi.nlm.nih.gov/40567998","LaVerriere 2025",2025,"Open Forum Infectious Diseases","Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024","RSV","Pediatric"
391,"#2043",0,1,0,1,1,1,1,0,0,"10.1093/ofid/ofaf334",40567998,,"https://pubmed.ncbi.nlm.nih.gov/40567998","LaVerriere 2025",2025,"Open Forum Infectious Diseases","Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024","RSV","Adult"
392,"#7881",1,0,0,1,1,1,1,0,0,"10.1136/bmjresp-2023-001992",38081769,"PMC10729117","https://pmc.ncbi.nlm.nih.gov/articles/PMC10729117","Lee 2023",2023,"BMJ Open Respir Res","Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)","COVID","Pediatric"
392,"#7881",1,0,0,1,1,1,1,0,0,"10.1136/bmjresp-2023-001992",38081769,"PMC10729117","https://pmc.ncbi.nlm.nih.gov/articles/PMC10729117","Lee 2023",2023,"BMJ Open Respir Res","Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)","COVID","Adult"
393,"#7882",1,0,0,0,1,1,1,0,0,"10.1016/j.mayocp.2024.03.026",39093271,,"https://pubmed.ncbi.nlm.nih.gov/39093271","Lee 2024",2024,"Mayo Clin Proc","COVID-19 Vaccination-Related Pericarditis: A Korean Nationwide Study","COVID","Pediatric"
393,"#7882",1,0,0,0,1,1,1,0,0,"10.1016/j.mayocp.2024.03.026",39093271,,"https://pubmed.ncbi.nlm.nih.gov/39093271","Lee 2024",2024,"Mayo Clin Proc","COVID-19 Vaccination-Related Pericarditis: A Korean Nationwide Study","COVID","Adult"
394,"#16349",1,0,0,1,1,1,1,0,0,"10.1111/all.15968",38071735,,"https://pubmed.ncbi.nlm.nih.gov/38071735","Lee 2024",2024,"Allergy","Global burden of vaccine-associated anaphylaxis and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database","COVID","Pediatric"
394,"#16349",1,0,0,1,1,1,1,0,0,"10.1111/all.15968",38071735,,"https://pubmed.ncbi.nlm.nih.gov/38071735","Lee 2024",2024,"Allergy","Global burden of vaccine-associated anaphylaxis and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database","COVID","Adult"
396,"#2066",1,0,1,1,1,1,1,0,0,"10.1002/jmv.70408",40454841,,"https://pubmed.ncbi.nlm.nih.gov/40454841","Lee 2025",2025,"J Med Virol","Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data","COVID","Pediatric"
396,"#2066",1,0,1,1,1,1,1,0,0,"10.1002/jmv.70408",40454841,,"https://pubmed.ncbi.nlm.nih.gov/40454841","Lee 2025",2025,"J Med Virol","Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data","Influenza","Pediatric"
396,"#2066",1,0,1,1,1,1,1,0,0,"10.1002/jmv.70408",40454841,,"https://pubmed.ncbi.nlm.nih.gov/40454841","Lee 2025",2025,"J Med Virol","Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data","COVID","Adult"
396,"#2066",1,0,1,1,1,1,1,0,0,"10.1002/jmv.70408",40454841,,"https://pubmed.ncbi.nlm.nih.gov/40454841","Lee 2025",2025,"J Med Virol","Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data","Influenza","Adult"
398,"#2076",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2025.127300",40424706,,"https://pubmed.ncbi.nlm.nih.gov/40424706","Lee 2025",2025,"Vaccine","Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada","COVID","Adult"
399,"#2089",0,0,1,0,1,1,1,0,0,"10.1080/21645515.2024.2435156",39704470,,"https://pubmed.ncbi.nlm.nih.gov/39704470","Lei 2025",2025,"Hum Vaccin Immunother","Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China","Influenza","Pediatric"
399,"#2089",0,0,1,0,1,1,1,0,0,"10.1080/21645515.2024.2435156",39704470,,"https://pubmed.ncbi.nlm.nih.gov/39704470","Lei 2025",2025,"Hum Vaccin Immunother","Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China","Influenza","Adult"
400,"#7937",1,0,0,0,0,1,1,0,0,"10.3390/vaccines12060593",38932322,"PMC11209536","https://pmc.ncbi.nlm.nih.gov/articles/PMC11209536","Leung 2024",2024,"Vaccines","Risk of Seizure Aggravation after COVID-19 Vaccinations in Patients with Epilepsy","COVID","Adult"
401,"#7846",1,0,0,0,1,1,1,0,0,"10.1212/wnl.0000000000207847",37788935,,"https://pubmed.ncbi.nlm.nih.gov/37788935","LeVu 2023",2023,"Neurology","Risk of Guillain-Barr Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study","COVID","Pediatric"
401,"#7846",1,0,0,0,1,1,1,0,0,"10.1212/wnl.0000000000207847",37788935,,"https://pubmed.ncbi.nlm.nih.gov/37788935","LeVu 2023",2023,"Neurology","Risk of Guillain-Barr Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study","COVID","Adult"
402,"#7847",1,0,0,0,1,1,1,0,0,"10.1038/s41467-024-52038-6",39232036,"PMC11374778","https://pmc.ncbi.nlm.nih.gov/articles/PMC11374778","LeVu 2024",2024,"Nat Commun","Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis","COVID","Pediatric"
402,"#7847",1,0,0,0,1,1,1,0,0,"10.1038/s41467-024-52038-6",39232036,"PMC11374778","https://pmc.ncbi.nlm.nih.gov/articles/PMC11374778","LeVu 2024",2024,"Nat Commun","Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis","COVID","Adult"
403,"#7943",1,0,0,1,1,1,1,0,0,"10.1093/infdis/jiae364",39028664,,"https://pubmed.ncbi.nlm.nih.gov/39028664","Levy 2024",2024,"J Infect Dis","Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant","COVID","Pediatric"
403,"#7943",1,0,0,1,1,1,1,0,0,"10.1093/infdis/jiae364",39028664,,"https://pubmed.ncbi.nlm.nih.gov/39028664","Levy 2024",2024,"J Infect Dis","Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant","COVID","Adult"
404,"#2105",0,1,0,0,0,0,0,0,1,"10.3390/vaccines13040398",40333311,"PMC12031295","https://pmc.ncbi.nlm.nih.gov/articles/PMC12031295","Levy 2025",2025,"Vaccines","Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains","RSV","Immunocomp"
405,"#2106",1,0,0,0,0,1,1,0,0,"10.3389/fimmu.2025.1470609",40034704,"PMC11872700","https://pmc.ncbi.nlm.nih.gov/articles/PMC11872700","Levy 2025",2025,"Front Immunol","XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants","COVID","Adult"
406,"#22737",0,0,1,0,0,1,1,0,1,"10.1093/infdis/jiaf185",40198276,,"https://pubmed.ncbi.nlm.nih.gov/40198276","Lewis 2025",2025,"J Infect Dis","Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024","Influenza","Immunocomp"
407,"#7951",1,0,0,0,1,1,1,0,0,"10.1038/s41467-024-52668-w",39362845,"PMC11450198","https://pmc.ncbi.nlm.nih.gov/articles/PMC11450198","Lewnard 2024",2024,"Nat Commun","Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage","COVID","Pediatric"
407,"#7951",1,0,0,0,1,1,1,0,0,"10.1038/s41467-024-52668-w",39362845,"PMC11450198","https://pmc.ncbi.nlm.nih.gov/articles/PMC11450198","Lewnard 2024",2024,"Nat Commun","Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage","COVID","Adult"
408,"#8025",1,0,0,0,1,1,1,0,0,"10.2196/51007",39008362,"PMC11287098","https://pmc.ncbi.nlm.nih.gov/articles/PMC11287098","Li 2024",2024,"JMIR Public Health Surveill","Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis","COVID","Pediatric"
408,"#8025",1,0,0,0,1,1,1,0,0,"10.2196/51007",39008362,"PMC11287098","https://pmc.ncbi.nlm.nih.gov/articles/PMC11287098","Li 2024",2024,"JMIR Public Health Surveill","Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis","COVID","Adult"
410,"#32258",0,1,0,0,0,0,0,1,0,"10.1016/j.pmedr.2025.103150",40678810,"PMC12269873","https://pmc.ncbi.nlm.nih.gov/articles/PMC12269873","Li 2025",2025,"Prev Med Rep","Post-licensure safety of respiratory syncytial virus vaccines, Vaccine Adverse Event Reporting System, United States, May 2023-December 2024","RSV","Pregnant"
411,"#2165",1,0,0,0,0,1,1,0,0,"10.1111/ene.70020",39739424,"PMC11683473","https://pmc.ncbi.nlm.nih.gov/articles/PMC11683473","Lim 2025",2025,"Eur J Neurol","The association between acute transverse myelitis and COVID-19 vaccination in Korea: Self-controlled case series study","COVID","Adult"
412,"#8092",1,0,0,0,0,1,0,0,0,"10.21315/mjms2024.31.3.10",38984235,"PMC11229573","https://pmc.ncbi.nlm.nih.gov/articles/PMC11229573","Lin 2024",2024,"Malaysian Journal of Medical Sciences","Risk Factors Associated with Cutaneous Reactions Following COVID-19 Vaccine Immunisation: A Registry-Based Case-Control Study","COVID","Adult"
413,"#8103",1,0,0,0,0,1,0,0,1,"10.15585/mmwr.mm7312a5",38547037,"PMC10986819","https://pmc.ncbi.nlm.nih.gov/articles/PMC10986819","Link-Gelles 2024",2024,"MMWR Morb Mortal Wkly Rep","Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged 18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024","COVID","Immunocomp"
414,"#2183",1,0,0,0,0,0,0,0,1,"10.1001/jamanetworkopen.2025.17402",40560584,"PMC12199055","https://pmc.ncbi.nlm.nih.gov/articles/PMC12199055","Link-Gelles 2025",2025,"JAMA Netw Open","Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults","COVID","Immunocomp"
415,"#2182",1,0,0,0,0,1,1,0,1,"10.15585/mmwr.mm7406a1",40014628,"PMC11867580","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867580","Link-Gelles 2025",2025,"MMWR Morb Mortal Wkly Rep","Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged 18 Years - VISION and IVY Networks, September 2024-January 2025","COVID","Immunocomp"
417,"#22899",1,0,0,0,0,0,1,0,0,"10.1016/j.cmi.2025.05.002",40349967,,"https://pubmed.ncbi.nlm.nih.gov/40349967","Livne 2025",2025,"Clin Microbiol Infect","Hybrid and vaccination immunity against severe COVID-19 in the post-pandemic era-a retrospective cohort study","COVID","Adult"
418,"#2231",1,0,0,0,1,1,1,0,0,"10.1002/pds.70151",40328431,,"https://pubmed.ncbi.nlm.nih.gov/40328431","Lloyd 2025",2025,"Pharmacoepidemiol Drug Saf","Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States","COVID","Pediatric"
418,"#2231",1,0,0,0,1,1,1,0,0,"10.1002/pds.70151",40328431,,"https://pubmed.ncbi.nlm.nih.gov/40328431","Lloyd 2025",2025,"Pharmacoepidemiol Drug Saf","Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States","COVID","Adult"
419,"#2229",0,0,1,0,0,0,1,0,0,"10.1016/j.vaccine.2025.127069",40203591,,"https://pubmed.ncbi.nlm.nih.gov/40203591","Lloyd 2025",2025,"Vaccine","Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older","Influenza","Adult"
420,"#8201",0,0,1,0,0,0,1,0,0,"10.1186/s12889-023-16768-4",37784088,"PMC10546661","https://pmc.ncbi.nlm.nih.gov/articles/PMC10546661","Lophatananon 2023",2023,"BMC Public Health","The association of herpes zoster and influenza vaccinations with the risk of developing dementia: a population-based cohort study within the UK Clinical Practice Research Datalink","Influenza","Adult"
422,"#8238",0,0,1,0,0,0,1,0,0,"10.1001/jamanetworkopen.2024.23926",39037818,"PMC11265121","https://pmc.ncbi.nlm.nih.gov/articles/PMC11265121","Lu 2024",2024,"JAMA Netw Open","Stroke After Influenza Vaccines in Older Adults in the US, 2016 to 2019","Influenza","Adult"
423,"#8240",1,0,0,0,0,0,1,0,0,"10.1001/jama.2024.1059",38502075,"PMC10951737","https://pmc.ncbi.nlm.nih.gov/articles/PMC10951737","Lu 2024",2024,"Jama","Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults","COVID","Adult"
424,"#8278",1,0,0,0,1,1,1,0,0,"10.15585/mmwr.mm7342a1",39446667,"PMC11500842","https://pmc.ncbi.nlm.nih.gov/articles/PMC11500842","Ma 2024",2024,"MMWR Morb Mortal Wkly Rep","Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024","COVID","Pediatric"
424,"#8278",1,0,0,0,1,1,1,0,0,"10.15585/mmwr.mm7342a1",39446667,"PMC11500842","https://pmc.ncbi.nlm.nih.gov/articles/PMC11500842","Ma 2024",2024,"MMWR Morb Mortal Wkly Rep","Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024","COVID","Adult"
425,"#8294",1,0,0,0,0,1,1,0,0,"10.1097/hep.0000000000000787",38358465,,"https://pubmed.ncbi.nlm.nih.gov/38358465","Maan 2024",2024,"Hepatology","Extensive splanchnic vein thrombosis after SARS-CoV-2 vaccination: A Vascular Liver Disease Group (VALDIG) initiative","COVID","Adult"
426,"#8305",0,0,1,0,1,1,1,0,0,"10.1080/21645515.2024.2322196",38448394,"PMC10936612","https://pmc.ncbi.nlm.nih.gov/articles/PMC10936612","Machado 2024",2024,"Hum Vaccin Immunother","Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season","Influenza","Pediatric"
426,"#8305",0,0,1,0,1,1,1,0,0,"10.1080/21645515.2024.2322196",38448394,"PMC10936612","https://pmc.ncbi.nlm.nih.gov/articles/PMC10936612","Machado 2024",2024,"Hum Vaccin Immunother","Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season","Influenza","Adult"
427,"#2314",1,0,0,1,1,1,1,0,0,"10.1016/j.vaccine.2025.126892",39983541,,"https://pubmed.ncbi.nlm.nih.gov/39983541","Mackenzie 2025",2025,"Vaccine","What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA)","COVID","Pediatric"
427,"#2314",1,0,0,1,1,1,1,0,0,"10.1016/j.vaccine.2025.126892",39983541,,"https://pubmed.ncbi.nlm.nih.gov/39983541","Mackenzie 2025",2025,"Vaccine","What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA)","COVID","Adult"
428,"#2316",0,1,0,0,0,0,0,1,0,"10.1097/aog.0000000000005817",39746206,,"https://pubmed.ncbi.nlm.nih.gov/39746206","Madhi 2025",2025,"Obstet Gynecol","Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine","RSV","Pregnant"
430,"#8320",1,0,0,0,0,1,0,0,0,"10.1007/s10654-024-01170-0",39503924,"PMC11599392","https://pmc.ncbi.nlm.nih.gov/articles/PMC11599392","Magnus 2024",2024,"Eur J Epidemiol","Covid-19 vaccination and menstrual bleeding disturbances among women of fertile age: a Norwegian registry study","COVID","Adult"
431,"#8394",1,0,0,0,1,1,1,0,0,"10.3390/medicina60081343",39202624,"PMC11356762","https://pmc.ncbi.nlm.nih.gov/articles/PMC11356762","Manniche 2024",2024,"Medicina (Kaunas)","Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden","COVID","Pediatric"
431,"#8394",1,0,0,0,1,1,1,0,0,"10.3390/medicina60081343",39202624,"PMC11356762","https://pmc.ncbi.nlm.nih.gov/articles/PMC11356762","Manniche 2024",2024,"Medicina (Kaunas)","Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden","COVID","Adult"
432,"#8397",1,0,0,0,1,1,1,0,0,"10.3390/vaccines12121409",39772070,"PMC11680294","https://pmc.ncbi.nlm.nih.gov/articles/PMC11680294","Mansou 2024",2024,"Vaccines","Reported Adverse Events Following SARS-CoV-2 Vaccinations in the Canadian Province of Alberta and Associated Risk Factors: A Retrospective Cohort Study","COVID","Pediatric"
432,"#8397",1,0,0,0,1,1,1,0,0,"10.3390/vaccines12121409",39772070,"PMC11680294","https://pmc.ncbi.nlm.nih.gov/articles/PMC11680294","Mansou 2024",2024,"Vaccines","Reported Adverse Events Following SARS-CoV-2 Vaccinations in the Canadian Province of Alberta and Associated Risk Factors: A Retrospective Cohort Study","COVID","Adult"
433,"#16883",1,0,0,0,0,1,0,0,0,"10.3390/biomedicines12122852",39767757,"PMC11673082","https://pmc.ncbi.nlm.nih.gov/articles/PMC11673082","Mantovani 2024",2024,"Biomedicines","Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study","COVID","Adult"
434,"#8432",0,0,1,0,1,1,1,1,1,"10.1111/irv.70023",39623514,"PMC11611713","https://pmc.ncbi.nlm.nih.gov/articles/PMC11611713","Marron 2024",2024,"Influenza Other Respir Viruses","Influenza Vaccine Effectiveness Against Symptomatic Influenza in Primary Care: A Test Negative Case Control Study Over Two Influenza Seasons 2022/2023 and 2023/2024 in Ireland","Influenza","Immunocomp"
435,"#2405",0,0,1,0,1,1,1,0,0,"10.1016/j.ijid.2024.107364",39694231,"PMC11735411","https://pmc.ncbi.nlm.nih.gov/articles/PMC11735411","Martnez-Baz 2025",2025,"Int J Infect Dis","Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study","Influenza","Pediatric"
435,"#2405",0,0,1,0,1,1,1,0,0,"10.1016/j.ijid.2024.107364",39694231,"PMC11735411","https://pmc.ncbi.nlm.nih.gov/articles/PMC11735411","Martnez-Baz 2025",2025,"Int J Infect Dis","Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study","Influenza","Adult"
438,"#8481",1,0,0,0,0,1,1,0,0,"10.1177/20503121241272518",39220747,"PMC11363057","https://pmc.ncbi.nlm.nih.gov/articles/PMC11363057","Matsuzono 2024",2024,"SAGE Open Medicine","Effect of COVID 19 pandemic on the neurology department hospitalization with analysis of the neurological complications secondary to COVID 19 and vaccination against COVID 19","COVID","Adult"
439,"#8492",0,0,1,1,1,1,1,0,0,"10.2807/1560-7917.Es.2024.29.8.2400089",38390651,,"https://pubmed.ncbi.nlm.nih.gov/38390651","Maurel 2024",2024,"Euro Surveill","Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024","Influenza","Pediatric"
439,"#8492",0,0,1,1,1,1,1,0,0,"10.2807/1560-7917.Es.2024.29.8.2400089",38390651,,"https://pubmed.ncbi.nlm.nih.gov/38390651","Maurel 2024",2024,"Euro Surveill","Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024","Influenza","Adult"
440,"#23153",0,1,0,0,0,1,0,0,0,"10.1093/cid/ciaf292",40464662,,"https://pubmed.ncbi.nlm.nih.gov/40464662","Mayer 2025",2025,"Clin Infect Dis","Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years","RSV","Adult"
441,"#2444",1,0,0,0,0,1,1,0,0,"10.1016/j.jinf.2025.106447",39978439,,"https://pubmed.ncbi.nlm.nih.gov/39978439","Mazarakis 2025",2025,"J Infect","The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose","COVID","Adult"
442,"#8535",1,0,0,0,0,1,1,0,0,"10.1016/j.jinf.2024.106346",39550007,,"https://pubmed.ncbi.nlm.nih.gov/39550007","McLeod 2024",2024,"J Infect","The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old","COVID","Adult"
443,"#17051",1,0,0,0,1,0,0,0,0,,39555720,,"https://pubmed.ncbi.nlm.nih.gov/39555720","Memon 2024",2024,"Ir Med J","Cardiac Investigations in Paediatric Patients with Chest Pain Following COVID-19 mRNA Vaccination","COVID","Pediatric"
444,"#8576",1,0,0,0,0,0,1,0,0,"10.1111/irv.70009",39523781,"PMC11551475","https://pmc.ncbi.nlm.nih.gov/articles/PMC11551475","Merdrignac 2024",2024,"Influenza Other Respir Viruses","Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024","COVID","Adult"
445,"#8593",0,0,1,0,1,1,1,0,0,"10.1080/21645515.2024.2394255",39208849,"PMC11364069","https://pmc.ncbi.nlm.nih.gov/articles/PMC11364069","Mi 2024",2024,"Hum Vaccin Immunother","Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study","Influenza","Pediatric"
445,"#8593",0,0,1,0,1,1,1,0,0,"10.1080/21645515.2024.2394255",39208849,"PMC11364069","https://pmc.ncbi.nlm.nih.gov/articles/PMC11364069","Mi 2024",2024,"Hum Vaccin Immunother","Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study","Influenza","Adult"
446,"#17154",1,0,0,0,0,1,1,0,0,"10.7759/cureus.75889",39822416,"PMC11737604","https://pmc.ncbi.nlm.nih.gov/articles/PMC11737604","Mohamed 2024",2024,"Cureus","Safety of COVID-19 Vaccines in Patients With Multiple Sclerosis: A Cross-Sectional Study From a Tertiary Rehabilitation Center in Saudi Arabia","COVID","Adult"
447,"#8672",1,0,0,0,0,0,0,0,1,"10.1212/wnl.0000000000209662",39141880,,"https://pubmed.ncbi.nlm.nih.gov/39141880","Moisset 2024",2024,"Neurology","Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series","COVID","Immunocomp"
448,"#2557",1,0,0,0,0,1,1,0,0,"10.1016/j.jinf.2024.106374",39657850,,"https://pubmed.ncbi.nlm.nih.gov/39657850","Mok 2025",2025,"J Infect","Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine","COVID","Adult"
449,"#8678",0,0,1,0,0,1,1,0,1,"10.1093/cid/ciad477",37584344,"PMC10810716","https://pmc.ncbi.nlm.nih.gov/articles/PMC10810716","Mombelli 2024",2024,"Clin Infect Dis","Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial)","Influenza","Immunocomp"
451,"#8692",1,0,0,0,1,1,1,0,0,"10.17966/JMI.2024.29.3.117",,,"https://doi.org/10.17966/JMI.2024.29.3.117","Moon 2024",2024,"Journal of Mycology and Infection","Cutaneous Manifestations of COVID-19 Vaccination and COVID-19 Infection: a Questionnaire-based, Multi-center Study in Korea","COVID","Pediatric"
451,"#8692",1,0,0,0,1,1,1,0,0,"10.17966/JMI.2024.29.3.117",,,"https://doi.org/10.17966/JMI.2024.29.3.117","Moon 2024",2024,"Journal of Mycology and Infection","Cutaneous Manifestations of COVID-19 Vaccination and COVID-19 Infection: a Questionnaire-based, Multi-center Study in Korea","COVID","Adult"
452,"#8703",1,0,0,0,1,1,1,0,0,"10.1007/s40264-024-01462-0",39068268,"PMC11485117","https://pmc.ncbi.nlm.nih.gov/articles/PMC11485117","Morciano 2024",2024,"Drug Saf","Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study","COVID","Pediatric"
452,"#8703",1,0,0,0,1,1,1,0,0,"10.1007/s40264-024-01462-0",39068268,"PMC11485117","https://pmc.ncbi.nlm.nih.gov/articles/PMC11485117","Morciano 2024",2024,"Drug Saf","Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study","COVID","Adult"
453,"#8718",1,0,1,0,1,1,1,0,0,"10.1007/s40264-024-01406-8",38411838,"PMC11646557","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646557","Moro 2024",2024,"Drug Saf","Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)","COVID","Pediatric"
453,"#8718",1,0,1,0,1,1,1,0,0,"10.1007/s40264-024-01406-8",38411838,"PMC11646557","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646557","Moro 2024",2024,"Drug Saf","Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)","Influenza","Pediatric"
453,"#8718",1,0,1,0,1,1,1,0,0,"10.1007/s40264-024-01406-8",38411838,"PMC11646557","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646557","Moro 2024",2024,"Drug Saf","Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)","COVID","Adult"
453,"#8718",1,0,1,0,1,1,1,0,0,"10.1007/s40264-024-01406-8",38411838,"PMC11646557","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646557","Moro 2024",2024,"Drug Saf","Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)","Influenza","Adult"
454,"#8735",1,0,1,0,0,1,1,0,0,"10.1016/j.vaccine.2023.07.043",37544827,,"https://pubmed.ncbi.nlm.nih.gov/37544827","Moscara 2023",2023,"Vaccine","Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study","COVID","Adult"
454,"#8735",1,0,1,0,0,1,1,0,0,"10.1016/j.vaccine.2023.07.043",37544827,,"https://pubmed.ncbi.nlm.nih.gov/37544827","Moscara 2023",2023,"Vaccine","Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study","Influenza","Adult"
455,"#8739",1,0,1,0,0,1,1,0,0,"10.3390/vaccines11101624",37897026,"PMC10610948","https://pmc.ncbi.nlm.nih.gov/articles/PMC10610948","Moss 2023",2023,"Vaccines","Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 20222023 Winter Season","COVID","Adult"
455,"#8739",1,0,1,0,0,1,1,0,0,"10.3390/vaccines11101624",37897026,"PMC10610948","https://pmc.ncbi.nlm.nih.gov/articles/PMC10610948","Moss 2023",2023,"Vaccines","Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 20222023 Winter Season","Influenza","Adult"
457,"#23354",1,0,0,0,0,1,1,0,0,"10.1093/braincomms/fcae448",39777257,"PMC11703551","https://pmc.ncbi.nlm.nih.gov/articles/PMC11703551","Mukherjee 2025",2025,"Brain Commun","Vaccination prior to SARS-CoV-2 infection does not affect the neurologic manifestations of long COVID","COVID","Adult"
458,"#8796",1,0,1,0,0,1,0,0,0,"10.1007/s40121-023-00863-5",37698774,"PMC10581992","https://pmc.ncbi.nlm.nih.gov/articles/PMC10581992","Murdoch 2023",2023,"Infectious Diseases and Therapy","Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults","COVID","Adult"
458,"#8796",1,0,1,0,0,1,0,0,0,"10.1007/s40121-023-00863-5",37698774,"PMC10581992","https://pmc.ncbi.nlm.nih.gov/articles/PMC10581992","Murdoch 2023",2023,"Infectious Diseases and Therapy","Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults","Influenza","Adult"
460,"#8844",0,0,1,0,0,1,1,0,1,"10.1136/bmjgast-2024-001370",38897611,"PMC11200233","https://pmc.ncbi.nlm.nih.gov/articles/PMC11200233","Nakafero 2024",2024,"BMJ Open Gastroenterology","Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: A UK-wide study","Influenza","Immunocomp"
461,"#8848",0,0,1,0,0,1,1,0,1,"10.1016/j.jiac.2023.07.008",37481070,,"https://pubmed.ncbi.nlm.nih.gov/37481070","Nakashima 2023",2023,"J Infect Chemother","Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study","Influenza","Immunocomp"
462,"#17350",1,0,0,0,0,1,0,0,0,"10.1016/j.heliyon.2024.e34347",39108860,"PMC11301373","https://pmc.ncbi.nlm.nih.gov/articles/PMC11301373","Namiki 2024",2024,"Heliyon","Comparison of adverse events following the second/third dose of BNT162b2 in a medical institute in Japan","COVID","Adult"
463,"#17357",1,0,0,0,0,1,0,0,0,"10.7759/cureus.71671",39553063,"PMC11568403","https://pmc.ncbi.nlm.nih.gov/articles/PMC11568403","Naqid 2024",2024,"Cureus","Evaluating the Adverse Effects and Associated Risk Factors of COVID-19 Vaccines Among Healthcare Workers: A Retrospective Study in the Duhok Province, Iraq","COVID","Adult"
464,"#2677",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127291",40440921,,"https://pubmed.ncbi.nlm.nih.gov/40440921","Nasreen 2025",2025,"Vaccine","Risk of Guillain-Barr syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study","COVID","Pediatric"
464,"#2677",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127291",40440921,,"https://pubmed.ncbi.nlm.nih.gov/40440921","Nasreen 2025",2025,"Vaccine","Risk of Guillain-Barr syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study","COVID","Adult"
465,"#8873",1,0,0,0,1,1,1,0,0,"10.1093/ehjcvp/pvae063",39174484,,"https://pubmed.ncbi.nlm.nih.gov/39174484","Nazar 2024",2024,"Eur Heart J Cardiovasc Pharmacother","Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data","COVID","Pediatric"
465,"#8873",1,0,0,0,1,1,1,0,0,"10.1093/ehjcvp/pvae063",39174484,,"https://pubmed.ncbi.nlm.nih.gov/39174484","Nazar 2024",2024,"Eur Heart J Cardiovasc Pharmacother","Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data","COVID","Adult"
466,"#2684",1,0,0,0,1,1,1,0,0,"10.1038/s41598-025-03428-3",40425703,"PMC12116907","https://pmc.ncbi.nlm.nih.gov/articles/PMC12116907","Nazar 2025",2025,"Sci Rep","Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database","COVID","Pediatric"
466,"#2684",1,0,0,0,1,1,1,0,0,"10.1038/s41598-025-03428-3",40425703,"PMC12116907","https://pmc.ncbi.nlm.nih.gov/articles/PMC12116907","Nazar 2025",2025,"Sci Rep","Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database","COVID","Adult"
467,"#2692",1,0,0,0,0,1,1,0,1,"10.3390/vaccines13040392",40333305,"PMC12031221","https://pmc.ncbi.nlm.nih.gov/articles/PMC12031221","Nelli 2025",2025,"Vaccines","Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study","COVID","Immunocomp"
468,"#2695",1,1,1,0,0,0,1,0,0,"10.3390/vaccines13020158",40006705,"PMC11860858","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860858","Neutel 2025",2025,"Vaccines","Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults  65 Years of Age","COVID","Adult"
468,"#2695",1,1,1,0,0,0,1,0,0,"10.3390/vaccines13020158",40006705,"PMC11860858","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860858","Neutel 2025",2025,"Vaccines","Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults  65 Years of Age","RSV","Adult"
468,"#2695",1,1,1,0,0,0,1,0,0,"10.3390/vaccines13020158",40006705,"PMC11860858","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860858","Neutel 2025",2025,"Vaccines","Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults  65 Years of Age","Influenza","Adult"
469,"#8892",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2024.126462",39454292,,"https://pubmed.ncbi.nlm.nih.gov/39454292","Ng 2024",2024,"Vaccine","Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore","COVID","Adult"
470,"#23468",1,0,0,0,0,1,1,1,1,"10.1016/j.eclinm.2024.102995",39726669,"PMC11669791","https://pmc.ncbi.nlm.nih.gov/articles/PMC11669791","Nguyen 2025",2025,"EClinicalMedicine","Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform","COVID","Immunocomp"
471,"#23473",0,1,0,0,0,0,1,0,0,"10.1016/j.lanwpc.2025.101506",40092586,"PMC11910125","https://pmc.ncbi.nlm.nih.gov/articles/PMC11910125","Nguyen 2025",2025,"Lancet Reg Health West Pac","Short term safety profile of respiratory syncytial virus vaccine in adults aged  60 years in Australia","RSV","Adult"
472,"#2715",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2025.127275",40398327,,"https://pubmed.ncbi.nlm.nih.gov/40398327","Nham 2025",2025,"Vaccine","Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months","COVID","Adult"
473,"#2742",1,0,0,0,0,1,1,0,0,"10.1016/j.joca.2024.12.010",39855291,"PMC11954666","https://pmc.ncbi.nlm.nih.gov/articles/PMC11954666","Nong 2025",2025,"Osteoarthritis Cartilage","Association of COVID-19 vaccinations with osteoarthritis flares: A case-crossover study","COVID","Adult"
474,"#8955",1,0,0,0,0,0,1,0,0,"10.1080/14760584.2024.2428800",39535047,,"https://pubmed.ncbi.nlm.nih.gov/39535047","Nunes 2024",2024,"Expert Rev Vaccines","Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR Network Study","COVID","Adult"
475,"#8961",1,0,0,0,1,0,0,0,0,"10.1007/s00246-023-03200-2",37294336,"PMC10251331","https://pmc.ncbi.nlm.nih.gov/articles/PMC10251331","Nv 2024",2024,"Pediatr Cardiol","Longitudinal Assessment of Left Ventricular Function in Patients with Myopericarditis After mRNA COVID-19 Vaccination","COVID","Pediatric"
477,"#2762",1,0,0,0,0,1,1,0,0,"10.5858/arpa.2024-0095-OA",39246098,,"https://pubmed.ncbi.nlm.nih.gov/39246098","Obeng 2025",2025,"Arch Pathol Lab Med","Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines","COVID","Adult"
478,"#2773",0,0,1,0,0,0,1,0,0,"10.1002/pds.70082",39777941,"PMC11706699","https://pmc.ncbi.nlm.nih.gov/articles/PMC11706699","Ogawa 2025",2025,"Pharmacoepidemiol Drug Saf","Safety Assessment of Influenza Vaccination for Neurological Outcomes Among Older Adults in Japan: A Self-Controlled Case Series Study","Influenza","Adult"
479,"#17515",1,0,1,1,1,1,1,0,0,"10.1111/1756-185x.15294",39171515,,"https://pubmed.ncbi.nlm.nih.gov/39171515","Oh 2024",2024,"Int J Rheum Dis","Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database","COVID","Pediatric"
479,"#17515",1,0,1,1,1,1,1,0,0,"10.1111/1756-185x.15294",39171515,,"https://pubmed.ncbi.nlm.nih.gov/39171515","Oh 2024",2024,"Int J Rheum Dis","Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database","Influenza","Pediatric"
479,"#17515",1,0,1,1,1,1,1,0,0,"10.1111/1756-185x.15294",39171515,,"https://pubmed.ncbi.nlm.nih.gov/39171515","Oh 2024",2024,"Int J Rheum Dis","Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database","COVID","Adult"
479,"#17515",1,0,1,1,1,1,1,0,0,"10.1111/1756-185x.15294",39171515,,"https://pubmed.ncbi.nlm.nih.gov/39171515","Oh 2024",2024,"Int J Rheum Dis","Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database","Influenza","Adult"
480,"#9013",1,0,0,0,0,1,1,0,0,"10.1016/j.jamda.2024.105251",39245233,,"https://pubmed.ncbi.nlm.nih.gov/39245233","Okoye 2024",2024,"J Am Med Dir Assoc","Delirium Incidence and Predictors in SARS-CoV-2 Vaccinated Residents in Long-Term Care Facilities (LTCF): Insights from the GeroCovid Vax Study","COVID","Adult"
481,"#2796",1,0,0,0,0,1,1,0,0,"10.3390/vaccines13020192",40006738,"PMC11860627","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860627","Omole 2025",2025,"Vaccines","Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults 50 Years of Age","COVID","Adult"
483,"#9334",1,0,0,0,0,1,1,0,0,"10.23736/s0026-4806.24.09379-0",39392292,,"https://pubmed.ncbi.nlm.nih.gov/39392292","P_atkowska-Adamska 2024",2024,"Minerva Med","BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy","COVID","Adult"
484,"#9105",1,0,0,0,0,1,0,0,0,"10.1007/s00266-024-04274-w",39046483,,"https://pubmed.ncbi.nlm.nih.gov/39046483","Padilla-Pantoja 2024",2024,"Aesthetic Plast Surg","Temporary Delayed Hypersensitivity Reaction to Botulinum Toxin-A After COVID-19 Vaccination: A Case Series","COVID","Adult"
485,"#2845",1,0,0,0,0,1,1,0,0,"10.1016/j.jvacx.2025.100645",,,"https://doi.org/10.1016/j.jvacx.2025.100645","Pakanen 2025",2025,"VACCINE: X","COVID-19 vaccination as a rare potential etiology for cause of death after medicolegal autopsy. A Finnish nationwide study","COVID","Adult"
487,"#9151",1,0,0,0,1,1,1,0,0,"10.3346/jkms.2024.39.e309",39536790,"PMC11557253","https://pmc.ncbi.nlm.nih.gov/articles/PMC11557253","Park 2024",2024,"J Korean Med Sci","Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea","COVID","Pediatric"
487,"#9151",1,0,0,0,1,1,1,0,0,"10.3346/jkms.2024.39.e309",39536790,"PMC11557253","https://pmc.ncbi.nlm.nih.gov/articles/PMC11557253","Park 2024",2024,"J Korean Med Sci","Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea","COVID","Adult"
488,"#9154",1,0,0,0,1,1,1,0,0,"10.3346/jkms.2024.39.e274",39497564,"PMC11538574","https://pmc.ncbi.nlm.nih.gov/articles/PMC11538574","Park 2024",2024,"J Korean Med Sci","Reported Adverse Events and Associated Factors in Korean Coronavirus Disease 2019 Vaccinations","COVID","Pediatric"
488,"#9154",1,0,0,0,1,1,1,0,0,"10.3346/jkms.2024.39.e274",39497564,"PMC11538574","https://pmc.ncbi.nlm.nih.gov/articles/PMC11538574","Park 2024",2024,"J Korean Med Sci","Reported Adverse Events and Associated Factors in Korean Coronavirus Disease 2019 Vaccinations","COVID","Adult"
489,"#17692",1,0,0,0,0,1,0,0,0,"10.12669/pjms.40.7.8709",39092064,"PMC11255808","https://pmc.ncbi.nlm.nih.gov/articles/PMC11255808","Parveen 2024",2024,"Pak J Med Sci","COVID-19 vaccination and menstrual disturbances: A prospective study from Pakistan","COVID","Adult"
491,"#23715",1,0,1,0,0,1,1,0,0,"10.1016/j.virol.2025.110613",40561867,,"https://pubmed.ncbi.nlm.nih.gov/40561867","Pasquale 2025",2025,"Virology","Safety of SARS-CoV-2 XBB.1.5 and seasonal influenza vaccines co-administration: data from a perspective observational active surveillance study. Puglia (Italy), season 2023/2024","COVID","Adult"
491,"#23715",1,0,1,0,0,1,1,0,0,"10.1016/j.virol.2025.110613",40561867,,"https://pubmed.ncbi.nlm.nih.gov/40561867","Pasquale 2025",2025,"Virology","Safety of SARS-CoV-2 XBB.1.5 and seasonal influenza vaccines co-administration: data from a perspective observational active surveillance study. Puglia (Italy), season 2023/2024","Influenza","Adult"
492,"#23729",1,0,0,0,1,1,1,0,0,"10.1016/j.jaad.2025.03.021",40107504,,"https://pubmed.ncbi.nlm.nih.gov/40107504","Pathak 2025",2025,"J Am Acad Dermatol","Vitiligo development following COVID-19 vaccination: A retrospective analysis of 128 cases using the Vaccine Adverse Events Reporting System","COVID","Pediatric"
492,"#23729",1,0,0,0,1,1,1,0,0,"10.1016/j.jaad.2025.03.021",40107504,,"https://pubmed.ncbi.nlm.nih.gov/40107504","Pathak 2025",2025,"J Am Acad Dermatol","Vitiligo development following COVID-19 vaccination: A retrospective analysis of 128 cases using the Vaccine Adverse Events Reporting System","COVID","Adult"
493,"#9213",1,0,1,0,1,1,1,0,0,"10.1016/j.ebiom.2024.105103",38574407,"PMC11004685","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004685","Pattinson 2024",2024,"EBioMedicine","Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses","COVID","Pediatric"
493,"#9213",1,0,1,0,1,1,1,0,0,"10.1016/j.ebiom.2024.105103",38574407,"PMC11004685","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004685","Pattinson 2024",2024,"EBioMedicine","Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses","Influenza","Pediatric"
493,"#9213",1,0,1,0,1,1,1,0,0,"10.1016/j.ebiom.2024.105103",38574407,"PMC11004685","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004685","Pattinson 2024",2024,"EBioMedicine","Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses","COVID","Adult"
493,"#9213",1,0,1,0,1,1,1,0,0,"10.1016/j.ebiom.2024.105103",38574407,"PMC11004685","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004685","Pattinson 2024",2024,"EBioMedicine","Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses","Influenza","Adult"
494,"#9227",0,1,0,0,0,0,0,0,1,"10.1016/s0140-6736(24)01738-0",39426837,,"https://pubmed.ncbi.nlm.nih.gov/39426837","Payne 2024",2024,"Lancet","Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis","RSV","Immunocomp"
495,"#2925",1,0,0,0,0,1,1,0,1,"10.1016/j.vaccine.2025.127010",40184817,,"https://pubmed.ncbi.nlm.nih.gov/40184817","Payne 2025",2025,"Vaccine","Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged 18 years with end stage kidney disease - United States, September 2023-April 2024","COVID","Immunocomp"
496,"#9233",1,0,0,0,1,1,1,0,0,"10.4103/singaporemedj.SMJ-2023-258",39324928,,"https://pubmed.ncbi.nlm.nih.gov/39324928","Peck 2024",2024,"Singapore Med J","Anaphylaxis post-COVID-19 vaccinations in Singapore","COVID","Pediatric"
496,"#9233",1,0,0,0,1,1,1,0,0,"10.4103/singaporemedj.SMJ-2023-258",39324928,,"https://pubmed.ncbi.nlm.nih.gov/39324928","Peck 2024",2024,"Singapore Med J","Anaphylaxis post-COVID-19 vaccinations in Singapore","COVID","Adult"
497,"#9241",1,0,0,0,0,1,1,0,0,"10.1007/s12026-024-09540-2",39285049,,"https://pubmed.ncbi.nlm.nih.gov/39285049","Pekdiker 2024",2024,"Immunol Res","ASIA syndrome after BNT162b2 vaccination: Is it a distinct rheumatoid arthritis phenotype?","COVID","Adult"
498,"#17803",1,0,0,0,0,1,1,0,1,"10.1097/txd.0000000000001645",38769974,,"https://pubmed.ncbi.nlm.nih.gov/38769974","Petr 2024",2024,"Transplant Direct","Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine Booster Doses in Kidney Transplant Recipients: Results of a 12-mo Follow-up From a Prospective Observational Study","COVID","Immunocomp"
499,"#9319",1,0,0,0,0,1,1,0,0,"10.1089/vim.2024.0019",39149804,,"https://pubmed.ncbi.nlm.nih.gov/39149804","Pinto 2024",2024,"Viral Immunol","Comparison of Adverse Events and Antibody Responses Among Different COVID-19 Vaccination Schedules","COVID","Adult"
500,"#9320",1,0,0,0,0,1,1,0,0,"10.3390/vaccines12091016",39340046,"PMC11436231","https://pmc.ncbi.nlm.nih.gov/articles/PMC11436231","Pira 2024",2024,"Vaccines","COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid","COVID","Adult"
501,"#9345",0,0,1,0,0,1,0,0,0,"10.3390/vaccines11101528",37896932,"PMC10611124","https://pmc.ncbi.nlm.nih.gov/articles/PMC10611124","Poder 2023",2023,"Vaccines","Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 5064 Years of Age","Influenza","Adult"
502,"#3014",1,1,1,1,1,1,1,0,0,"10.1111/apm.70010",40017167,,"https://pubmed.ncbi.nlm.nih.gov/40017167","Pratt 2025",2025,"APMIS","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis","COVID","Pediatric"
502,"#3014",1,1,1,1,1,1,1,0,0,"10.1111/apm.70010",40017167,,"https://pubmed.ncbi.nlm.nih.gov/40017167","Pratt 2025",2025,"APMIS","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis","RSV","Pediatric"
502,"#3014",1,1,1,1,1,1,1,0,0,"10.1111/apm.70010",40017167,,"https://pubmed.ncbi.nlm.nih.gov/40017167","Pratt 2025",2025,"APMIS","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis","Influenza","Pediatric"
502,"#3014",1,1,1,1,1,1,1,0,0,"10.1111/apm.70010",40017167,,"https://pubmed.ncbi.nlm.nih.gov/40017167","Pratt 2025",2025,"APMIS","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis","COVID","Adult"
502,"#3014",1,1,1,1,1,1,1,0,0,"10.1111/apm.70010",40017167,,"https://pubmed.ncbi.nlm.nih.gov/40017167","Pratt 2025",2025,"APMIS","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis","RSV","Adult"
502,"#3014",1,1,1,1,1,1,1,0,0,"10.1111/apm.70010",40017167,,"https://pubmed.ncbi.nlm.nih.gov/40017167","Pratt 2025",2025,"APMIS","Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis","Influenza","Adult"
503,"#3018",1,0,0,0,0,1,1,0,0,"10.1016/j.jns.2025.123536",40373476,,"https://pubmed.ncbi.nlm.nih.gov/40373476","Primicerio 2025",2025,"J Neurol Sci","Small fiber neuropathy following COVID-19 vaccination: A case series","COVID","Adult"
504,"#3019",0,0,1,0,0,1,1,0,1,"10.3389/ti.2025.14187",40454297,"PMC12124284","https://pmc.ncbi.nlm.nih.gov/articles/PMC12124284","Prins 2025",2025,"Transpl Int","A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Influenza Among Immunocompromised Adults With a Solid Organ Transplant","Influenza","Immunocomp"
505,"#9407",1,0,0,0,0,1,1,0,0,"10.3389/fcvm.2024.1435038",39494234,"PMC11527644","https://pmc.ncbi.nlm.nih.gov/articles/PMC11527644","Pudasaini 2024",2024,"Frontiers in Cardiovascular Medicine","Levels of high-sensitive troponin T and mid-regional pro-adrenomedullin after COVID-19 vaccination in vulnerable groups: monitoring cardiovascular safety of COVID-19 vaccination","COVID","Adult"
509,"#9582",1,0,0,0,1,1,1,0,0,"10.3390/vaccines12090971",39340003,"PMC11435866","https://pmc.ncbi.nlm.nih.gov/articles/PMC11435866","Reynolds 2024",2024,"Vaccines (Basel)","Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia","COVID","Pediatric"
509,"#9582",1,0,0,0,1,1,1,0,0,"10.3390/vaccines12090971",39340003,"PMC11435866","https://pmc.ncbi.nlm.nih.gov/articles/PMC11435866","Reynolds 2024",2024,"Vaccines (Basel)","Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia","COVID","Adult"
510,"#9595",1,0,1,0,0,1,1,0,0,"10.3390/vaccines12040425",38675807,"PMC11054385","https://pmc.ncbi.nlm.nih.gov/articles/PMC11054385","Riccomi 2024",2024,"Vaccines","Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination","COVID","Adult"
510,"#9595",1,0,1,0,0,1,1,0,0,"10.3390/vaccines12040425",38675807,"PMC11054385","https://pmc.ncbi.nlm.nih.gov/articles/PMC11054385","Riccomi 2024",2024,"Vaccines","Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination","Influenza","Adult"
512,"#3168",0,0,1,0,1,1,1,0,0,"10.2807/1560-7917.Es.2025.30.7.2500102",39980423,,"https://pubmed.ncbi.nlm.nih.gov/39980423","Rose 2025",2025,"Euro Surveill","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025","Influenza","Pediatric"
512,"#3168",0,0,1,0,1,1,1,0,0,"10.2807/1560-7917.Es.2025.30.7.2500102",39980423,,"https://pubmed.ncbi.nlm.nih.gov/39980423","Rose 2025",2025,"Euro Surveill","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025","Influenza","Adult"
513,"#9686",1,0,0,0,0,1,0,0,1,"10.1080/07853890.2023.2295979",38289017,"PMC10829820","https://pmc.ncbi.nlm.nih.gov/articles/PMC10829820","Rossier 2024",2024,"Ann Med","SARS-CoV-2 vaccination in inflammatory bowel disease patients is not associated with flares: a retrospective single-centre Swiss study","COVID","Immunocomp"
514,"#3178",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127217",40344810,,"https://pubmed.ncbi.nlm.nih.gov/40344810","Rouleau 2025",2025,"Vaccine","New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada","COVID","Pediatric"
514,"#3178",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127217",40344810,,"https://pubmed.ncbi.nlm.nih.gov/40344810","Rouleau 2025",2025,"Vaccine","New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada","COVID","Adult"
515,"#9701",1,0,0,0,0,1,0,0,0,"10.3390/vaccines12070802",39066440,"PMC11281689","https://pmc.ncbi.nlm.nih.gov/articles/PMC11281689","Rousculp 2024",2024,"Vaccines (Basel)","Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines","COVID","Adult"
516,"#9734",0,0,1,0,0,0,1,0,0,"10.1016/j.medcli.2024.07.023",39414550,,"https://pubmed.ncbi.nlm.nih.gov/39414550","RuzafaMartinez 2024",2024,"Med Clin (Barc)","Vaccine effectiveness in patients admitted for influenza during the 2023-2024 season","Influenza","Adult"
517,"#9740",1,0,0,0,0,0,1,0,1,"10.3346/jkms.2024.39.e190",38915282,"PMC11196855","https://pmc.ncbi.nlm.nih.gov/articles/PMC11196855","Ryu 2024",2024,"J Korean Med Sci","Cardiovascular Safety of COVID-19 Vaccination in Patients With Cancer: A Self-Controlled Case Series Study in Korea","COVID","Immunocomp"
518,"#3209",1,0,0,0,0,1,1,0,0,"10.3390/vaccines13020161",40006708,"PMC11861607","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861607","Saavedra 2025",2025,"Vaccines","Prevalence of Adverse Events Reported Following the First Dose of COVID-19 Vaccines in Bahia State, Brazil, from 2021 to 2022","COVID","Adult"
519,"#9763",1,0,0,0,0,1,0,0,0,"10.23736/s2724-606x.22.05148-x",36193832,,"https://pubmed.ncbi.nlm.nih.gov/36193832","Safrai 2024",2024,"Minerva Obstet Gynecol","BNT162b2 COVID-19 vaccine does not affect fertility as explored in a pilot study of women undergoing IVF treatment","COVID","Adult"
520,"#3241",1,0,0,0,1,1,1,0,0,"10.1007/s10072-024-07870-5",39560882,,"https://pubmed.ncbi.nlm.nih.gov/39560882","Salmaggi 2025",2025,"Neurol Sci","Impact of COVID-19 disease and COVID-19 vaccinations on hospital admissions for neurological diseases in the Lombardia over-12 population. Data from a self-controlled case series analysis","COVID","Pediatric"
520,"#3241",1,0,0,0,1,1,1,0,0,"10.1007/s10072-024-07870-5",39560882,,"https://pubmed.ncbi.nlm.nih.gov/39560882","Salmaggi 2025",2025,"Neurol Sci","Impact of COVID-19 disease and COVID-19 vaccinations on hospital admissions for neurological diseases in the Lombardia over-12 population. Data from a self-controlled case series analysis","COVID","Adult"
521,"#24180",1,0,0,0,1,1,1,0,0,"10.1007/s40264-025-01547-4",40238055,"PMC12259799","https://pmc.ncbi.nlm.nih.gov/articles/PMC12259799","Sankar 2025",2025,"Drug Saf","Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System","COVID","Pediatric"
521,"#24180",1,0,0,0,1,1,1,0,0,"10.1007/s40264-025-01547-4",40238055,"PMC12259799","https://pmc.ncbi.nlm.nih.gov/articles/PMC12259799","Sankar 2025",2025,"Drug Saf","Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System","COVID","Adult"
524,"#18485",1,0,0,0,1,1,0,0,0,"10.1001/jama.2024.16380",39186694,"PMC11348078","https://pmc.ncbi.nlm.nih.gov/articles/PMC11348078","Semenzato 2024",2024,"Jama","Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies","COVID","Pediatric"
524,"#18485",1,0,0,0,1,1,0,0,0,"10.1001/jama.2024.16380",39186694,"PMC11348078","https://pmc.ncbi.nlm.nih.gov/articles/PMC11348078","Semenzato 2024",2024,"Jama","Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies","COVID","Adult"
525,"#3337",0,0,1,0,0,0,1,0,0,"10.2807/1560-7917.Es.2025.30.4.2500059",39885824,,"https://pubmed.ncbi.nlm.nih.gov/39885824","Separovic 2025",2025,"Euro Surveill","Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25","Influenza","Adult"
526,"#10011",1,0,0,0,1,1,1,0,0,"10.1177/19417381231208677",37946492,"PMC11195857","https://pmc.ncbi.nlm.nih.gov/articles/PMC11195857","Shah 2024",2024,"Sports Health","Cardiovascular Safety of the COVID-19 Vaccine in Team USA Athletes","COVID","Pediatric"
526,"#10011",1,0,0,0,1,1,1,0,0,"10.1177/19417381231208677",37946492,"PMC11195857","https://pmc.ncbi.nlm.nih.gov/articles/PMC11195857","Shah 2024",2024,"Sports Health","Cardiovascular Safety of the COVID-19 Vaccine in Team USA Athletes","COVID","Adult"
527,"#3351",1,0,0,0,0,1,1,0,0,"10.1111/1756-185x.70043",39791506,,"https://pubmed.ncbi.nlm.nih.gov/39791506","Shaharir 2025",2025,"Int J Rheum Dis","Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study","COVID","Adult"
528,"#10032",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2024.04.097",38729910,,"https://pubmed.ncbi.nlm.nih.gov/38729910","Shani 2024",2024,"Vaccine","The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities","COVID","Pediatric"
528,"#10032",1,0,0,0,1,1,1,0,0,"10.1016/j.vaccine.2024.04.097",38729910,,"https://pubmed.ncbi.nlm.nih.gov/38729910","Shani 2024",2024,"Vaccine","The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities","COVID","Adult"
529,"#10041",0,0,1,0,0,0,1,0,0,"10.1186/s12979-023-00367-3",37644610,"PMC10463383","https://pmc.ncbi.nlm.nih.gov/articles/PMC10463383","Shapiro 2023",2023,"Immunity and Ageing","The intersection of biological sex and gender in adverse events following seasonal influenza vaccination in older adults","Influenza","Adult"
530,"#10043",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2024.126440",39442285,,"https://pubmed.ncbi.nlm.nih.gov/39442285","Sharff 2024",2024,"Vaccine","Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an integrated health system","COVID","Adult"
531,"#10056",0,1,0,0,0,0,1,0,0,"10.1093/infdis/jiae081",38385566,"PMC11420773","https://pmc.ncbi.nlm.nih.gov/articles/PMC11420773","Shaw 2024",2024,"J Infect Dis","Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults","RSV","Adult"
532,"#10057",0,1,0,0,0,1,0,0,0,"10.1093/infdis/jiae035",38298125,"PMC11420805","https://pmc.ncbi.nlm.nih.gov/articles/PMC11420805","Shaw 2024",2024,"J Infect Dis","Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial","RSV","Adult"
533,"#24345",1,0,0,0,0,1,1,0,0,"10.3390/vaccines13020176",40006723,"PMC11860193","https://pmc.ncbi.nlm.nih.gov/articles/PMC11860193","Shemer 2025",2025,"Vaccines (Basel)","COVID-19 Vaccination and Acute Anterior Uveitis-A Case Control Study","COVID","Adult"
534,"#10083",1,0,0,0,1,0,0,0,0,"10.1093/jpids/piae062",38860591,"PMC11344470","https://pmc.ncbi.nlm.nih.gov/articles/PMC11344470","Sher 2024",2024,"J Pediatric Infect Dis Soc","Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds","COVID","Pediatric"
535,"#10101",0,0,1,0,0,0,1,0,0,"10.1016/j.vaccine.2024.04.051",38704258,,"https://pubmed.ncbi.nlm.nih.gov/38704258","Shi 2024",2024,"Vaccine","Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older","Influenza","Adult"
536,"#18637",1,0,0,0,0,1,1,0,0,"10.35772/ghm.2024.01053",39741991,"PMC11680453","https://pmc.ncbi.nlm.nih.gov/articles/PMC11680453","Shoji 2024",2024,"Glob Health Med","Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan","COVID","Adult"
537,"#10138",1,0,0,0,0,1,0,0,0,"10.1093/cid/ciae132",38465901,,"https://pubmed.ncbi.nlm.nih.gov/38465901","Shrestha 2024",2024,"Clin Infect Dis","Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine","COVID","Adult"
539,"#3434",1,1,1,1,0,0,1,0,0,"10.1016/j.eimc.2025.03.006",40467410,,"https://pubmed.ncbi.nlm.nih.gov/40467410","Silva-Afonso 2025",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department","COVID","Pediatric"
539,"#3434",1,1,1,1,0,0,1,0,0,"10.1016/j.eimc.2025.03.006",40467410,,"https://pubmed.ncbi.nlm.nih.gov/40467410","Silva-Afonso 2025",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department","RSV","Pediatric"
539,"#3434",1,1,1,1,0,0,1,0,0,"10.1016/j.eimc.2025.03.006",40467410,,"https://pubmed.ncbi.nlm.nih.gov/40467410","Silva-Afonso 2025",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department","Influenza","Pediatric"
539,"#3434",1,1,1,1,0,0,1,0,0,"10.1016/j.eimc.2025.03.006",40467410,,"https://pubmed.ncbi.nlm.nih.gov/40467410","Silva-Afonso 2025",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department","COVID","Adult"
539,"#3434",1,1,1,1,0,0,1,0,0,"10.1016/j.eimc.2025.03.006",40467410,,"https://pubmed.ncbi.nlm.nih.gov/40467410","Silva-Afonso 2025",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department","RSV","Adult"
539,"#3434",1,1,1,1,0,0,1,0,0,"10.1016/j.eimc.2025.03.006",40467410,,"https://pubmed.ncbi.nlm.nih.gov/40467410","Silva-Afonso 2025",2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department","Influenza","Adult"
541,"#10228",0,0,1,0,1,1,1,0,0,"10.2807/1560-7917.Es.2024.29.7.2400076",38362622,,"https://pubmed.ncbi.nlm.nih.gov/38362622","Skowronski 2024",2024,"Euro Surveill","2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)","Influenza","Pediatric"
541,"#10228",0,0,1,0,1,1,1,0,0,"10.2807/1560-7917.Es.2024.29.7.2400076",38362622,,"https://pubmed.ncbi.nlm.nih.gov/38362622","Skowronski 2024",2024,"Euro Surveill","2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)","Influenza","Adult"
542,"#10236",0,0,1,0,0,1,1,0,0,"10.1007/s40264-023-01356-7",37882905,,"https://pubmed.ncbi.nlm.nih.gov/37882905","Slingerland 2023",2023,"Drug Saf","The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands","Influenza","Adult"
543,"#3468",1,0,0,0,1,1,1,0,0,"10.5694/mja2.52557",39655683,,"https://pubmed.ncbi.nlm.nih.gov/39655683","Smith 2025",2025,"Med J Aust","Clinical phenotype of COVID-19 vaccine-associated myocarditis in Victoria, 2021-22: a cross-sectional study","COVID","Pediatric"
543,"#3468",1,0,0,0,1,1,1,0,0,"10.5694/mja2.52557",39655683,,"https://pubmed.ncbi.nlm.nih.gov/39655683","Smith 2025",2025,"Med J Aust","Clinical phenotype of COVID-19 vaccine-associated myocarditis in Victoria, 2021-22: a cross-sectional study","COVID","Adult"
544,"#10254",0,0,1,0,1,1,1,0,1,"10.2807/1560-7917.Es.2024.29.2.2300709",38214082,,"https://pubmed.ncbi.nlm.nih.gov/38214082","Smolarchuk 2024",2024,"Euro Surveill","Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season","Influenza","Immunocomp"
545,"#3481",1,0,0,0,0,1,1,1,1,"10.1016/j.bbih.2024.100902",39686920,"PMC11646749","https://pmc.ncbi.nlm.nih.gov/articles/PMC11646749","Sodagari 2025",2025,"Brain, Behavior, and Immunity - Health","Examining vaccination-related adverse events in frequent neurodegenerative diseases","COVID","Immunocomp"
546,"#10264",1,0,0,0,0,0,1,0,0,"10.1016/j.vaccine.2024.04.096",38714447,,"https://pubmed.ncbi.nlm.nih.gov/38714447","Soe 2024",2024,"Vaccine","mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network","COVID","Adult"
547,"#10367",1,0,0,0,0,1,1,0,0,"10.1097/aog.0000000000005615",38781590,,"https://pubmed.ncbi.nlm.nih.gov/38781590","Strid 2024",2024,"Obstet Gynecol","Postmenopausal Bleeding After Coronavirus Disease 2019 (COVID-19) Vaccination: Vaccine Adverse Event Reporting System","COVID","Adult"
548,"#24573",1,0,0,0,0,1,1,0,0,"10.3389/fphar.2025.1561410",40356957,"PMC12066665","https://pmc.ncbi.nlm.nih.gov/articles/PMC12066665","Subaiea 2025",2025,"Front Pharmacol","Charting the COVID-19 vaccination journey in Saudi Arabia: Insights into post-vaccination adverse effects and immunization dynamics","COVID","Adult"
549,"#3602",0,0,1,1,1,1,1,0,0,"10.2807/1560-7917.Es.2025.30.7.2500084",39980425,,"https://pubmed.ncbi.nlm.nih.gov/39980425","Sun 2025",2025,"Euro Surveill","Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season","Influenza","Pediatric"
549,"#3602",0,0,1,1,1,1,1,0,0,"10.2807/1560-7917.Es.2025.30.7.2500084",39980425,,"https://pubmed.ncbi.nlm.nih.gov/39980425","Sun 2025",2025,"Euro Surveill","Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season","Influenza","Adult"
550,"#3592",1,0,0,0,1,1,1,0,1,"10.1016/j.vaccine.2024.126629",39700907,,"https://pubmed.ncbi.nlm.nih.gov/39700907","Sun 2025",2025,"Vaccine","Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States","COVID","Immunocomp"
551,"#10420",0,1,0,0,0,1,1,0,0,"10.1001/jama.2024.15775",39230920,"PMC11375516","https://pmc.ncbi.nlm.nih.gov/articles/PMC11375516","Surie 2024",2024,"Jama","RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older","RSV","Adult"
553,"#10431",1,0,0,0,1,1,1,0,0,"10.1093/ofid/ofae495",39290777,"PMC11406745","https://pmc.ncbi.nlm.nih.gov/articles/PMC11406745","Swift 2024",2024,"Open Forum Infectious Diseases","Association of COVID-19 Vaccination With Risk of Medically Attended Postacute Sequelae of COVID-19 During the Ancestral, Alpha, Delta, and Omicron Variant Eras","COVID","Pediatric"
553,"#10431",1,0,0,0,1,1,1,0,0,"10.1093/ofid/ofae495",39290777,"PMC11406745","https://pmc.ncbi.nlm.nih.gov/articles/PMC11406745","Swift 2024",2024,"Open Forum Infectious Diseases","Association of COVID-19 Vaccination With Risk of Medically Attended Postacute Sequelae of COVID-19 During the Ancestral, Alpha, Delta, and Omicron Variant Eras","COVID","Adult"
554,"#3634",1,0,0,0,1,1,1,0,0,"10.1016/j.jiac.2024.07.025",39103148,,"https://pubmed.ncbi.nlm.nih.gov/39103148","Takada 2025",2025,"J Infect Chemother","SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database","COVID","Pediatric"
554,"#3634",1,0,0,0,1,1,1,0,0,"10.1016/j.jiac.2024.07.025",39103148,,"https://pubmed.ncbi.nlm.nih.gov/39103148","Takada 2025",2025,"J Infect Chemother","SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database","COVID","Adult"
555,"#10466",1,0,0,0,0,1,1,0,0,"10.1016/j.jocmr.2024.101036",38479457,"PMC11004989","https://pmc.ncbi.nlm.nih.gov/articles/PMC11004989","Talib 2024",2024,"J Cardiovasc Magn Reson","Cardiovascular magnetic resonance imaging and clinical follow-up in patients with clinically suspected myocarditis after COVID-19 vaccination","COVID","Adult"
557,"#10479",0,0,1,0,0,1,1,0,0,"10.1111/ene.16172",38117538,"PMC11236019","https://pmc.ncbi.nlm.nih.gov/articles/PMC11236019","Tanaka 2024",2024,"Eur J Neurol","Risk of stroke within 3, 7, 14, 21 and 30 days after influenza vaccination in Alberta, Canada: A population-based study","Influenza","Adult"
558,"#19001",1,0,0,0,0,1,0,0,0,"10.1016/j.jvacx.2024.100489",38699157,"PMC11063515","https://pmc.ncbi.nlm.nih.gov/articles/PMC11063515","Tani 2024",2024,"Vaccine X","Reduction of adverse reactions and correlation between post-vaccination fever and specific antibody response across successive SARS-CoV-2 mRNA vaccinations","COVID","Adult"
560,"#19019",1,0,0,0,0,1,0,0,0,"10.1093/ofid/ofae370",39015348,"PMC11250225","https://pmc.ncbi.nlm.nih.gov/articles/PMC11250225","Tartof 2024",2024,"Open Forum Infect Dis","Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages","COVID","Adult"
561,"#10507",0,1,0,0,0,0,1,0,0,"10.1001/jamanetworkopen.2024.50832",39671195,"PMC11645642","https://pmc.ncbi.nlm.nih.gov/articles/PMC11645642","Tartof 2024",2024,"JAMA Netw Open","Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease","RSV","Adult"
562,"#10522",1,0,0,0,0,1,1,0,0,"10.15585/mmwr.mm7339a2",39361542,"PMC11449267","https://pmc.ncbi.nlm.nih.gov/articles/PMC11449267","Taylor 2024",2024,"MMWR Morb Mortal Wkly Rep","COVID-19-Associated Hospitalizations Among U.S. Adults Aged 18 Years - COVID-NET, 12 States, October 2023-April 2024","COVID","Adult"
564,"#10548",1,0,0,0,1,0,0,0,0,"10.1080/09273948.2023.2220782",37315304,,"https://pubmed.ncbi.nlm.nih.gov/37315304","Testi 2024",2024,"Ocul Immunol Inflamm","Ocular Inflammatory Events Following COVID-19 Vaccination in the Paediatric Population: A Multinational Case Series","COVID","Pediatric"
565,"#10549",1,0,0,0,1,1,1,0,0,"10.1136/bjo-2023-324503",38041661,,"https://pubmed.ncbi.nlm.nih.gov/38041661","Testi 2024",2024,"Br J Ophthalmol","Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK","COVID","Pediatric"
565,"#10549",1,0,0,0,1,1,1,0,0,"10.1136/bjo-2023-324503",38041661,,"https://pubmed.ncbi.nlm.nih.gov/38041661","Testi 2024",2024,"Br J Ophthalmol","Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK","COVID","Adult"
566,"#10550",1,0,0,0,0,1,0,0,0,"10.1016/j.jvacx.2024.100516",39040886,"PMC11260603","https://pmc.ncbi.nlm.nih.gov/articles/PMC11260603","Tetsuka 2024",2024,"VACCINE: X","Adverse events of COVID-19 vaccination during 20212022 suppressed by breakfast consumption and favorable sleeping habit among Japanese university students","COVID","Adult"
567,"#3688",1,0,0,0,1,1,1,0,0,"10.3390/vaccines13030289",40266198,"PMC11946013","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946013","Thanborisutkul 2025",2025,"Vaccines","Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines","COVID","Pediatric"
567,"#3688",1,0,0,0,1,1,1,0,0,"10.3390/vaccines13030289",40266198,"PMC11946013","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946013","Thanborisutkul 2025",2025,"Vaccines","Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines","COVID","Adult"
568,"#10568",0,0,1,0,0,1,1,0,1,"10.1093/cid/ciad458",39219510,"PMC10724468","https://pmc.ncbi.nlm.nih.gov/articles/PMC10724468","Thomas 2023",2023,"Clin Infect Dis","Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients","Influenza","Immunocomp"
569,"#10585",0,0,1,0,0,1,0,0,0,"10.3390/vaccines12111237",39591140,"PMC11599008","https://pmc.ncbi.nlm.nih.gov/articles/PMC11599008","Tian 2024",2024,"Vaccines","Protective Impact of Influenza Vaccination on Healthcare Workers","Influenza","Adult"
570,"#10617",1,0,0,0,1,1,1,1,1,"10.1016/j.vaccine.2024.126445",39413493,,"https://pubmed.ncbi.nlm.nih.gov/39413493","Top 2024",2024,"Vaccine","Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study","COVID","Immunocomp"
571,"#37186",1,0,0,0,1,1,1,0,0,"10.3389/fpubh.2025.1520821",40672927,"PMC12263602","https://pmc.ncbi.nlm.nih.gov/articles/PMC12263602","Tursinov 2025",2025,"Front Public Health","COVID-19 vaccination pharmacovigilance in Khojaly district, Uzbekistan: an epidemiological evaluation","COVID","Pediatric"
571,"#37186",1,0,0,0,1,1,1,0,0,"10.3389/fpubh.2025.1520821",40672927,"PMC12263602","https://pmc.ncbi.nlm.nih.gov/articles/PMC12263602","Tursinov 2025",2025,"Front Public Health","COVID-19 vaccination pharmacovigilance in Khojaly district, Uzbekistan: an epidemiological evaluation","COVID","Adult"
572,"#24824",1,0,0,0,0,1,1,0,0,"10.7759/cureus.81085",40271323,"PMC12017381","https://pmc.ncbi.nlm.nih.gov/articles/PMC12017381","Umezawa 2025",2025,"Cureus","A Series of Glomerular Diseases That Developed After COVID-19 Vaccination","COVID","Adult"
573,"#3796",1,0,0,0,1,1,0,0,0,"10.1016/j.jvacx.2024.100593",39734394,"PMC11681879","https://pmc.ncbi.nlm.nih.gov/articles/PMC11681879","vanEwijk 2025",2025,"Vaccine X","Innate immune response after BNT162b2 COVID-19 vaccination associates with reactogenicity","COVID","Pediatric"
573,"#3796",1,0,0,0,1,1,0,0,0,"10.1016/j.jvacx.2024.100593",39734394,"PMC11681879","https://pmc.ncbi.nlm.nih.gov/articles/PMC11681879","vanEwijk 2025",2025,"Vaccine X","Innate immune response after BNT162b2 COVID-19 vaccination associates with reactogenicity","COVID","Adult"
576,"#10824",1,0,0,0,0,1,1,0,0,"10.1080/21645515.2024.2323853",38445666,"PMC10936640","https://pmc.ncbi.nlm.nih.gov/articles/PMC10936640","Villanueva 2024",2024,"Hum Vaccin Immunother","Factors influencing adverse events following COVID-19 vaccination","COVID","Adult"
577,"#24912",1,0,0,0,0,1,1,0,1,"10.3390/vaccines13030273",40266144,"PMC11946322","https://pmc.ncbi.nlm.nih.gov/articles/PMC11946322","Vita 2025",2025,"Vaccines (Basel)","COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer","COVID","Immunocomp"
578,"#10878",0,1,0,0,0,1,1,0,0,"10.1093/infdis/jiae185",38606958,"PMC11481295","https://pmc.ncbi.nlm.nih.gov/articles/PMC11481295","Walsh 2024",2024,"J Infect Dis","Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination","RSV","Adult"
579,"#24941",0,1,0,0,0,0,1,0,0,"10.1093/cid/ciaf061",39928572,,"https://pubmed.ncbi.nlm.nih.gov/39928572","Walsh 2025",2025,"Clin Infect Dis","Efficacy, Immunogenicity, and Safety of the Bivalent RSV Prefusion F (RSVpreF) Vaccine in Older Adults Over 2 RSV Seasons","RSV","Adult"
580,"#10883",1,0,0,0,1,1,1,0,0,"10.1016/j.ijid.2024.107149",38909928,,"https://pubmed.ncbi.nlm.nih.gov/38909928","Wan 2024",2024,"Int J Infect Dis","Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation","COVID","Pediatric"
580,"#10883",1,0,0,0,1,1,1,0,0,"10.1016/j.ijid.2024.107149",38909928,,"https://pubmed.ncbi.nlm.nih.gov/38909928","Wan 2024",2024,"Int J Infect Dis","Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation","COVID","Adult"
581,"#10952",1,0,0,0,1,1,1,0,0,"10.3389/fphar.2024.1374320",38841369,"PMC11150672","https://pmc.ncbi.nlm.nih.gov/articles/PMC11150672","Wang 2024",2024,"Frontiers in Pharmacology","COVID-19 vaccination-related tinnitus is associated with pre-vaccination metabolic disorders","COVID","Pediatric"
581,"#10952",1,0,0,0,1,1,1,0,0,"10.3389/fphar.2024.1374320",38841369,"PMC11150672","https://pmc.ncbi.nlm.nih.gov/articles/PMC11150672","Wang 2024",2024,"Frontiers in Pharmacology","COVID-19 vaccination-related tinnitus is associated with pre-vaccination metabolic disorders","COVID","Adult"
582,"#3927",1,0,0,0,0,0,1,0,0,"10.1016/j.jinf.2025.106461",40054670,,"https://pubmed.ncbi.nlm.nih.gov/40054670","Ward 2025",2025,"J Infect","Understanding the effectiveness of the Comirnaty monovalent and bivalent vaccines during the Winter Coronavirus (COVID-19) Infection Study","COVID","Adult"
583,"#3937",1,0,0,0,0,1,1,0,0,"10.1093/cid/ciae598",39657038,,"https://pubmed.ncbi.nlm.nih.gov/39657038","Wee 2025",2025,"Clin Infect Dis","Bivalent Boosters and Risk of Postacute Sequelae Following Vaccine-Breakthrough SARS-CoV-2 Omicron Infection: A Cohort Study","COVID","Adult"
584,"#12733",1,0,0,0,0,1,1,0,0,"10.1186/s12916-023-03064-6",37726711,"PMC10510262","https://pmc.ncbi.nlm.nih.gov/articles/PMC10510262","Werner 2023",2023,"BMC Med","Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study","COVID","Adult"
585,"#19530",0,0,1,0,1,1,1,0,0,"10.1111/irv.13284",38773753,"PMC11109477","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Whitaker 2024",2024,"Influenza Other Respir Viruses","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom","Influenza","Pediatric"
585,"#19530",0,0,1,0,1,1,1,0,0,"10.1111/irv.13284",38773753,"PMC11109477","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Whitaker 2024",2024,"Influenza Other Respir Viruses","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom","Influenza","Adult"
586,"#11049",0,1,1,0,0,0,1,0,0,"10.1093/infdis/jiad594",38134393,"PMC11326816","https://pmc.ncbi.nlm.nih.gov/articles/PMC11326816","Widagdo 2024",2024,"J Infect Dis","Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial","RSV","Adult"
586,"#11049",0,1,1,0,0,0,1,0,0,"10.1093/infdis/jiad594",38134393,"PMC11326816","https://pmc.ncbi.nlm.nih.gov/articles/PMC11326816","Widagdo 2024",2024,"J Infect Dis","Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial","Influenza","Adult"
587,"#3972",1,0,0,0,0,0,1,0,1,"10.1101/2025.03.27.25324770v1",39708059,,"https://pubmed.ncbi.nlm.nih.gov/39708059","Wilson 2025",2025,"Infect Dis Ther","Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Associated Hospitalizations and Medically Attended COVID-19 among adults aged  18 years in the United States","COVID","Immunocomp"
589,"#11097",0,0,1,0,0,0,1,0,0,"10.1016/j.vaccine.2024.03.078",38641496,,"https://pubmed.ncbi.nlm.nih.gov/38641496","Won 2024",2024,"Vaccine","Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly","Influenza","Adult"
590,"#11107",0,0,1,0,1,1,0,0,0,"10.1016/j.vaccine.2024.126290",39241357,"PMC12136157","https://pmc.ncbi.nlm.nih.gov/articles/PMC12136157","Woo 2024",2024,"Vaccine","Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024)","Influenza","Pediatric"
590,"#11107",0,0,1,0,1,1,0,0,0,"10.1016/j.vaccine.2024.126290",39241357,"PMC12136157","https://pmc.ncbi.nlm.nih.gov/articles/PMC12136157","Woo 2024",2024,"Vaccine","Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024)","Influenza","Adult"
591,"#3989",1,0,0,0,0,1,1,0,0,"10.1136/rmdopen-2024-005138",40295118,"PMC12039019","https://pmc.ncbi.nlm.nih.gov/articles/PMC12039019","Woo 2025",2025,"RMD Open","Risk of new-onset polymyalgia rheumatica following COVID-19 vaccination in South Korea: a self-controlled case-series study","COVID","Adult"
592,"#3999",0,0,1,0,0,1,1,0,0,"10.1371/journal.pone.0310474",40392910,"PMC12091759","https://pmc.ncbi.nlm.nih.gov/articles/PMC12091759","Wu 2025",2025,"PLoS One","Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis","Influenza","Adult"
593,"#11161",1,0,0,0,0,1,1,0,0,"10.1016/j.ijid.2024.107080",38701913,,"https://pubmed.ncbi.nlm.nih.gov/38701913","Xiang 2024",2024,"Int J Infect Dis","Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: A study using data from the UK Biobank","COVID","Adult"
594,"#11175",1,0,0,0,0,1,1,0,0,"10.1016/j.vaccine.2024.04.070",38670844,,"https://pubmed.ncbi.nlm.nih.gov/38670844","Xie 2024",2024,"Vaccine","COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population","COVID","Adult"
595,"#11174",1,0,1,0,0,1,1,0,0,"10.1001/jama.2024.7395",38748411,"PMC11097092","https://pmc.ncbi.nlm.nih.gov/articles/PMC11097092","Xie 2024",2024,"Jama","Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024","COVID","Adult"
595,"#11174",1,0,1,0,0,1,1,0,0,"10.1001/jama.2024.7395",38748411,"PMC11097092","https://pmc.ncbi.nlm.nih.gov/articles/PMC11097092","Xie 2024",2024,"Jama","Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024","Influenza","Adult"
596,"#11193",1,0,0,0,0,1,1,0,0,"10.2196/53807",38916940,"PMC11234065","https://pmc.ncbi.nlm.nih.gov/articles/PMC11234065","Xu 2024",2024,"JMIR Public Health Surveill","Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study","COVID","Adult"
598,"#4039",1,0,0,0,0,1,1,0,0,"10.1093/eurheartj/ehae639",39344920,"PMC11704415","https://pmc.ncbi.nlm.nih.gov/articles/PMC11704415","Xu 2025",2025,"Eur Heart J","Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study","COVID","Adult"
599,"#11227",1,0,0,0,0,1,1,0,0,"10.3389/fpubh.2024.1406315",39139673,"PMC11320210","https://pmc.ncbi.nlm.nih.gov/articles/PMC11320210","Yamamoto 2024",2024,"Front Public Health","Group of longitudinal adverse event patterns after the fourth dose of COVID-19 vaccination with a latent class analysis","COVID","Adult"
600,"#4093",0,0,1,0,0,0,1,0,1,"10.1038/s41541-025-01065-5",39788985,"PMC11718019","https://pmc.ncbi.nlm.nih.gov/articles/PMC11718019","Yaron 2025",2025,"npj Vaccines","Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations","Influenza","Immunocomp"
601,"#19817",1,0,1,0,1,1,1,0,1,"10.1038/s43856-024-00588-7",39181950,"PMC11344792","https://pmc.ncbi.nlm.nih.gov/articles/PMC11344792","Yechezkel 2024",2024,"Commun Med (Lond)","Comparison of physiological and clinical reactions to COVID-19 and influenza vaccination","COVID","Immunocomp"
601,"#19817",1,0,1,0,1,1,1,0,1,"10.1038/s43856-024-00588-7",39181950,"PMC11344792","https://pmc.ncbi.nlm.nih.gov/articles/PMC11344792","Yechezkel 2024",2024,"Commun Med (Lond)","Comparison of physiological and clinical reactions to COVID-19 and influenza vaccination","Influenza","Immunocomp"
602,"#11312",1,0,0,0,1,1,1,0,0,"10.1016/j.amjoto.2024.104448",39096568,"PMC11634645","https://pmc.ncbi.nlm.nih.gov/articles/PMC11634645","Yih 2024",2024,"Am J Otolaryngol","Tinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink","COVID","Pediatric"
602,"#11312",1,0,0,0,1,1,1,0,0,"10.1016/j.amjoto.2024.104448",39096568,"PMC11634645","https://pmc.ncbi.nlm.nih.gov/articles/PMC11634645","Yih 2024",2024,"Am J Otolaryngol","Tinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink","COVID","Adult"
603,"#4110",1,0,0,0,0,1,0,0,1,"10.4103/apjtm.apjtm_253_24",,,"https://doi.org/10.4103/apjtm.apjtm_253_24","Yildirim 2025",2025,"Asian Pacific Journal of Tropical Medicine","COVID-19 vaccination in patients on biologic or targeted-synthetic disease modifying anti-rheumatic drug therapy: A multi center real-world data","COVID","Immunocomp"
604,"#11317",1,0,1,0,0,1,0,0,0,"10.1186/s13293-024-00625-z",38890702,"PMC11184791","https://pmc.ncbi.nlm.nih.gov/articles/PMC11184791","Yin 2024",2024,"Biol Sex Differ","Sex and gender differences in adverse events following influenza and COVID-19 vaccination","COVID","Adult"
604,"#11317",1,0,1,0,0,1,0,0,0,"10.1186/s13293-024-00625-z",38890702,"PMC11184791","https://pmc.ncbi.nlm.nih.gov/articles/PMC11184791","Yin 2024",2024,"Biol Sex Differ","Sex and gender differences in adverse events following influenza and COVID-19 vaccination","Influenza","Adult"
605,"#11335",1,0,0,0,0,1,1,0,0,"10.3201/eid3011.240610",39378869,"PMC11521192","https://pmc.ncbi.nlm.nih.gov/articles/PMC11521192","Yoon 2024",2024,"Emerg Infect Dis","Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021-2022","COVID","Adult"
606,"#11344",1,0,0,0,0,1,0,0,0,"10.1016/j.jri.2024.104246",38677139,,"https://pubmed.ncbi.nlm.nih.gov/38677139","Youngster 2024",2024,"J Reprod Immunol","The effect of COVID-19 vaccination during IVF stimulation on cycle outcomes- a retrospective cohort study","COVID","Adult"
607,"#11374",1,0,0,0,0,1,0,0,0,"10.4274/BMB.galenos.2024.2024-03-030",,,"https://doi.org/10.4274/BMB.galenos.2024.2024-03-030","Yumrueliksoy 2024",2024,"Bagcilar Medical Bulletin","Impact of Pfizer-BioNTech COVID-19 Vaccination on the Menstrual Cycle","COVID","Adult"
610,"#11385",1,0,0,0,1,1,0,0,0,"10.2147/IJGM.S467586",39070223,"PMC11283260","https://pmc.ncbi.nlm.nih.gov/articles/PMC11283260","Zahrani 2024",2024,"International Journal of General Medicine","Occurrence of Myopericarditis Following COVID-19 Vaccination Among Adults in the Eastern Region, Saudi Arabia: A Multicenter Study","COVID","Pediatric"
610,"#11385",1,0,0,0,1,1,0,0,0,"10.2147/IJGM.S467586",39070223,"PMC11283260","https://pmc.ncbi.nlm.nih.gov/articles/PMC11283260","Zahrani 2024",2024,"International Journal of General Medicine","Occurrence of Myopericarditis Following COVID-19 Vaccination Among Adults in the Eastern Region, Saudi Arabia: A Multicenter Study","COVID","Adult"
611,"#4155",1,0,0,0,0,1,1,0,0,"10.3389/fpubh.2025.1420291",40115337,"PMC11922928","https://pmc.ncbi.nlm.nih.gov/articles/PMC11922928","Zaidi 2025",2025,"Front Public Health","COVID-19 vaccines side effects among the general population during the pandemic: a cross-sectional study","COVID","Adult"
612,"#4169",0,0,1,0,0,1,1,0,1,"10.3390/vaccines13020189",40006735,"PMC11861709","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861709","Zawiasa-Bryszewska 2025",2025,"Vaccines","Safety and Efficacy of Influenza Vaccination in Kidney Graft Recipients in Late Period After Kidney Transplantation","Influenza","Immunocomp"
613,"#11414",0,0,1,0,1,1,1,0,0,"10.15585/mmwr.mm7339a1",39361525,"PMC11449270","https://pmc.ncbi.nlm.nih.gov/articles/PMC11449270","Zeno 2024",2024,"MMWR Morb Mortal Wkly Rep","Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024","Influenza","Pediatric"
613,"#11414",0,0,1,0,1,1,1,0,0,"10.15585/mmwr.mm7339a1",39361525,"PMC11449270","https://pmc.ncbi.nlm.nih.gov/articles/PMC11449270","Zeno 2024",2024,"MMWR Morb Mortal Wkly Rep","Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024","Influenza","Adult"
614,"#11416",1,0,0,0,0,1,1,0,0,"10.1016/j.jvacx.2024.100571",39474208,"PMC11513630","https://pmc.ncbi.nlm.nih.gov/articles/PMC11513630","Zethelius 2024",2024,"Vaccine X","Pulmonary embolism after SARS-CoV-2 vaccination","COVID","Adult"
615,"#4195",0,0,1,1,1,1,1,0,0,"10.1016/j.vaccine.2024.126662",39731809,,"https://pubmed.ncbi.nlm.nih.gov/39731809","Zhang 2025",2025,"Vaccine","Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season","Influenza","Pediatric"
615,"#4195",0,0,1,1,1,1,1,0,0,"10.1016/j.vaccine.2024.126662",39731809,,"https://pubmed.ncbi.nlm.nih.gov/39731809","Zhang 2025",2025,"Vaccine","Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season","Influenza","Adult"
616,"#11585",0,0,1,0,0,0,1,0,0,"10.3390/vaccines12080935",39204058,"PMC11360506","https://pmc.ncbi.nlm.nih.gov/articles/PMC11360506","Zhu 2024",2024,"Vaccines","Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged 60 Years and Older","Influenza","Adult"
617,"#11574",0,0,1,0,1,1,1,0,0,"10.15585/mmwr.mm7308a4",38421946,"PMC10907038","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907038","Zhu 2024",2024,"MMWR Morb Mortal Wkly Rep","Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024","Influenza","Pediatric"
617,"#11574",0,0,1,0,1,1,1,0,0,"10.15585/mmwr.mm7308a4",38421946,"PMC10907038","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907038","Zhu 2024",2024,"MMWR Morb Mortal Wkly Rep","Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024","Influenza","Adult"
618,"#25499",0,0,1,0,1,1,1,0,0,"10.1093/infdis/jiaf248",40359401,"PMC12353657","https://pmc.ncbi.nlm.nih.gov/articles/PMC12353657","Zhu 2025",2025,"J Infect Dis","Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season","Influenza","Pediatric"
618,"#25499",0,0,1,0,1,1,1,0,0,"10.1093/infdis/jiaf248",40359401,"PMC12353657","https://pmc.ncbi.nlm.nih.gov/articles/PMC12353657","Zhu 2025",2025,"J Infect Dis","Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season","Influenza","Adult"
619,"#4272",0,0,1,0,1,0,0,0,0,"10.3390/vaccines13010004",39852783,"PMC11768588","https://pmc.ncbi.nlm.nih.gov/articles/PMC11768588","Zhu 2025",2025,"Vaccines","Evaluation of Influenza Vaccine Effectiveness from 2021 to 2024: A Guangdong-Based Test-Negative CaseControl Study","Influenza","Pediatric"
620,"#11603",0,0,1,0,1,0,0,0,0,"10.1111/irv.13331",39031876,"PMC11190946","https://pmc.ncbi.nlm.nih.gov/articles/PMC11190946","ZornozaMoreno 2024",2024,"Influenza Other Respir Viruses","Adverse Effects Related to Paediatric Influenza Vaccination and Its Influence on Vaccination Acceptability. The FLUTETRA Study: A Survey Conducted in the Region of Murcia, Spain","Influenza","Pediatric"
621,"#32816",1,0,0,0,0,1,1,0,0,"10.1093/cid/ciae405",39107255,,"https://pubmed.ncbi.nlm.nih.gov/39107255","Ma 2024",2024,"Clin Infect Dis","Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024","COVID","Adult"
623,"#38920",1,0,1,0,1,1,1,0,0,"10.23958/ijirms/vol09-i11/1982",,,"https://doi.org/10.23958/ijirms/vol09-i11/1982","Rogers 2024",2024,"International Journal of Innovative Research in Medical Science","COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes","COVID","Pediatric"
623,"#38920",1,0,1,0,1,1,1,0,0,"10.23958/ijirms/vol09-i11/1982",,,"https://doi.org/10.23958/ijirms/vol09-i11/1982","Rogers 2024",2024,"International Journal of Innovative Research in Medical Science","COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes","Influenza","Pediatric"
623,"#38920",1,0,1,0,1,1,1,0,0,"10.23958/ijirms/vol09-i11/1982",,,"https://doi.org/10.23958/ijirms/vol09-i11/1982","Rogers 2024",2024,"International Journal of Innovative Research in Medical Science","COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes","COVID","Adult"
623,"#38920",1,0,1,0,1,1,1,0,0,"10.23958/ijirms/vol09-i11/1982",,,"https://doi.org/10.23958/ijirms/vol09-i11/1982","Rogers 2024",2024,"International Journal of Innovative Research in Medical Science","COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes","Influenza","Adult"
627,"#38977",0,1,0,1,1,0,0,0,0,"10.1002/ppul.71059",40662491,"PMC12261432","https://pmc.ncbi.nlm.nih.gov/articles/PMC12261432","Guerrero-Del-Cueto 2025",2025,"Pediatr Pulmonol","Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital","RSV","Pediatric"
628,"#38986",0,0,1,0,0,0,1,0,0,"10.1038/s41598-025-10633-7",40634642,"PMC12241609","https://pmc.ncbi.nlm.nih.gov/articles/PMC12241609","Mutter 2025",2025,"Sci Rep","Association between influenza vaccine effectiveness and chronic diseases among older adults with dementia","Influenza","Adult"
629,"#39029",0,1,0,1,0,0,0,0,0,"10.1016/s2352-4642(25)00155-5",40690922,,"https://pubmed.ncbi.nlm.nih.gov/40690922","Williams 2025",2025,"Lancet Child Adolesc Health","Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study","RSV","Pediatric"
630,"#39217",0,1,0,0,0,0,1,0,0,"10.1016/j.jamda.2025.105760",40651496,,"https://pubmed.ncbi.nlm.nih.gov/40651496","Popham 2025",2025,"J Am Med Dir Assoc","Disproportionate Impact of Respiratory Syncytial Virus (RSV) Among Older Adults in Long-Term Care Settings","RSV","Adult"
631,"#39260",0,0,1,0,0,1,0,1,0,"10.1016/j.vaccine.2025.127483",40660660,"PMC12305427","https://pmc.ncbi.nlm.nih.gov/articles/PMC12305427","Reeves 2025",2025,"Vaccine","Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age","Influenza","Adult"
631,"#39260",0,0,1,0,0,1,0,1,0,"10.1016/j.vaccine.2025.127483",40660660,"PMC12305427","https://pmc.ncbi.nlm.nih.gov/articles/PMC12305427","Reeves 2025",2025,"Vaccine","Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age","Influenza","Pregnant"
632,"#39262",0,0,1,0,1,1,0,0,0,"10.1093/jpids/piaf069",40736196,"PMC12392406","https://pmc.ncbi.nlm.nih.gov/articles/PMC12392406","Nguyen 2025",2025,"J Pediatric Infect Dis Soc","Effectiveness of cell culture-based influenza vaccine, 2023-2024","Influenza","Pediatric"
632,"#39262",0,0,1,0,1,1,0,0,0,"10.1093/jpids/piaf069",40736196,"PMC12392406","https://pmc.ncbi.nlm.nih.gov/articles/PMC12392406","Nguyen 2025",2025,"J Pediatric Infect Dis Soc","Effectiveness of cell culture-based influenza vaccine, 2023-2024","Influenza","Adult"
633,"#39341",1,0,0,0,0,1,1,0,0,"10.1038/s41467-025-61613-4",40664645,"PMC12264068","https://pmc.ncbi.nlm.nih.gov/articles/PMC12264068","Pan 2025",2025,"Nat Commun","Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study","COVID","Adult"
634,"#39349",1,0,0,0,0,1,0,0,0,"10.1080/09286586.2025.2522724",40658089,,"https://pubmed.ncbi.nlm.nih.gov/40658089","Sumer 2025",2025,"Ophthalmic Epidemiol","Evaluation of the Effects of mRNA-COVID 19 Vaccines on Corneal Endothelium","COVID","Adult"
635,"#39405",0,0,1,1,1,1,1,0,0,"10.1038/s41598-025-04049-6",40592905,"PMC12215190","https://pmc.ncbi.nlm.nih.gov/articles/PMC12215190","Jeong 2025",2025,"Sci Rep","Global estimates of vaccine-associated narcolepsy from 1967 to 2023","Influenza","Pediatric"
635,"#39405",0,0,1,1,1,1,1,0,0,"10.1038/s41598-025-04049-6",40592905,"PMC12215190","https://pmc.ncbi.nlm.nih.gov/articles/PMC12215190","Jeong 2025",2025,"Sci Rep","Global estimates of vaccine-associated narcolepsy from 1967 to 2023","Influenza","Adult"
636,"#39547",0,0,1,1,1,0,0,0,0,"10.1001/jama.2025.11534",40736730,"PMC12311823","https://pmc.ncbi.nlm.nih.gov/articles/PMC12311823","Silverman 2025",2025,"Jama","Influenza-Associated Acute Necrotizing Encephalopathy in US Children","Influenza","Pediatric"
637,"#39722",0,0,1,0,0,1,1,0,0,"10.1016/j.vaccine.2025.127514",40714528,,"https://pubmed.ncbi.nlm.nih.gov/40714528","Omole 2025",2025,"Vaccine","A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50years of age or older","Influenza","Adult"
638,"#39863",1,0,0,0,0,1,1,0,0,"10.1007/s40121-025-01185-4",40591130,"PMC12339817","https://pmc.ncbi.nlm.nih.gov/articles/PMC12339817","Diya 2025",2025,"Infect Dis Ther","Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial","COVID","Adult"
639,"#39866",1,0,0,0,0,1,0,0,0,"10.1186/s12879-025-11254-1",40624462,"PMC12232647","https://pmc.ncbi.nlm.nih.gov/articles/PMC12232647","Prabhu 2025",2025,"BMC Infect Dis","Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia","COVID","Adult"
640,"#39867",0,0,1,0,0,0,1,0,0,"10.1080/21645515.2025.2525603",40641250,"PMC12258169","https://pmc.ncbi.nlm.nih.gov/articles/PMC12258169","Li 2025",2025,"Hum Vaccin Immunother","The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018-2024","Influenza","Adult"
643,"#39963",1,0,1,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127548",40716143,,"https://pubmed.ncbi.nlm.nih.gov/40716143","Xu 2025",2025,"Vaccine","Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study","COVID","Pediatric"
643,"#39963",1,0,1,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127548",40716143,,"https://pubmed.ncbi.nlm.nih.gov/40716143","Xu 2025",2025,"Vaccine","Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study","Influenza","Pediatric"
643,"#39963",1,0,1,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127548",40716143,,"https://pubmed.ncbi.nlm.nih.gov/40716143","Xu 2025",2025,"Vaccine","Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study","COVID","Adult"
643,"#39963",1,0,1,0,1,1,1,0,0,"10.1016/j.vaccine.2025.127548",40716143,,"https://pubmed.ncbi.nlm.nih.gov/40716143","Xu 2025",2025,"Vaccine","Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study","Influenza","Adult"
